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Abstract. 
Tumour suppressor p53 is frequently mutated in cancers. While wild type p53 is 
normally a rapidly degraded protein, mutant forms of p53 are stabilised and accumulate to 
high  levels  in  tumour  cells.  Several  studies  have  shown  that  mutant  p53  acquires 
oncogenic properties and actively contributes to tumourigenesis. It is therefore important 
to understand how the stability of mutant p53 is regulated. This thesis shows that mutant 
and  wild  type  p53  are  ubiquitinated  and  degraded  through  overlapping  but  distinct 
pathways. While Mdm2 can drive the degradation of both mutant and wild type p53, this 
study suggests that the ability of Mdm2 to function as a ubiquitin ligase is less important in 
the degradation of mutant p53, which is heavily ubiquitinated in an Mdm2-independent 
manner. The contribution of Mdm2 to the degradation of mutant p53 may reflect an ability 
of Mdm2 to deliver the ubiquitinated mutant p53 to the proteasome. Ubiquitination does 
not efficiently target mutant p53 for the proteasomal degradation, however ubiquitinated 
p53 mutants localize to the cytoplasm. This thesis suggests the role for the chaperone-
associated  ubiquitin  ligase  CHIP  in  ubiquitination  of  mutant  p53,  although  other 
unidentified  ubiquitin  ligases  appear  to  contribute.  Interaction  of  mutant  p53  with  its 
family member p73 decreases ubiquitination, suggesting p73 can play a role in regulation 
of stability of mutant p53.  Acknowledgements. 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AA   Amino acids 
APS   ammonium persulfate 
ATCC  American Type Culture Collection 
ATP   Adenosine 5’-triphosphate 
BSA   Bovine serum albumin 
Cdk    cyclin dependent kinase 
cDNA     DNA complementary to mRNA 
CHIP  Carboxyl terminus of Hsc70-interacting protein 
DAPI   4',6-Diamidino-2-phenylindole 
DBD    DNA binding domain 
DDW  Double distilled water 
DMEM    Dulbecco’s Modified Eagles Medium 
DMSO    Dimethyl sulphoxide 
DNA    Deoxyribonucleic acid 
DTT  Dithiothreitol 
ECL    Enhanced chemiluminescence 
EDTA     Ethylene diamine triacetic acid 
EtBr    Ethidium bromide  
FCS    Foetal calf serum 
GAPDH   Glyceraldehyde-3-Phosphate Dehydrogenase 
h   hours 
HEPES    4-(2-hydroxyethyl)-1-piperazineethane-sulfonic acid 
HRP    Horseradish peroxidase 
IARC  International Agency for Research on Cancer 
kDa   kilodalton 
LB    Luria-Bertani medium 
min   minutes 
mRNA   messenger RNA 
NLS    Nuclear localisation signal 
NES  Nuclear export signal 
NP-40   Nonidet P40 
OD   Oligomerization domain   5 
PBS   Phosphate buffered saline 
PCR  Polymerase chain reaction 
PD   Proline rich domain 
PFA   Paraformaldehyde 
PMSF    phenylmethylsulphonyl fluoride 
RD  Regulatory domain 
RNA    Ribonucleic acid 
RNase    Ribonuclease 
RPE   Retinal pigment epithelia 
Rpm    Revolutions per minute 
rRNA   Ribosomal RNA 
RT-PCR  Reverse transcription polymerase chain reaction 
SDS   Sodium dodecyl sulphate 
siRNA    Short interfering RNA 
T   Thymine 
TA  Transactivation domain 
TBS    Tris buffered saline 
TBST   TBS-Tween 
TE    Tris-EDTA buffer 
TEMED   N,N,N',N'-Tetramethylethylenediamine 
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Chapter 1. Introduction.   16 
1  Introduction. 
1.1  Cancer. 
Cancer is a complex disease evolving as a result of a multi-step deregulation of 
normal processes controlling cell growth and proliferation. Different cellular stresses, such 
as DNA damage and oncogene activation, can lead to accumulation of mutations in cells, 
which can deregulate crucial cell regulatory pathways. The current model suggests that 
several  genetic  alterations  conferring  growth  advantage  to  the  cell  are  necessary  for 
oncogenic transformation (1, 2). These hallmarks of cancer have been originally described 
as self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
apoptosis and limitless replication potential, sustained angiogenesis and tissue invasion (3). 
Most  of  these  changes  occur  as  cell-autonomous  events  or  can  target  cell 
microenvironment. Later the avoidance of immunosurveillance has been proposed as a 
seventh hallmark of cancer, representing a more complex cell-extrinsic view of cancer 
development (4).  The current update of this model also describes the alteration in tumour 
metabolism as an important cancer-associated feature (5), which is linked to most of the 
mentioned molecular changes and becomes the eighth hallmark of cancer. 
Most of the genes altered in cancer have been classified as oncogenes and tumour 
suppressors (6). Under normal conditions oncogenes stimulate cell growth, subject to a 
tight  regulatory  mechanism.  Oncogenes  are  mutated  in  a  way  that  makes  the  gene 
consitutively active under the conditions when the wild type gene is inactive. This can 
result from chromosomal translocations, gene amplifications or from single amino acid 
substitutions  affecting  residues  crucial  for  the  activity  of  the  protein.  An  activating 
mutation in an oncogene confers growth advantage on the cell. For example, Ras proteins 
are a family of small GTPases, and are frequently mutated in cancer. The GTPase activity 
shuttles the protein from active to inactive state. Oncogenic mutation in Ras (for example 
Gln61Leu in H-Ras) leads to structural alteration of the protein, which impairs the GTPase 
activity,  “locking”  Ras  in  active  state.  Activated  Ras  leads  to  aberrant  growth  via 
activation  of  MAPK  pathway  (7).  Ras  oncogenes  play  a  key  role  in  malignant 
transformation of primary cells (8-10). Other examples of oncogenes include B-Raf, c-
Myc, EGFR, met, and many others (11). In contrast to oncogenes, genetic alterations in 
tumour-suppressor genes lead to inactivation of their function. Such alterations usually 
represent missense mutations at residues essential for the activity, mutations leading to a 
truncated  protein,  deletions  or  insertions  or  epigenetic  silencing  of  the  gene.  Though 
inactivation of only one allele of some of the tumour suppressor genes can be enough to   17 
confer growth advantage upon the cells, in most other cases mutations in both alleles are 
required to confer growth advantage (6). The loss of heterozygosity commonly occurs 
through the deletion of the second allele via a large chromosomal event, such as loss of 
chromosomal arm (12). The best characterized examples of tumour-suppressor genes are 
p53, Rb and APC, which are often inactivated in cancers (13, 14). One of the examples is 
the  frequently  inactivated  in  retinoblastomas  Rb  (retinoblastoma)  tumour  suppressor, 
which  encodes  the  Rb  protein,  which  blocks  proliferation  by  sequestering  E2F  (15). 
Another tumour suppressor frequently inactivated in cancers is p16Ink4A, which inhibits 
cyclin dependent kinases (16). The subgroup of the tumor suppressor genes important in 
cancer is defined by the stability genes. This group involves genes whose products are 
involved  in  DNA  repair  during  normal  processes,  such  as  replication,  mitotic 
recombination and chromosomal segregation, or upon exposure to mutagens. These genes 
are exemplified by BRCA1, ATM, BLM and many others. Inactivation of the stability 
genes  leads  to  higher  rate  of  accumulation  of  mutations,  which  can  accelerate  cancer 
progression (17). Many hereditary cancer predisposition syndromes occur by mutations of 
the stability genes (6). 
Mutations can be of either germline or somatic origin. Germline mutations lead to 
increased frequency of occurrence of cancer. Some of the examples of the hereditary types 
of  cancers  include familial  adenomatous  polyposis  (mutations  in APC),  familial  breast 
cancer  (mutations  in  BRCA1  or  BRCA2)  or  Li-Fraumeni  syndrome  (LFS,  caused  by 
mutations in p53). Somatic mutations are acquired in somatic tissue during the lifetime and 
predominantly give rise to cancer with mutations restricted to cancer cells (12).  
Genetic changes in tumours have a different weight in contributing to malignant 
progression. Some of them are crucial for sustaining tumour growth, such as oncogenic 
changes in Myc and Ras. Elimination of such oncogenes from tumours leads to tumour 
regression and has been termed “oncogene addiction” effect (18). Other changes that were 
selected  in  early  stages  of  tumour  development  may  not  be  required  for  growth  of 
advanced  aggressive  tumour  or  could  occur  as  secondary  alterations  due  to  genetic 
instability of tumours.  
The  concept  of  cancer  being  a  heterogeneous  disease,  which  arises  through  a 
number of several mutations, is supported by recent evidence of cancer-genome studies. 
One  such  study,  which  analyzed  13000  genes  in  11  breast  and  11  colorectal  cancers, 
revealed that on average there are about 11 mutated genes per tumour, which contribute to 
tumour  progression.  Noteworthy,  each  tumour  specimen  had  its  own  distinct  gene 
signature with maximum of 6 genes overlap. Though this could be due to the limited 
number of samples, it seems to reflect the high heterogeneity of tumours even from the   18 
same tissue origin. More recent studies focused on pancreatic cancers and glioblastomas 
and carried out more extensive analysis (19-21). These studies have found that there are on 
average 63 genetic alterations in pancreatic cancer and about 47 mutations in glioblastoma 
with significant variation between the samples. It remains to be determined which of these 
genes are the “driving” force of tumour progression and which were accumulated on the 
way.  Mutations  in  pancreatic  cancer  affected  only  12  pathways  and  3  pathways  in 
glioblastoma, which implies that several pathways are disrupted in tumour development 
and several genetic alterations are required to deregulate the pathway.  
In addition to mutations, discussed above, there are many other genes, involved in 
tumourigenesis,  which  are  not  mutated,  however  their  expression  levels  are  altered. 
Changes  in  expression  are  generally  associated  with  the  epigenetic  changes,  such  as 
methylation of DNA, which silences the gene. These changes can be found in normal cells 
at  some  stage  of  development,  suggesting  their  reversibility.  In  many  cancers  the 
promoters  of  some  tumour-suppressor  genes,  such  as  Rb,  VHL  and  BRCA1,  are 
hypermethylated, which results in inactivation of these genes (22, 23). 
One of the most commonly found alterations in cancer is inactivation of the p53 
pathway (24) (IARC TP53 database http://www-p53.iarc.fr/). p53 gene is mutated in about 
50% of most human cancers (25, 26) and large proportion of the cancers that retain wild 
type p53 have mutations in pathways directly regulating p53. The germline mutation in 
p53 causes the cancer predisposition syndrome Li-Fraumeni (27). The key role of p53 in 
tumourigenesis is also reflected in the literature with over 40000 publications since its 
discovery.  p53  has  been  well  described  as  a  tumour  suppressor,  which  is  involved  in 
numerous sometimes opposing biological processes preventing the rise of malignant cells 
(28). 
1.2  p53 is  a tumour suppressor gene: history of discovery.  
Already during the first years after its discovery the unique character of p53 was 
revealed, which distinguishes it among other tumour suppressors. p53 was identified in 
1979 as a protein in complex with large T-antigen oncoprotein of the SV40 DNA tumour 
virus (29, 30). Another study reported high levels of p53 in transformed, but not normal 
cells, with no history of viral infection, suggesting it was coded by cellular genes (31). p53 
gene was cloned (32-34) and originally described as an oncogene, due to its ability to 
transform  cells  in  cooperation  with  other  H-Ras  oncogene  (35,  36).  In  support  of  this 
notion,  expression  of  p53  then  was  shown  to  immortalize  the  cells  (37)  and  enhance 
tumourigenic potential of cells injected in mice (38, 39). Later it was realized that the 
originally  studied  p53  protein  was  the  product  of  a  mutated  p53  gene,  which  indeed   19 
promoted tumourigenesis. However, after the wild type p53 gene was cloned it became 
evident that wild type p53 protein blocked the ability of oncogenes to transform cells (40-
42).  It  also  became  clear  that  SV40  needed  to  inactivate  wild  type  p53  in  order  to 
transform cells (43). Wild type p53 was then reclassified as a tumour suppressor gene and 
numerous studies since then have demonstrated its key role in protecting cells from cancer 
(24). The fact that p53 is mutated in at least half of all human cancers indicates a strong 
selection for its loss during tumour progression (25, 26). Additional support for its crucial 
role in tumourigenesis came from the study of Li-Fraumeni patients, who inherit one allele 
of  mutant  p53  gene  and  are  extremely  predisposed  to  cancer  (44).  Most  convincing 
evidence for the tumour suppressive role of p53 has come from the study of p53 knock-out 
mice (45, 46). Those mice can develop without gross abnormalities, though some problems 
with development have been reported, however they all spontaneously develop tumours by 
the age of 6 months. Recognition of p53’s prominent role in protection from cancer has 
boosted a huge amount of scientific reports (around 20000) describing the function of p53 
as a tumour suppressor. Quite an unusual feature of a tumour suppressor was noted – p53 
is point mutated rather than inactivated in cancers and is highly expressed in tumours. 
Mutation of p53 gene confers novel oncogenic properties on p53 protein. 
 
1.3  Function of p53.  
p53  is  activated  in  response  to  oncogene  activation,  DNA  damage  and  spindle 
damage, which can potentially increase the mutation occurrence in cells and increase the 
risk of becoming cancerous. p53 is also induced in response to other types of cellular 
stresses such as hypoxia, rNTP depletion and nutrient deprivation which can predispose 
cells to malignant transformation (Fig.1.1).  Activated p53 can induce cell-cycle arrest, 
allowing DNA repair, or cause senescence, or promote apoptosis, eliminating the damaged 
cells (24, 28). Numerous studies have demonstrated that p53 can influence many other 
biological  processes,  such  as  invasion  and  motility,  angiogenesis,  differentiation,  cell 
survival and more recently discovered glycolysis (47, 48) and autophagy (49) (Fig.1.1).  
1.3.1  p53 is a transcription factor. 
The p53 gene encodes a transcription factor and mediates much of its biological 
activities by regulating the expression of numerous p53 target genes (Fig.1.1). p53 binds to 
the specific sequences – p53 responsive elements - in the regulatory region of its target 
genes and more than hundred different p53 target genes have been described with various 
biological functions and the list is likely to grow (50). p53 activates transcription of most   20 
of its targets by recruiting general transcription factors (TATA-binding protein-associated 
factors)  and  histone  acetyltransferases  (HAT)  CBP,  p300  and  PCAF  to  the  promoter    
    
 
 
 
 
(51-54).  One  of  the  first  discovered  p53  target  genes  was  the  cyclin-dependent  kinase 
inhibitor (CDK) p21, which induces a cell cycle arrest (55). Other p53-regulated genes 
mediating cell cycle arrest include 14-3-3σ (56), GADD45 (57) and Reprimo (58). p53 
induces apoptosis by activating genes mediating extrinsic and intrinsic apoptotic pathways 
(59).  Such  targets  include  genes  encoding  death  receptors,  Fas/CD95/Apo-1  (60)  and 
Killer/R5  (61),  and  mitochondrial  proteins  Bax  (62),  Noxa  (63)  and  PUMA  (64).  The 
mitochondrial proteins function by inducing the loss of mitochondrial membrane potential, 
leading to release of cytochrome C and activating caspases leading to apoptosis. Out of 
FIGURE 1.1 Scheme of p53 response.  
p53 is activated by a number of cellular stresses (blue boxes) and regulates 
different biological processes (red boxes) via transcriptional activation of 
its target genes (marked in black).   21 
these proteins PUMA is the key mediator of apoptosis, as it is required for most of the 
apoptotic activity of p53 (65). In addition to its well-established role as a transcription 
factor,  p53  can  induce  apoptosis  independent  of  transcriptional  activity  by  direct 
interaction with members of the BCL2 family proteins at the mitochondria (66). PUMA 
also mediates induction of apoptosis by cytoplasmic p53 (67). Activation of autophagy via 
induction of novel gene DRAM by p53 also contributes to cell death (49, 68). Recent 
studies have identified microRNA miR-34 as a p53 target gene, adding a new twist on 
regulation of p53 gene network (69-72). miRNAs are a class of small regulatory RNAs that 
mediate post-transcriptional silencing of specific target mRNAs (73). The miR-34 family 
is directly induced by p53 in response to DNA damage and oncogenic stress, which can 
lead to induction of growth arrest and apoptosis through inhibiting gene expression of 
proliferative  and  anti-apoptotic  genes  (69,  72).  p53  can  contribute  to  cell  survival  by 
allowing DNA repair by activating genes such as Gadd45 (57), p53R2 (74). p53 has also 
been  suggested  to  play  a  direct  role  in  mediating  DNA  repair  by  interacting  with 
components  of  the  repair  machinery  (75).  In  addition,  p53  plays  a  survival  role  by 
protecting the genome from damage by reactive oxygen species (ROS). This activity of 
p53 is mediated by activation of TIGAR (47), sestrins (76), aldehyde dehydrogenase-4 
(77) and Sco2 (78), which can decrease the levels of intracellular ROS. TIGAR, one of the 
most recently described p53 target genes, is involved in regulation of glycolysis, and plays 
anti-oxidant  role  by  decreasing  ROS,  which  attenuates  cell  death  (47).  The  survival 
function of p53 is suggested to be important under conditions of basal physiological stress 
in normally growing cells to prevent accumulation of DNA damage (79). In the absence of 
severe stress, low levels of p53 activate the expression of antioxidant genes. This has been 
demonstrated by removal of p53 in unstressed cells, which leads to down-regulation of 
levels of sestrins and Sco2. The current model suggests that at low levels of stress p53 
plays  a  survival  role  and  helps  the  cell  to  cope  with  stress,  by  decreasing  ROS  and 
allowing  DNA  repair.  When  stress  is  severe  and/or  DNA  damage  is  irrepairable,  p53 
triggers irreversible growth arrest or apoptosis, to eliminate the damaged cells from the 
healthy pool (28). In light of the current data, the role of p53 therefore emerges as a master 
regulator of cells well-being, which prevents cancer development. 
Several  p53  target  genes  inhibit  p53  activity  in  a  negative  feedback  loop.  p53 
transcriptionally activates its major negative regulator Mdm2 (mouse double minute) (80, 
81), a ubiquitin ligase, which inactivates p53 mainly by targeting p53 it for proteasomal 
degradation and promoting p53 nuclear export (82). Similarly to Mdm2, p53 target genes 
Cop1 (83) and Pirh2 encode ubiquitin ligases which can degrade p53 (84).    22 
Though binding of p53 to the response element of most of its target genes results in 
activation of their transcription, some genes are repressed by p53. p53 can prevent the 
activation of the promoters of the genes in a number of different ways. p53 can prevent the 
binding  of  more  potent  transcription  factors,  for  example  NF-Y  and  CEBP,  due  to 
overlapping  binding  sites  in  the  promoter.  By  this  mechanism,  p53  can  repress 
transcription of BRCA1 and some other genes (85). Similarly, p53 represses anti-apoptotic 
gene Bcl-2 by preventing its activation by POU4F1 family transcription factor (86). In 
addition, p53 can directly interact with the transcription factors, such as Sp1 and AP1 and 
others,  preventing  their  binding  to  the  target  genes.    By  this  mechanism  p53  leads  to 
repression  of  genes  such  as  cyclin  B1  (87)  and  TERT  (88).  p53  also  recruits  histone 
deacetylases (HDACs) to the promoters which is mediated by the interaction with SIN3A 
(89).  HDAC2  deacetylates  lysine  residues  of  histones  in  chromatin,  repressing 
transcription of genes (90). By this mechanism, p53 represses transcription of genes such 
as MAP4 and stathmin (89). 
One of the novel target genes CD44 is inhibited by p53 under conditions of basal 
stress (91). CD44 plays a key role in mediating tumour progression in cells lacking p53. 
CD44  encodes  a  cell-surface  molecule  and  can  block  p53-dependent  stress-induced 
apoptotic  signals.  Inactivation  of  p53  function  in  tumour  cells  derepresses  CD44 
expression,  which  is  essential  for  tumour-initiating  ability  of  transformed  mammary 
epithelial cells (91). 
The repertoire of p53 target genes is extremely broad and in addition to genes 
mentioned  above  also  includes  secreted  proteins  regulating  migration  (92)  and 
angiogenesis  (93,  94).  Though  some  of  these  biological  responses  have  sometimes 
opposing roles, they all seem to contribute to the tumour suppressive function of p53.  
The choice of p53 response depends on the type of the particular stress and cellular 
context and is the active area of research (50), which has mostly focused on the choice 
between the fundamental p53 responses – cell cycle arrest and apoptosis. Posttranslational 
modifications are involved in dictating the choice of transcriptional target genes by p53. 
Upon UV and DNA damage HIPK2 (95, 96) and DYRK2 (97) phosphorylate p53 on S46. 
This promotes induction of apoptosis by p53 via activation of pro-apoptotic p53AIP1 gene 
(95,  98).  Acetylation  of  p53  on  lysine  120  by  MOF  and  TIP60  also  promotes  p53-
dependent apoptosis in response to DNA damage, via recruitment of p53 to pro-apoptotic 
target genes, PUMA and Bax (99, 100). Ubiquitination of p53 on Lys320 by E3 ligase 
E4F1 promotes cell cycle arrest function of p53 via activation of p21, Gadd45 and cyclin 
G1, while not affecting the pro-apoptotic target genes (101). p53 family members p63 and   23 
p73  can  also  selectively  enhance  the  apoptotic  activity  of  p53  in  some  cell  types,  by 
promoting transactivation of PERP and BAX but not p21(102).  
p53 interacting partners play an important role in the outcome of p53 response. The 
members of the ASPP (ankyrin-repeat-SH3-domain- and proline-rich-region-containing) 
family play an important role in regulating the apoptotic function of p53. The family of 
ASPPs, which also stands for apoptosis-stimulating protein, includes three members: pro-
apoptotic - ASPP1, ASPP2 and anti-apoptotic iASPP (inhibitory) and their function is 
evolutionary  conserved.  The  ASPP  family  members  contain  highly  conserved  ankyrin 
repeats, an SH3 domain and proline rich region in their C-terminus (103). Unlike many 
other proteins, ASPP family members interact with the DNA binding domain of p53 (104). 
ASPP1 and ASPP2 specifically stimulate the induction of apoptosis by p53, but not cell 
cycle arrest (105). ASPPs act by selectively enhancing the p53 binding and transactivating 
promoters  of  pro-apoptotic  target  genes  such  as  Bax,  PIG3  (p53-induced  gene  3)  and 
PUMA,  while  not  affecting  the  promoters  of  the  CDKN1A  and  mdm2  genes.  The 
mechanism of the promoter selectivity is currently unknown, but could involve the change 
of conformation of DBD of p53 or the recruitment of other chromatin-remodelling factors 
(105). iASPP specifically inhibits p53-induced apoptosis by inhibiting the transactivation 
of p53 of pro-apoptotic BAX and PIG3 genes, but not of Mdm2 and CDKN1A. It has been 
suggested that iASPP acts by displacing ASPP2 from p53 (106). ASPP1 and ASPP2 can 
inhibit the transforming activity of the oncogenes RAS and E1A in cells, suggesting they 
can act as tumour suppressors. On the other hand iASPP can enhance the transforming 
activity of RAS and E1A in the same system, suggesting its potential proto-oncogenic role 
(105,  106).  Interestingly,  ASPP2+/-  mice  develop  spontaneous  tumours,  which  is 
accelerated in p53+/- background (107). Downregulation of ASPP1 and ASPP2 expression 
has  been  reported  in  several  types  of  cancer,  reflecting  their  important  role  in 
tumourigenesis.  Consistent  with  its  anti-apoptotic  role,  iASPP  has  been  found 
overexpressed in breast carcinomas (103).  
 
1.3.2  Activation of p53. 
Cellular  stresses  engage  different,  sometimes  overlapping,  pathways  to  activate 
p53. The most well understood signals that activate the p53 protein in cells are DNA 
damage  and  oncogene  activation  (Fig.1.2).  There  are  different  types  of  DNA  damage 
resulting from gamma or UV irradiation, alkylation of bases, depurination of DNA and 
reactive oxygen species (108). The major sensors of DNA damage are ATM and ATR   24 
(109-112) and their downstream kinases Chk1 and Chk2 (113-115), respectively, which 
primarily act by phosphorylation of p53 leading to its stabilization and activation.   
 
 
 
 
 
 
 
 
Oncogene  activation  leads  to  accumulation  of  p53  by  a  mechanism,  which  is 
mostly mediated by the tumour suppressor protein ARF (p19ARF in mouse and p14ARF 
in human) (14, 116). The ARF protein (Alternative Reading Frame) is a product of the 
INK4a locus, which also encodes the cyclin-dependent kinase inhibitor p16INK4a (117). 
Deregulated oncogenes, such as overexpressed Myc, oncogenic Ras or deregulated E2F, 
induce ARF expression, resulting in activation of p53 response (118-120). ARF leads to 
p53 activation, by inhibiting its major negative regulator Mdm2 (121-124). Mice lacking 
ARF are tumour-prone, although the phenotype is not as severe as in p53-null mice (125, 
126). Interestingly, tumour cell lines retaining wild type p53 almost always lose ARF, 
suggesting the importance of signalling through this pathway in tumour development (16). 
Loss  of  ARF  does  not  prevent  the  activation  of  p53  in  response  to  DNA  damage, 
suggesting oncogene activation and DNA damage are independent signals (127). However, 
the situation is more complex as oncogenes activation has been shown to induce DNA 
damage response in precancerous lesions (128, 129), suggesting the cross-talk between the 
two pathways. Indeed, loss of ARF can attenuate the DNA damage response and loss of 
ATM can impair the ARF response. The contribution of these two fundamental pathways 
FIGURE 1.2. Regulation of p53.  
Core regulatory pathway of p53 is shown. Mdm2 is the 
major  negative  regulator  of  p53,  whereas  p53 
transcriptionally activates Mdm2. Stresses, such as DNA 
damage    and  oncogenes  activation,  via  ARF,  activate 
p53 by inhibiting its negative regulation by Mdm2.  
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of p53 activation to tumour-suppression by p53 remains quite controversial. On one hand it 
has been shown that DNA damage pathway is an early event and is constitutively activated 
in  tumours,  and  activation  of  p53  response  has  been  shown  to  protect  from  tumour 
formation (130, 131). On the other hand, a study in mice generated to have switchable p53 
has  shown  that  p53  is  important  as  a  tumour  suppressor  only  after  most  of  the  DNA 
damage  has  been  resolved  (132).  Consistent  with  this,  another  group  has  shown  that 
signalling through the ARF pathway accounts for almost all tumour suppression activity by 
p53 (133) . This suggests that p53 response to oncogene activation is the most important in 
tumour suppression. These studies question the importance of one of the most fundamental 
signals activating p53 function, which remains an issue of debate.  
Ribosomal  stress,  such  as  treatment  with  the  RNA  polymeraseII  inhibitor 
actinomycin  D,  is  a  well  known  activator  of  p53.  This  is  mediated  via  a  number  of 
ribosomal proteins, such as L5, L11 and L23 which bind and inhibit Mdm2, leading to 
stabilization and activation of p53 (134-138).  
Metabolic  stress  due  to  lack  of  nutrients  can  activate  p53  through  a  pathway 
involving AMP kinase, where p53 induces reversible growth arrest playing a survival role 
during starvation (139). Loss of p53 can contribute to continued proliferation of tumour 
cells in the conditions when nutrients are scarce and therefore confer a growth advantage. 
Other stresses that activate p53 pathway include hypoxia, which can lead to growth arrest, 
autophagy  or  apoptosis,  depending  on  the  severity  of  hypoxic  stress.    Interestingly, 
hypoxia activates a different transcriptional program than DNA damage (140).  
 
1.3.3  Structure of p53. 
The p53 gene contains eleven exons with two alternative translation start sites in 
exon 2 and 4 (GenBank Accession Number: NC_000077) (141). The p53 protein contains 
three major functional domains: N-terminal transcriptional activation domain (TA), the 
central sequence-specific DNA-binding domain (DBD) and the oligomerization domain 
(OD) in the C-terminus (Fig.1.3). There is also an N-terminal proline rich domain involved 
in protein interactions and regulatory domain in the C-terminus (Fig.1.3). p53 also contains 
several nuclear localization (NLS) and nuclear export signals (NES) (Fig.1.3) (142). There 
are five highly evolutionary conserved regions in p53 protein boxes I to V (Fig.1.4). Box I 
(13-18aa)  lies  in  the  TA  domain  of  p53  and  encompasses  the  region  interacting  with 
Mdm2, whereas boxes II, III, IV and V reside in the DBD of p53 and are regions most 
frequently mutated in cancer (143).    26 
 
 
 
 
The transcriptional activation domain of p53 is crucial for its function. Two TA 
domains are defined in the N-terminus – TA1 (1-42aa) and TA2 (43-92aa) (144, 145) 
(Fig.1.3).  Both  TA1  and  TA2  interact  with  the  basal  transcriptional  machinery  and 
independently  are  sufficient  to  activate  transcription  when  fused  to  heterologous  DBD 
(144). TA1 and TA2 are regulated by associated proteins such as p300, Mdm2 and Pin1. 
Structural studies reveal that N-terminal domain is natively unfolded and fully folds upon 
binding to its interaction partners (146, 147). A fragment containing 15-29aa adopts an 
alpha-helical conformation upon binding to N-terminus of Mdm2 (148). N-terminus of p53 
is also subject to multiple phosphorylations by different protein kinases. Next to the TA 
lies  the  proline-rich  domain  (64-92aa)  (PD),  containing  five  PXXP  motifs,  which  is 
involved in multiple protein interactions (149). The function of the PD is not entirely 
understood and has been suggested to contribute to proapoptotic function of p53 (150).   
The  DNA  binding  domain  (DBD)  of  p53  is  essential  for  its  sequence-specific 
transcriptional activation. The p53 DBD spans amino acids 102-292 and contains four of 
the five highly evolutionary conserved regions defined in p53 – boxes II (117-142aa), III 
(171-181aa), IV (234-256aa) and V (270-286aa) (143) (Fig.1.4). The crystal structure of 
p53-DBD bound to DNA has been solved (151). Several other structures of p53 DBD have 
been reported (147) including structures of p53-DBD in solution in its DNA-free form 
(152) and in complex with interacting patners (104, 153). The structural studies show that 
the conserved regions are crucial for the p53-DNA interaction. The larger part of the DBD 
forms  an  anti-parallel  β-sandwich.  This  sandwich  serves  as  a  scaffold  for  structures 
interacting  with  DNA.  The  DNA-binding  surface  consists  of  loop-sheet-helix  and  two 
large loops interacting with the minor and major grooves of DNA respectively. The loop-
FIGURE 1.3. Structure of p53 protein.  
The  main  domains  of  p53,  nuclear  export  (NES),  nuclear  localization  (NLS) 
signals and the location of the conserved boxes I, II, III, IV and V are shown.  
TA  -  transactivation  domain,  PD  -  proline-rich  domain,  DBD  -  DNA  binding 
domain, OD - oligomerization domain, RD – regulatory domain. 
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sheet-helix motif spans conserved region V (151, 152). Two large loops are stabilized by a 
zinc ion, which is coordinated by residues C176 and H179, located in box III and C238 
and  C242,  located  in  box  IV  (154).  The  p53  consensus  site  contains  two  half-sites 
RRRCWWGYYY,  separated  by  a  spacer  of  0-13bp,  where  R=purine,  C=cytosine, 
W=adenine  or  thymidine,  G=guanine  and  Y=pyrimidine.  Residues  S241,  R248,  K120, 
R273, A276, R283, C277 and R280 directly contact DNA (151, 155). The DBD of p53 is 
only marginally stable, which is likely to have evolved to allow high flexibility between 
folded  and  unfolded  states.  This  can  provide  the  structural  basis  for  diversity  of  p53-
mediated responses (151, 152). Most of the p53 mutations found in cancers affect the DNA 
binding domain and occur as point mutations of either amino acids contacting DNA or 
residues important for the structure of the DBD, implying the crucial role of the DBD for 
tumour suppression (147).  
 
Figure 1.4. Comparison of p53 protein sequence across species.  
Alignment  of  human  p53  protein  sequence  with  p53  from  other  species:  Mus 
musculus, Gallus gallus, Xenopus laevis and Danio rerio was done using the ClustalX 
program. Evolutionary conserved residues are highlighted in black. Divergent amino 
acids belonging to the same class are highlighted in gray. Highly conserved boxes I, 
II, III, IV, V are marked in blue.  
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Full-length p53 functions as a tetramer, which is mediated by the oligomerization 
domain in the C-terminus of the protein (325-356aa) (Fig.1.3). Structural studies describe 
the tetrameric structure as a dimer of primary dimers (156). Tetramerisation of p53 is 
required for high-affinity DNA binding and transcriptional activation. The model suggests 
that one DBD dimer binds to one half of the consensus DNA binding site, and second 
dimer to the adjacent half of the site (155). Oligomerization domain also regulates the 
binding to Mdm2 and nuclear export of p53 (157, 158). 
The  extreme  C-terminus  of  p53  (364-393aa)  is  considered  to  be  a  regulatory 
domain  and  is  subjected  to  extensive  posttranslational  modifications,  including 
phosphorylation,  acetylation,  ubiquitination,  sumoylation,  neddylation  and  methylation, 
which  regulate  p53  activity  and  stability  (Fig.1.3).  Structure  reveals  it  is  intrinsically 
unstructured but can fold upon binding to other proteins or nonspecific DNA (159). The C-
terminus has been shown to be required for activation of many p53 target genes (160). 
 
1.4  Regulation of p53. 
Upon  cellular  stresses,  the  p53  protein  rapidly  accumulates  and  activates 
transcription of its target genes. The p53 protein has a very short half-life in normal cells 
and is primarily regulated at the level of protein stability, which provides the means to 
rapidly induce p53 when needed. In unstressed cells p53 protein levels are kept low due to 
continuous  ubiquitination  which  targets  p53  to  proteasomes  for  degradation.  This  is 
primarily mediated by the ubiquitin ligase Mdm2, a key negative regulator of p53. In 
addition  to  proteasomal  degradation,  ubiquitination  by  Mdm2  can  also  lead  to  nuclear 
export of p53. Several other ubiquitin ligases have also been reported to contribute to 
regulation of p53 stability (82, 161) and will be discussed later. 
 
1.4.1  Ubiquitination.  
Ubiquitin is a highly conserved 76-amino acid polypeptide, which is encoded on 
multiple genes. The genes encode oligomers of ubiquitin, which are processed to active 
monomers in cells. Ubiquitins are then covalently attached to lysines on target proteins in a 
specific and tightly regulated reactions cascade called ubiquitination (Fig.1.5) (162-165). 
Briefly, ubiquitination is a sequential reaction which is mediated by coordinated action of 
the E1 - ubiquitin activating enzyme, the E2 - ubiquitin conjugating enzyme, and E3 or 
ubiquitin protein ligase, which determines the substrate specificity. First E1 forms a thiol-
ester bond between its active site cysteine and the C-terminal glycine of ubiquitin through   29 
ATP-dependent process. The activated ubiquitin is then transferred from E1 to a conserved 
cysteine on E2 in a reaction of transthiolation. Next, E3 interacts with ubiquitin-bound E2 
and the substrate and facilitates formation of an isopeptide linkage between C-terminal 
glycine on ubiquitin and the ε-amino group of an internal lysine on the substrate (Fig.1.5). 
Polyubiquitin chains are formed by attachment of ubiquitin to the lysine on the ubiquitin 
already attached to the substrate (165). In some cases ubiquitin can be attached to the free 
α-amino group of the substrate  (166, 167).  
 
 
 
FIGURE 1.5. Ubiquitin-proteasome system.  
Ubiquitin  is  activated  by  a  ubiquitin-activating  enzyme  E1  and  is  transferred  to  a 
ubiquitin-conjugating enzyme E2. The ubiquitin ligase E3 mediates the transfer from the 
E2  to  the  protein  substrate.  Polyubiquitinated  substrates  are  targeted  to  the  26S 
proteasome  for  degradation.  The  ubiquitin  can  be  cleaved  off  the  by  deubiquitinating 
enzymes (DUBs). Pi, inorganic phosphate; PPi, pyroposphate; Ub, ubiquitin. (Modified 
from Weissman, A. M. (2001) Nat Rev Mol Cell Biol 2(3): 169-78.). 
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E1 
It is considered there is one E1 in mammals, which is essential for ubiquitination. 
There are two isoforms E1a and E1b, which result from alternative translation initiation 
(168). The reaction of activation of ubiquitin usually involves two steps: the ATP- 
dependent  formation  of  ubiquitin-adenylate  intermediate,  which  is  followed  by  the 
formation of the E1-ubiquitin thiol ester (169).  
E2 
There are about 13 genes encoding E2-like proteins in yeast and more than 30 E2 in 
mammalian  genomes.  Not  all  of  them  can  conjugate  ubiquitin,  for  example  Ubc9 
conjugates ubiquitin-like protein SUMO. They all have a characteristic domain (UBC) of ~ 
150 amino acids that contains cysteine that accepts ubiquitin from E1 and is conserved 
~35% between the family members. Many E2s also have N- or C-terminal extensions, 
which are involved in the interactions with E3s (163) and can facilitate the interaction 
between E3s and the substrate by serving as membrane anchors (170). Importantly, the 
ubiquitin binding site on the E2 does not overlap with the E3-binding site (171, 172). 
Another significant finding is the discovery that E1 and E3 binding sites on the E2 overlap, 
and  their  binding  to  E2  is  mutually  exclusive  (173).  This  implies  that  for 
polyubiquitination multiple cycles of E2-E3 binding and release need to occur. There are 
many  more  E3s  described  than  E2s.  The  structural  similarity  between  different  E2s 
suggests  redundancy  in  their  function.  Indeed,  UbcH5  and  UbcH7  for  example  can 
function with HECT domain (174) and RING domain E3 ligases (171, 175). The structures 
of UbcH7 bound to HECT domain of E6-AP (172) and RING domain of c-Cbl (171) have 
been solved. Interestingly, these different E2s interact with the same region on UbcH7. 
The conserved Phe63 on UbcH7 is crucial for the interaction between UbcH7 and the 
HECT of E6-AP and RING of c-Cbl and appears to be present in other E2s, suggesting its 
importance in mediating E2-E3 binding (176). In vitro studies suggest that E3s can also 
function  with  several  E2s.  For  example,  in  the  screen  for  Mdm2-specific  ubiquitin-
conjugating enzymes it has been found that that UbcH5A, -B, -C and E2-25K support 
Mdm2-mediated ubiquitination of p53 in vitro (177). Another report suggests that RING 
ubiquitin ligase Topors functions with UbcH5a, UbcH5c and UbcH6, but not with UbcH7, 
CDC34 or UbcH2b (178). It is possible that the E2 step might provide an additional point 
for  specifying  and  diversifying  the  signal  of  ubiquitination  and  by  this  dictate  the 
biological function of the ubiquitin conjugation. 
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E3.  
E3s, ubiquitin ligases, largely determine the substrate specificity (163, 179). There 
are more than 200 different ubiquitin ligases currently characterized and several hundreds 
are predicted by bioinformatics approach, based on the search for signature domain (180). 
Three large families of E3s are defined based on the presence of the functional 
domain: the HECT (Homologous to E6AP Carboxy Terminus), RING (Really Interesting 
New Gene) and U-box (UFD2) homology proteins. The RING family contains also a PHD 
(Plant  HomeoDomain)-containing  subfamily.  Each  of  the  functional  domains  directly 
interacts with the corresponding E2. 
HECT family.  
This family is defined by the presence of the HECT domain and was founded by 
the first discovered and recognized mammalian ubiquitin ligase E6-AP (E6-Associated 
Protein).  Upon  binding  to  the  E6  protein  of  the  human  papillomavirus  (HPV)  E6-AP 
ubiquitinates  and  degrades  p53 (181).  A  highly  conserved  C-terminal  domain  of  ~350 
amino acids is a characteristic feature of the members of the HECT family (182). The N-
terminus mediates the substrate recognition. The HECT domain binds the E2-ubiquitin 
intermediate and accepts ubiquitin at a conserved cysteine residue which is usually ~35 aa 
upstream the C-terminus of E3. The formation of the E3~ubiquitin intermediate is a unique 
feature of this family, whereas other E3s transfer ubiquitin directly to the substrate. Other 
family  members  involve  HUWE1/ARF-BP1/Mule  which  ubiquitinates  a  number  of 
substrates, such as: Mcl-1 (183), c-Myc (184) and p53 (185)  
RING family. 
The largest family of the E3s is defined by the presence of RING finger domain 
usually  in  the  range  of  40-100  amino  acids  (186).  The  RING  finger  consists  of  eight 
conserved  cysteines  and  histidines  [CX2CX(9-39)CX(1-3)HX(2-3)C/HX2CX(4-
48)CX2C] that together coordinate two zinc ions in a cross-braced arrangement. The RING 
domain directly binds E2 and is essential for the ubiquitin ligase activity (171). RING 
domain E3 functions as an adaptor that positions the substrate lysine in close proximity to 
E2-ubiquitin intermediate (186).  
RING domain ubiquitin ligases can consist of single- or multiple subunits. Mdm2 
is the single subunit ubiquitin ligase and contains amino-terminal p53-binding domain and 
the  RING  finger  domain  in  its  carboxyl  terminus.  Together  with  E1  and  E2  enzymes 
Mdm2  is  sufficient  to  ubiquitinate  p53  in  vitro  (175).    Multisubunit  ubiquitin  ligase 
complexes usually contain a RING finger subunit, a member of the cullin family and a F-  32 
box containing structural adaptor (187). The RING finger subunit provides ubiquitin ligase 
activity, cullins play a role of scaffold, and F-box proteins link the cullin to the substrate. 
For example, SCF (Skp1-Cul-F-box) complex consists of RING finger protein (Rbx1), 
cullin1 and Skp1 as an adaptor. The known SCF E3s play an important role in regulation 
of  the  G1/S  cell  cycle  transition.  The  subunits  of  the  complex  are  in  such  structural 
organization, which positions the core ubiquitin ligase activity with multiple substrates. 
The substrates of the SCF E3 ligases include oncogenes b-catenin, cyclin D, E2F1, as well 
as proteins involved in growth arrest such as p21, p27 (188). 
A small subfamily of RING E3s is defined by the presence of a PHD domain. 
Structural studies show that PHD domain resembles the RING domain in folding which 
also relies on the coordination of two zinc ions in a cross-brace arrangement. It usually 
includes a cysteine rather than a histidine in the fourth position and an invariant tryptophan 
before  the  seventh  zinc-binding  residue.  This  family  includes  viral  proteins  MIRs 
(modulator of immune recognition), which downregulate MHC class I (189).  
U-box. 
U-box domain is distantly related to the RING finger, but has no conserved zinc 
coordinating  residues.  Sequence  analysis  demonstrated  that  the  U-box  proteins  share 
conserved charged and polar residues and the structure prediction suggests similarity to the 
RING. Several U-box proteins have been shown to ubiquitinate in vitro in a manner similar 
to the RING finger (163). U-box domain was first identified in yeast Ufd2 ubiquitin ligase. 
Interestingly, Ufd2 lacks its own substrate and instead promotes the polyubiquitination of 
another E3’s substrate, which led to its classification as an “E4” (190). Another U-box 
protein,  C-terminus  of  Hsc70  Interacting  Protein  (CHIP)  also  displays  E4-like  activity 
(191, 192). CHIP is known to ubiquitinates several substrates, most of which are misfolded 
proteins associated with Hsp70 or Hsp90 chaperones (193).  It can also associate with 
Parkin, belonging to the RING family, and promotes Parkin-mediated ubiquitination of 
substrate protein Pael-R (194).  
Lysines on the substrates can be mono- and polyubiquitinated. A conjugation of 
single ubiquitin can also occur on several lysines and is termed multiubiquitination. The 
best studied role of monoubiquitination is regulation of endocytosis and DNA repair and 
has  been  shown  to  affect  subcellular  localization,  conformation,  activity  and  protein 
interactions of the substrates (195-197). Polyubiquitin chains are formed by conjugation of 
G76 carboxyl group of the next ubiquitin to the ε-amino group of a lysine within preceding 
ubiquitin (198, 199). Ubiquitin has seven internal lysine residues K6, K11, K27, K29, K33, 
K48  and  K63,  which  are  able  to  serve  for  conjugation  of  ubiquitin  (200).  The  best 
characterized  polyubiquitin  chains  are  those  linked  through  K48  and  K63  (201).  K48-  33 
linked ubiquitin chains of four ubiquitins or longer target the substrate to the proteasomes 
for degradation (202). However, K48 chains can have proteolysis-independent functions 
(101, 203). For example, K48- linked ubiquitination of p53 by E4F1 plays a novel role and 
has been reported to modulate p53 transcriptional activity without affecting proteolysis of 
p53 (101). K63-ubiquitination requires the action of distinct conjugating enzymes E2s and 
does not promote degradation, leading to different biological outcomes. For example, IKK 
is activated through the K63-linked polyubiquitination, mediated by TRAF6 (204). The 
K63-linked polyubiquitination of PCNA is essential for error-free repair of the damaged 
DNA (205). There is much less known about the role of the linkages of ubiquitin via K6, 
K11 and K29 (206-208). Chains that catalyze formation of K6 and K11 have been shown 
to bind the proteasomal subunit S5α, however, it is not clear whether they can promote the 
degradation of the substrates (207). K6-linked ubiquitination of BRCA1 seems to stabilize 
BRCA1 and direct it to the DNA repair foci (208). The biological significance of other 
ubiquitin chains remains to be determined.  The mechanisms regulating the choice of the 
lysine on the ubiquitin during ubiquitination are largely unknown. It is clear that the same 
E3 can conjugate K48 and K63 linkages. The possible step of specificity could be provided 
by E2, as distinct E2s are involved in K63 chain formation (209). It is also possible that the 
interaction partners of the ubiquitin ligases may direct which ubiquitin chain is formed. 
The same substrate can be modified by different types of ubiquitination, which leads to 
various biological outputs. For example, K48-linked polyubiquitination of the C-terminus 
of p53 leads to its proteasomal degradation, whereas K63-linked ubiquitination of lysine 
K320 modulates its transcriptional activity directing p53 to target genes mediating cell 
cycle arrest (101). 
The  ubiquitination  can  be  reversed  by  the  action  of  deubiquitinating  enzymes 
(DUBs):  ubiquitin  C-terminal  hydrolases  (UCHs)  and  ubiquitin-specific  processing 
proteases  (USPs),  both  of  which  are  cysteine  hydrolases  (210).  In  general,  UCHs  are 
capable of cleaving ubiquitin precursors to generate active ubiquitin. UBPs are a large and 
diverse group of enzymes which can cleave and disassemble ubiquitin chains. DUBs play 
several  biological  roles  in  generation  of  ubiquitin,  recycling  of  ubiquitin,  editing 
polyubiquitin  chains  and  aiding  in  proteasome-dependent  degradation  (211).  Various 
DUBs are associated with the 26S proteasome and regulate its function. For example, 
UCH37 is an intrinsic subunit of the 19S proteasome and is involved in ‘editing’ of the 
ubiquitinated substrates according to the length of polyubiquitinated chains (212). Rpn11 
also represents proteasome-associated DUB and releases the polyubiquitin chain from the 
substrate, allowing full translocation of the substrate protein to the proteolytic core of the 
proteasome (213). Some DUBs have been shown to have substrate specificity. HAUSP   34 
plays an important role in regulating p53 protein levels by deubiquitinating both p53 and 
Mdm2  (214,  215).  CYLD  deubiquitinates  TRAF2  leading  to  downregulation  of  NFkB 
signaling (216, 217). DUBs are currently intensively investigated and have been implicated 
in regulation of various processes (218).  
Since the discovery of the ubiquitin an entire family of ubiquitin-like molecules has 
been discovered which currently counts more than ten members including Nedd8, SUMO, 
ISG15 and Atg8 (219, 220). Though not having high sequence similarity, ubiquitin-like 
molecules are structurally similar to ubiquitin and all have characteristic ubiquitin, or β-
grasp, structural fold. Ubiquitin-like molecules are attached to the lysine on the substrate in 
a reaction similar to ubiquitination. Distinct E1 and E2 enzymes participate for each type 
of the ubiquitin-like modification. The best characterized so far SUMO and Nedd8 are the 
closest to ubiquitin with 20 and 60% sequence homology respectively. Several SUMO-
specific ligases have been identified: for example PIAS family (221), TOPORS (222). 
Interestingly, some of the ubiquitin ligases, including Mdm2, can also function as NEDD8 
E3 ligases (223). 
Conjugation of ubiquitin-like molecules leads to different physiological outputs. 
SUMOylation  is  involved  in  regulation  of  subcellular  localization  (224),  DNA  repair 
(205),  chromatin  remodelling  (225)  and  regulation  of  transcription  (226).  Neddylation 
often targets ubiquitin ligases, such as cullins, and can activate their function (227, 228). In 
addition, neddylation can inhibit the transcriptional activity of the target protein, as has 
been shown for p53 (223). Isgylation plays a role in regulation of immune response (229). 
The function of other ubiquitin-like molecules remains largely unknown. 
 
1.4.2  Proteasome.  
The fundamental role of the polyubiquitination chains is to target the substrates to 
the proteasomes for degradation (179, 230). Chains of four and more ubiquitins linked 
through K48 is the signal for proteasomal recognition (202). The 26S proteasome is a ~2.5 
MDa complex made up of two copies of at least 32 subunits which are highly conserved in 
eukaryotes (Fig.1.6). Proteasomes are highly abundant in cells and degrade proteins in the 
cytoplasm, the nucleus or the endoplasmic reticulum (ER).  The proteasome can be divided 
by biochemical methods into two major subcomplexes: the 20S core particle (CP) and two 
19S regulatory particles (RP) (Fig.1.6). Structural studies in yeast reveal that CP is a 670 
kDA  barrel-shaped  complex  consisting  of  four  stacked  rings,  each  composed  of  seven 
proteins  (231).  The  two  outer  rings  α  and  the  two  inner  rings  β  are  identical.    The   35 
proteolytic active sites are within a cavity formed by the two β rings at the center of the CP 
 
 
 
 
(Fig.1.6). Substrates gain access to the CP only through the narrow pores formed by the 
alpha  ring  subunit  and  a  mechanism  of  gate  opening  is  required  to  facilitate  substrate 
degradation (232). This function is mediated by the 19S RP. The RP is nearly a 1MDa 
complex and each one associates with the axial end of the CP. The RP is further divided 
into the base and the lid (233). The base is proximal to the CP and contains six AAA-type 
ATPases (Rpt1-6) and four non-ATPase subunits (Rpn1, Rpn2, Rpn10 and Rpn13). The 
six ATPases form a ring and function in substrate unfolding, which is thought to be a 
prerequisite for the degradation (234). Rpt2 plays a role in opening the pore, whereas Rpt5 
is  involved  in  recognition  of  the  substrate-bound  ubiquitin  chain  (235).  Non-ATPase 
Rpn10/S5α  functions  as  a  ubiquitin  receptor  (236).  Several  proteins  involved  in 
degradation  are  associated  with  the  proteasomes  –  Rad23,  Dsk2,  Ddi1,  which  share  a 
common ubiquitin-like domain, recognized by Rpn1 (237). These proteins also have a C-
terminal UbA domain which binds to the polyubiquitinated chains. Binding of the UbA 
domain can protect polyubiquinated chains from cleavage by deubiquitinating enzymes 
(DUBs)  (238).  It  is  not  clear  whether  the  function  of  these  proteins  is  to  shuttle  the 
substrates to the proteasome or tether the polyubiquitinated substrate to the proteasome 
(239). The lid of the RP is distal to the base and is an eight-subunit (Rpn3-Rpn11) complex 
highly  homologous  to  the  COP9  signalosome  and  translation  initiation  factor  eIF3, 
suggesting the functional homology between these different regulatory pathways (233). 
Rpn11 has been shown to possess deubiquitinating activity, which removes the ubiquitin 
molecules  from  the  substrates  (213).  There  are  other  DUBs  that  associate  with  the 
proteasome. For example, UCH37 trims polyubiquitin chains from substrates attached to 
the proteasome (212). In addition to deubiquitinating enzymes, ubiquitin ligase Hul6 has 
FIGURE 1.6. Structure of the 
proteasome.  
The  schematic  organization  of  26S 
proteasome  consisting  of  20S  core 
particle  (CP)  and  of  two  19S 
regulatory  particles  (RP)  is  shown. 
The 20S subunit is composed of four 
rings: two outer α-rings and two inner 
β-rings.  Each  ring  is  made  of  7 
homologous  subunits.  The  RP  is 
subdivided into the lid and the base. 
RPN10  is  found  outside  of  the 
proteasome.  (Modified  from  Hanna, 
J.  and  D.  Finley  (2007).  FEBS  Lett 
581(15): 2854-61). 
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recently  been  reported  to  associate  with  the  proteasome  (240),  which  can  extend  the 
polyubiquitin chain of the substrate at the proteasome.  
Therefore the proteasome represents a very complex subunit, with a number of 
activities.  In summary, ubiquitinated substrates are first recognized and bound by the 
ubiquitin  receptors  in  the  RP.  Ubiquitins  are  then  removed  from  the  substrate  by 
deubiquitinases  and  recycled.  Substrates  are  unfolded  and  then  enter  the  pore  of  CP 
through  the  gate.  Some  proteins  can  undergo  degradation  directly  by  20S  CP  in  a 
ubiquitin-independent manner, such as p21 (241), p53 (242) and Rb (243). This suggests, 
that  ubiquitination  is  indeed  required  for  recognition  of  the  proteins  by  the  RP  of  the 
proteasome.  
 
1.4.3  Ubiquitination and proteasomal degradation of p53 by Mdm2. 
 
1.4.3.1 Ubiquitin ligase Mdm2. 
The  major  mechanism,  that  keeps  p53  inactive  in  cells,  is  mediated  by  proto-
oncoprotein Mdm2 (244), which targets p53 for proteasomal degradation (245, 246). p53 
transcriptionally activates Mdm2 in an autoregulatory negative feedback loop (80, 81). 
Mdm2  was  identified  as  the  product  of  one  of  the  three  genes  located  on 
extrachromosomal amplifications in a spontaneously transformed murine cell line (3T3-
DM) (247, 248). Its key role in negatively regulating p53 is best illustrated by the studies 
of the knock-out mice. Mdm2-null mice die early in embryogenesis (E5.5-6) as a result of 
p53-dependent apoptosis due to accumulation of p53. Simultaneous inactivation of p53 
completely rescues the lethality of Mdm2-null mice, suggesting the key role of Mdm2 in 
negatively regulating p53 activity (249, 250).  
Mdm2  is  a  RING  finger  ubiquitin  ligase  and  ubiquitinates  p53  and  itself  in  a 
RING-dependent  manner  (175).  Though  several  E2s  can  support  Mdm2-mediated 
ubiquitination of p53 in vitro, in cells the most important are UbcH5B and C (177). At low 
levels Mdm2 can promote monoubiquitination of p53, which leads to the nuclear export, 
whereas at high levels Mdm2 efficiently polyubiquitinates p53 leading to its proteasomal 
degradation (245, 246, 251). In addition Mdm2 can inhibit the transcriptional activity of 
p53  by  binding  directly  to  its N -terminal  transactivation  domain  (252,  253).  The 
contribution of these roles of Mdm2 has been addressed in a recent study of mice with 
knock-in  of  Mdm2  mutant  lacking  the  E3  activity  (254).  This  has  been  done  by 
substituting  a  zinc-coordinating  cysteine  462  (464  in  human)  with  alanine,  which 
inactivates the ubiquitin ligase activity of Mdm2 but does not prevent the binding to p53.   37 
Mice homozygous for the RING mutation died early in embryogenesis (E7.5), and the 
lethality was rescued by the simultaneous deletion of p53. This demonstrates that though 
the Mdm2 RING mutant is capable of binding to p53, it cannot fully suppress p53 activity, 
suggesting that the ubiquitin ligase activity of Mdm2 plays the key role in inhibiting p53 
(254).  Many  mechanisms  of  p53  activation  converge  onto  disrupting  the  interaction 
between p53 and Mdm2, leading to accumulation of p53 in the nucleus and transactivation 
of its target genes. Such mechanisms involve posttranslational modifications of both p53 
and Mdm2, and their binding partners.  
Mdm2 gene consists of 12 exons and has two different promoters P1 and P2, the 
second  of  which  is  p53-responsive.  Alternative  translation  initiation  generates  two 
proteins, the full-length p90 and a shorter p76. p76 does not bind p53 and can act as a 
dominant-negative  inhibitor  of  p90  leading  to  activation  of  p53  (255-258).  Other 
alternative splice variants of Mdm2 lacking the p53-binding domain have been described 
and  some  of  them  are  overexpressed  in  tumours  (259).  One  of  them  Mdm2-ALT1 
sequesters full-length Mdm2 in the cytoplasm and inhibits the interaction of Mdm2 with 
p53, enhancing p53 activity (260). It is not yet clear why these alternative splice forms are 
overexpressed in cancers. 
Full-length  human  Mdm2  is  a  491-aa  protein  and  contains  several  functional 
domains (Fig.1.7). The p53 binding domain is in the N-terminal portion of Mdm2 and 
interacts with a highly conserved region on the N-terminus of p53 (Fig.1.7) (148, 256).  
Mdm2 also contains a central acidic domain, which is important for its E3 activity (261, 
262). Acidic domain is involved in interaction with several binding partners, such as ARF 
(121, 122), ribosomal proteins L5, L11 and L23 (134-138, 263) and also mediates the 
interaction with the central domain on p53 (264-266). Mdm2 also contains a zinc finger 
domain, which has been recently suggested to be involved in interaction with ribosomal 
proteins L5 and L11 (267). However, the exact function of this domain remains unclear. 
As already mentioned, RING finger domain is required for ubiquitin ligase activity of 
Mdm2 (Fig.1.7). The solution structure of the C2H2C4 RING domain of human Mdm2 
reveals  a  symmetrical  dimer  with  a  unique  cross-brace  zinc-binding  scheme  (268). 
Recently it has been shown that C-terminal tail of Mdm2 is also critical for efficient E3 
activity (269, 270).  
RING domain of Mdm2 also contains a conserved Walker A or P loop motif, found 
in  nucleotide  binding  proteins.  Mdm2  has  been  reported  to  interact  with  adenine-
containing nucleotides, which leads to conformational change at the C-terminus of Mdm2    38 
(271). Nucleotide binding is not required for the ubiquitin ligase activity of Mdm2, and is 
involved in regulating nucleolar localization of Mdm2. Other important structural elements 
of Mdm2 involve nuclear localization signal (NLS), which lies close to nuclear export 
signal (NES) (272) and a nucleolar localization signal (273).  
 
 
 
1.4.3.2 Interaction between p53 and Mdm2. 
The interaction between p53 and Mdm2 is necessary for the ubiquitination and 
degradation  of  p53  by  Mdm2  and  is  tightly  regulated.  A  conserved  region  in  the  N-
terminus of p53 binds to a deep hydrophobic binding cleft in the N-terminal domain of 
Mdm2 (25-109aa), as shown by crystal structure of the p53-Mdm2 complex (148). On 
Mdm2 the cleft is formed by the residues 26-108 and residues G58, G68, V75 and C77 are 
the most important, as shown by mutagenesis analysis (274). The Mdm2 interaction region 
on p53 has been mapped to 18-26aa and residues L14, F19, L22, W23 and Leu26 have 
been found to be important for the interaction by mutational analysis (256, 275-277). The 
crucial role of the residues F19, W23 and L26 has been also demonstrated by the structural 
study (148). The neighbouring residues also appear to contribute, probably by modulating 
the conformation of this region. Conserved box I (13-18aa) on p53 overlaps the Mdm2-
binding  site  on  p53  and  is  required  for  interaction  and  degradation  by  Mdm2  (158). 
FIGURE. 1.7. Structure of Mdm2 protein.  
The  main  domains  of  Mdm2  -  p53-binding  domain,  acidic  domain,  RING 
domain and zinc finger domain are depicted. The major p53 binding site (full 
line) is in the N-terminus and second p53 binding site (dashed line) is in the 
acidic domain of Mdm2. Other interacting partners ARF, L11, L5, L23 interact 
with the acidic domain of Mdm2.  
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Mutation of residues L22 and W23 on p53 inhibits the interaction with Mdm2 and also 
reduces  p53  transcriptional  activity  (278).  Mouse  models  with  p53  with  equivalent 
mutations of L25 and W26 have shown that p53 is very stable due to decreased binding to 
Mdm2 (279-281), confirming the importance of binding of Mdm2 to regulation of p53 
stability.  Small-molecule  inhibitors  named  nutlins  bind  to  the  p53-binding  pocket  on 
Mdm2 and effectively prevent the interaction, resulting in stabilization and activation of 
the p53 pathway (282). 
The C-terminus of p53 also plays an important role in regulating the interaction. 
Tetramerization of p53 is necessary for the efficient Mdm2 binding and degradation, as has 
been demonstrated by deletion studies (158). 
In addition to the N-terminus and C-terminus, the DNA binding domain of p53 
provides a secondary binding site for Mdm2, involving its acidic domain (264, 265). In 
agreement with this, structural study has shown that the acidic domain and part of the zinc 
finger domain of Mdm2 are involved in the interaction with the core domain of p53 (266). 
This  second  interaction  has  been  shown  to  contribute  to  efficient  ubiquitination.  The 
current model suggests that the N-terminal interaction between p53 and Mdm2 induces a 
conformational  change  in  Mdm2  and  leads  to  the  interaction  of  the  acidic  domain  of 
Mdm2 with the core domain on p53 (265). 
In response to different types of stress p53 is stabilized and activated due to several 
mechanisms, including posttranslational modifications and interacting partners. Most of 
these mechanisms affect Mdm2-mediated proteasomal degradation of p53 (161). 
 
1.4.3.3 Posttranslational modifications involved in regulation of p53 stability. 
In response to stresses p53 is phosphorylated and acetylated predominantly at its N-
terminus and C-terminus, which lead to accumulation and activation of p53 (283). The 
most characterized modifications of p53, which can regulate p53 stability, are summarized 
on Figure 1.8. p53 is phosphorylated in response to DNA damage and other stresses on 
numerous sites: S6, S9, S15, T18, S20, S33, S37, S46, T81 in the N-terminal domain of 
p53; S315 and S392 in C-terminus; and T150, T155 and S149 in the DBD. In addition, 
residues T55, S376 and S378 are constitutively phosphorylated in unstressed cells (283). 
Mdm2 has also been reported to undergo phosphorylations in response to DNA damage, 
such as Ser395 by ATM kinase (284) and Y394 by c-Abl (285), which impair its ability to 
degrade p53. Akt phosphorylates Mdm2 on residues 166 and 186, which promote nuclear 
import of Mdm2 resulting in increase in ubiquitination of p53 (286).   40 
 
 
 
N-terminal phosphorylations have been suggested to stabilize p53 by inhibiting the 
interaction  with  Mdm2  (111,  112).  Upon  DNA  damage,  kinases  ATM  and  Chk2  
phosphorylate p53 on S15 and S20 respectively (110, 287, 288) (113-115), whereas ATR 
and Chk1 phosphorylate p53 at S15  and S37 (109, 115, 289). The biological significance 
of N-terminal phosphorylations sites on p53, which have been best characterized in cells 
systems, has been addressed in mouse models. p53 knock-in mice with mutation S18A and 
S23A  (equivalent  to  S15  and  S20  in  human)  have  been  generated  which  would  be 
predicted  to  have  increase  in  binding  of  Mdm2  to  p53  and  impaired  stabilization  and 
transactivation if p53. However, the knock-in mice with single mutations do not have a 
gross phenotype and p53 stability and response are not largely affected (290, 291). Knock-
in  mice  with  mutations  in  both  residues  have  mild  alterations  in  p53  stability  and 
transactivation capability (292). They also develop tumours, however after long latency 
(>1 year). These observations suggest that although S15 and S20 partially contribute to 
regulating  the  interaction,  other  mechanisms  might  be  involved.  There  is  a  significant 
redundancy in that some sites are phosphorylated by different kinases, and one kinase can 
phosphorylate  several  residues  on  p53.  This  could  potentially  explain  the  lack  of 
pronounced phenotypes in mice. For example, several kinases can phosphorylate Ser15, 
and Chk2 can phosphorylate several different residues (283). In support of the functional 
redundancy,  mutations  of  these  sites  are  very  rare  in  cancers.  The  variety  of 
phosphorylation sites and kinases suggests that it could be the way of regulating the choice  
FIGURE. 1.8. Modifications of p53 regulating its stability.  
The schematic organization of p53 and the Mdm2 binding sites are shown. The 
best described phosphorylations of the N-terminus and of the DBD of p53 and 
modifications of the C-terminal lysines indicated. 
p-phosphorylation; ac – acetylation; ub – ubiquitination; nd – neddylation; su – 
sumoylation. 
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of p53 response to different stimuli. Other phosphorylations in the N-terminus lead to 
accumulation of p53 possibly by modulating the interaction with local alterations of the 
conformation. Their physiological relevance remains to be elucidated. 
Three phosphorylation sites (S33, T81 and S315) are followed by proline sites, 
which  are  subject  to  regulation  by  Pin1  (293,  294).  Phosphorylation  of  these  sites  in 
response  to  certain  types  of  stress  promotes  interaction  with  Pin1,  which  isomerises 
prolines, and is required for full activation of p53. Loss of Pin1 impairs p53 response to 
DNA damage. The mechanism is not entirely clear but it is proposed that conformational 
change on p53 induced by Pin1 reduces the interaction with Mdm2, leading to stabilization 
of p53 and also increases transcriptional activity of p53 (293, 294). In agreement with this, 
p53  lacking  proline-rich  domain  (PD),  which  removes  one  Pin1-binding  site,  is 
hypersensitive to Mdm2-mediated degradation (295). The study in which mice lacking 
murine PD were generated, has confirmed the role of PD in regulation of stability of p53. 
Contradictory to in vitro data, however, p53ΔP fails to induce cell cycle arrest, but can 
promote apoptosis (296).  
Modifications of p53 in the DBD are much less well characterized but also have 
been shown to affect the stability of p53. In contrast to N-terminal phosphorylations, which 
stabilize p53, phosphorylation of the DBD of p53 (S149, T150 and T155) targets it for 
degradation (297). This is mediated by COP9 signalosome kinase and occurs in unstressed 
cells,  providing  another  way  to  restrain  p53  activity.  Some  of  the  recently  reported 
modifications also involve glycosylation of p53 on S149 in the DBD of p53, which leads 
to stabilization of p53 by blocking its ubiquitination and degradation. This modification 
prevents T155 phosphorylation (298).  
Mdm2  binds  to  the  N-terminus  of  p53  and  ubiquitinates  its  C-terminal  lysines 
(K370,  K372,  K373,  K381,  K382  and  K386)  (Fig.1.8),  targeting  p53  for  proteasomal 
degradation. Mutation of these lysines (6KR) impairs the degradation of p53 by Mdm2 
(299, 300) (301). However, some amount of Mdm2-dependent ubiquitination of p53-6KR 
has been noted, suggesting that other lysines on p53 can be targeted by Mdm2. In addition 
to ubiquitination C-terminal lysines on p53 are modified with ubiquitin-like molecules – 
Nedd8 and SUMO-1. Neddylation of p53 is promoted by Mdm2 on lysines K370, K372 
and K373 (Fig.1.8) (223). In addition to Mdm2, a member of F-box family FBXO11 has 
been identified as a new p53-interacting protein, which can neddylate p53 on K320 and 
K321 (302). Neddylation inhibits transcriptional activity of p53, probably by preventing 
acetylation of these residues. Modification of p53 with another ubiquitin-like molecule 
SUMOylation of p53 occurs on K386, however its biological significance remains unclear 
as it has been shown to both positively and negatively regulate p53 function (226, 303-  42 
305). Since these modifications affect the same lysines it is possible that they can inhibit or 
potentiate each other.  
p53 stability and activity is also regulated by the acetylation on C-terminal lysines 
by p300/CBP and PCAF which activate p53-mediated transcription  PCAF acetylates p53 
at K320 and p300/CBP heterodimers are recruited to the N-terminus of p53 and acetylates 
p53  on  C-terminal  lysines  (K370,  K372,  K373,  K381,  K382,  K386)  (54,  306-308). 
Acetylation  of  p53  is  regulated  by  deacetylaton  by  HDAC-1  (histone  deacetylase1)-
containing  complex  or  by  Sir2a  (silent  information  regulator  2α)  (309,  310).  The  C-
terminal lysines are also used for ubiquitination (299) and acetylation of these lysines has 
been proposed to compete with ubiquitination (311). Acetylation inhibits ubiquitination 
and  stabilizes  p53,  whereas  deacetylation  of  p53  results  in  its  ubiquitination  and 
degradation. Similarly to acetylation, methylation of lysine 370 by SET9 also leads to 
stabilization of p53 and upregulation of its target genes (312).  
The  physiological  significance  of  the  C-terminal  lysines  has  recently  been 
addressed in two studies which generated the knock-in mice with substitutions of 6 or 7 C-
terminal lysines of p53 with arginines. Surprisingly, p53-7KR or p53-6KR mice develop 
normally and only have a mild phenotype, which proposes their role in fine-tuning the 
response  of  p53  (313,  314).  This  suggests  the  C-terminal  lysines  are  not  required  for 
regulation of the stability of p53 and other lysines can be the targets of ubiquitination. 
Consistent with this, significant amount of Mdm2-dependent ubiquitination of p53-6KR 
has been detected (299), suggesting that other lysines can be used when the C-terminal 
lysines are not available. It is possible to envision that ubiquitination is quite promiscuous 
and if the primary lysines are removed, ubiquitin ligase moves to the other lysines. In fact, 
p53 protein contains 20 different lysines, which can potentially be used for the ubiquitin 
conjugation.  
 
1.4.3.4 Regulation of p53 stability by proteins interacting with p53 and Mdm2.  
In  addition  to  modifications,  p53  and  Mdm2  interacting  partners  can  regulate 
Mdm2-mediated ubiquitination and degradation of p53 and are summarized on Table 1.1. 
Several factors appear to contribute to efficient ubiquitination and degradation of p53 by 
Mdm2. p300, a transcriptional co-activator, has been suggested to act as E4 in Mdm2-
mediated ubiquitination of p53. In in vitro system, when Mdm2 can only monoubiquitinate 
p53, p300 acting together with Mdm2 can further polyubiquitinate p53. In cells, p300 has 
been shown to play an important role in p53 turnover (315). Several other proteins promote 
ubiquitination by binding to Mdm2 and/or p53, such as: YY1 (316, 317), gankyrin (318) 
and MTBP (319) (Table 1.1A). Gankyrin, an ankyrin repeat protein, interacts with Mdm2   43 
and  enhances  the  p53-mediated  ubiquitination  and  degradation  (316,  317).  The 
transcription factor YY1 binds to both p53 and Mdm2 and facilitates their interaction, 
promoting  the  ubiquitination  of  p53  (316,  317).  Consistent  with  their  role  as  negative 
regulators  of  p53,  gankyrin  is  often  overexpressed  in  hepatocellular  carcinomas  (320), 
whereas YY1 has been found to be overexpressed in several types of tumours (321). These 
studies  suggest  that  factors  such  as  YY1  and  gankyrin  promote  Mdm2-mediated 
ubiquitination  by  facilitating  the  binding  of  p53  and  Mdm2.  Another  co-factor  of 
ubiquitination MTBP was identified in a yeast-two-hybrid screen as an Mdm2-binding 
protein and promotes ubiquitination of p53 by Mdm2 in a different way. It interacts with 
Mdm2 and inhibits autoubiquitination of Mdm2, resulting in stabilization of Mdm2. This 
results  in  increased  ubiquitination  and  degradation  of  p53  (319).  However,  the  early 
embryonic lethality phenotype of inactivation of MTBP is not rescued by the simultaneous 
loss of p53 leaving the physiological relevance of the MTBP unclear (322). It is possible   
that these co-factors play an important role when Mdm2 levels are less abundant, and their 
physiological relevance remains to be elucidated.  
Table 1.1 Proteins interacting with Mdm2/p53 and affecting ubiquitination. 
A. Binding partners which promote ubiquitination. 
Protein  Description  Binding   effect  ref 
gankyrin  Ankyrin repeat 
protein 
Binds to Mdm2 
and facilitates 
p53/Mdm2 
binding 
Enhances ubiquitination 
and degradation of p53 
(318) 
YY1 (Yin 
Yang1) 
Transcription 
factor 
Binds to Mdm2 
and p53 
Enhances ubiquitination 
and degradation of p53 
(316, 
317) 
P300  Transcriptional 
coactivator 
Binds Mdm2 and 
p53 
E4, polyubiquitinates p53  (315) 
MTBP  Mdm2 binding 
protein 
Binds to Mdm2  Enhances ubiquitination 
and degradation of p53, 
but not Mdm2 
(319) 
B. Binding partners which inhibit ubiquitination. 
Protein  Description  Binding   effect  ref 
ARF  Alternative 
reading frame 
product of ink4a 
locus 
Interacts with 
Mdm2 
Inhibits E3 activity of 
Mdm2, leads to 
stabilization of p53 
(121) 
L11, L5, 
L23 
Ribosomal 
proteins 
Interact with 
Mdm2 
Inhibits E3 activity of 
Mdm2, leads to 
stabilization of p53 
(137, 
263, 
323) 
Numb  Notch 
antagonizer 
Binds Mdm2  Inhibits  (324, 
325) 
TSG101  tumour 
susceptibility 
gene 
Binds Mdm2 and 
p53 
Inhibits autoubiquitination, 
downregulates p53 
(326)   44 
In addition to ARF and ribosomal proteins mentioned above, other proteins inhibit 
Mdm2-mediated  ubiquitination  and  lead  to  stabilization  and  activation  of  p53  (Table 
1.1B). Recent report shows that the Numb protein, Notch antagonizer, which plays a role 
in cell fate and differentiation, can enter a tricomplex with p53 and Mdm2 and inhibit 
ubiquitination of p53. Numb seems to play an important role in tumour development, as it 
is frequently lost in breast cancers leading to inactivation of p53 pathway (324). It is worth 
mentioning another regulator of Mdm2 - TSG101 (tumour susceptibility gene). TSG101 
physically interacts with both p53 and Mdm2 and leads to inhibition of autoubiquitination 
of Mdm2, elevating its protein levels. This is associated with the downregulation of p53 
protein (326), suggesting that TSG101 does not inhibit E3 activity of Mdm2 towards p53. 
tsg101 knock-out mice embryos die at day 6.5 which is partly due to accumulation of p53 
(327). However, inactivation of TSG101 results in transformation of NIH 3T3 cells and 
their ability to generate metastatic tumours in nude mice (326), which is inconsistent with 
the negative role of TSG101 in regulation of p53 and the reason is not clear. The existence 
of  multiple  positive  and  negative  regulators  might  provide  the  way  to  differentially 
regulate p53/Mdm2 pathway in response to various stresses and cellular context. 
In addition to its ubiquitin ligase activity, Mdm2 has been suggested to play a role 
at the post-ubiquitination step. Acidic domain of Mdm2 might play a role in this function, 
as some acidic domain mutants of Mdm2 retain the ubiquitin ligase activity, but fail to 
degrade p53 (328-330). The details of such function of Mdm2 are not clear and could 
involve  the  interaction  with  hHR23A  (Rad23)  protein.  However,  there  is  a  certain 
discrepancy  in  the  role  of  hHR23  in  p53  degradation,  with  one  report  suggesting  that 
hHR23A  blocks  the  entry  of  p53  to  the  proteasome (330)  and  the  other  showing  that 
hRH23 delivers p53 to the proteasome and promotes its degradation (331).  
The  important  role  of  Mdm2  in  antagonizing  p53  is  reflected  in  its  frequent 
overexpression in human cancers. Mdm2 gene is amplified in about 7% of human tumours, 
most frequently in sarcomas (30-40%) and is overexpressed in leukemias (332-336). In a 
subset of tumours the overexpression of Mdm2 is mutually exclusive to inactivation of 
p53, suggesting it can functionally substitute for loss of p53 function.  
A  more  recent  study  suggests  that  single  nucleotide  polymorphism  within  the 
Mdm2 promoter can lead to increased susceptibility to cancer in population. This study 
shows that SNP309 in Mdm2 promoter can lead to increased affinity for the transcription 
factor SP1, which results in higher levels of Mdm2 mRNA and protein. This can result in 
attenuation of p53 pathway and is associated with an increased cancer incidence (337, 
338).    45 
p53/Mdm2 pathway can also be regulated by deubiquitination. The deubiquitinase 
HAUSP  (Herpes  virus-associated  ubiquitin-specific  protease)  was  originally  shown  to 
deubiquitinate p53 in vitro and in vivo and stabilize p53 protein (215). However, another 
report has demonstrated that disruption of HAUSP leads to p53 accumulation (214, 339). 
Later it has been realized that the interplay between p53, Mdm2 and HAUSP is complex, 
as the primary target of HAUSP is Mdm2, and HAUSP deubiquitinates Mdm2 in vitro and 
in vivo (340). This seems to be required for maintaining a sufficient level of Mdm2 to act 
as  a  ubiquitin  ligase  on  p53.  In  addition  to  HAUSP,  another  deubiquitinase  of  Mdm2 
Usp2a play an important role in regulation of stability of p53. Usp2a has been identified in 
bacterial two-hybrid screen. Usp2a selectively deubiquitinates Mdm2 in cells, but does not 
have deubiquitinating activity towards p53. Downregulation of Usp2a destabilises Mdm2 
and  leads  to  accumulation  of  p53,  whereas  overexpression  of  Usp2a  stabilises  Mdm2, 
which degrades p53 (341). Deubiquitinating p53 can provide a quick way for stabilizing 
p53 in response to stress, however a p53-specific deubiquitinase is yet to be found.  
 
1.4.4  Other ubiquitin ligases. 
Mdmx is another important regulator of p53, structurally related to Mdm2, and has 
been identified as a product of extrachromosomal amplification similarly to Mdm2 (342). 
Mdmx  shows  significant  homology  to  Mdm2,  including  the  N-terminal  p53-binding 
domain  and  C-terminal  RING  finger  domain  (343).  Despite  similarity  between  RING 
domains Mdmx does not possess the intrinsic ubiquitin ligase activity. Mdmx interacts 
with the N-terminus of p53 similarly to Mdm2 (344), however fails to ubiquitinate p53 and 
does not target p53 for degradation (345, 346). Mdm2 and Mdmx heterodimerize with each 
other  (347)  and  Mdmx  can  cooperate  with  Mdm2,  contributing  to  its  ubiquitin  ligase 
activity (270) when overexpressed in cells. At physiological levels Mdmx has been shown 
to play an important role in negative regulation of p53 activity. This has been demonstrated 
by  the  rescue  of  embryonic  lethal  phenotype  of  Mdmx-/-  mice  by  simultaneous 
inactivation  of  p53  (348-350).  These  studies  have  suggested  that  Mdm2  can  not 
compensate for the loss of Mdmx and they might have distinct roles in regulation of p53. 
The  recent  study  of  roles  of  Mdm2  and  Mdmx  done  with  mice  with  conditional  p53 
expression suggests that Mdmx inhibits the transcriptional activity of p53 independently of 
Mdm2, whereas Mdm2 is required for regulation p53 protein levels (351, 352). Loss of 
Mdmx does no lead to accumulation of p53, suggesting that Mdmx does not regulate p53 
stability (351, 352). However, the effect of Mdmx on downregulation of p53 protein can be   46 
masked by Mdm2-mediated degradation due to an increase in transcriptional activity of 
p53. Further analysis is needed to resolve the role of Mdmx in regulation of p53 stability. 
Other E3 ligases which can ubiquitinate p53 independently of Mdm2 have been 
reported.  Their  number  is  constantly  growing  and  the  currently  known  p53-specific 
ubiquitin ligases are summarized in Table 1.2. The first discovered ubiquitin ligase acting 
on p53 was E6-AP (E6-associated protein). E6-AP ubiquitinates and degrades p53 in cells 
infected with oncogenic HPV (human papilloma virus) where it forms complex with the 
viral  protein  E6  (353).  Other  ubiquitin  ligases  have  also  been  discovered  (Table  1.2). 
These include  Pirh2 (84), Cop1 (83), TOPORS (178, 354), ARF-BP1 (185),  
 
Table 1.2. p53 ubiquitin ligases. 
 
Ubiquitin ligase  Class  function  reference 
Mdm2  RING  Mono and polyubiquitination, degradation, 
nuclear export 
(175) 
Mdmx  RING  Does not ubiquitinate p53, inhibits 
transcriptional activity of p53 
(345, 346) 
Pirh2  RING  Ubiquitination and degradation   (84) 
Cop1  RING  Ubiquitination and degradation  (83) 
ARF-BP1/ 
HectH9/ 
MULE 
HECT  Ubiquitination and degradation.  (185) 
E6-AP  HECT  Ubiquitination and degradation  (181) 
CHIP  U-box  Ubiquitination and degradation  (355) 
Cullin7   RING  Mono- and di-ubiquitination; reduces 
transactivation of p53 
(356) 
E4F1  atypical  K48 ubiquitination, modulates p53 activity 
to induce growth arrest 
(101) 
Synoviolin  RING  Ubiquitination and degradation, sequesters 
in the cytoplasm 
(357) 
WWP1  HECT  Ubiquitination, accumulation of p53 in the 
cytoplasm 
(358) 
Topors  RING  Ubiquitination and degradation  (178) 
Carps  RING  Ubiquitination and degradation  (359) 
 
Synoviolin (360), Carps (361) and CHIP (C-terminal of Hsp70-interacting protein) (355),  
WWP1 (358), E4F1 (101) and Cullin 7 (356). They belong to different classes of ubiquitin  
ligases and all can ubiquitinate p53 independently of Mdm2. Similarly to Mdm2, Pirh2 and 
Cop1 are p53 target genes  and both belong to the RING family of ubiquitin ligases (83, 
84). ARF-BP1/HectH9/Mule, a HECT-domain ubiquitin ligase, was purified as a major 
ARF-binding protein from p53-null cells. However, ARF-BP1 has been shown to bind and 
ubiquitinate  p53  (185).  ARF  interacts  with  ARF-BP1  and  inhibits  its  ubiquitin  ligase   47 
activity, suggesting it could control p53 in response to oncogenes activation. Synoviolin 
and CHIP are ER-associated ubiquitin ligases. Synoviolin ubiquitinates p53 and sequesters 
it  in  the  cytoplasm  and  could  be  involved  in  response  to  ER  stress  (357).  CHIP  can 
ubiquitinate and degrade p53 bound by the chaperones Hsp70 and Hsp90, suggesting it 
degrades the misfolded p53 protein (355, 362). Most of these ubiquitin ligases affect the 
stability of p53, with the exception of E4F1, which changes the transcriptional activity of 
p53 without affecting its proteolysis (101). TOPORS has been reported to conjugate both 
ubiquitin and SUMO to p53, however, the biological output of this is not clear (222). Some 
of the ubiquitin ligases as CHIP, Synoviolin, Cullin-7 reside in the cytoplasm, suggesting 
they contribute more to regulation of cytoplasmic p53. p53 has also been shown to undergo 
K63-linked ubiquitination mediated by an E2 ubiquitin-conjugating enzyme Ubc13, which 
increases  p53  stability  and  leads  to  its  cytoplasmic  localization  (363).  Other  ubiquitin 
ligases and their function are much less well characterized and are listed in the table. A 
variety of ubiquitin ligases targetting p53 may be necessary to specifically regulate p53 in 
response to different types of stresses, however their biological significance needs to be 
validated. 
 
1.4.5  Ubiquitin‐independent mechanism of p53 degradation. 
In addition to ubiquitination-mediated degradation of p53 in 26S proteasome, p53 
can also be degraded directly by 20S subunit of the proteasome, which does not require its 
prior ubiquitination (242). Several other proteins have been shown to be degraded via the 
the ubiquitin-independent pathway (241, 243, 364). This mechanism is regulated by NQO1 
(NAD(P)H quinone oxidoreductase 1) which is associated with 20S proteasome, where it 
is proposed to act as a gate-keeper. NQO1 has been shown to interact with p53, which 
prevents the degradation of p53 by 20S. DNA damage signals increase the association of 
p53  with  NQO1,  which  can  contribute  to  stabilization  of  p53 (242,  365).  However,  it 
seems that ubiquitin-independent mechanisms plays a minor role in p53 stabilization in 
cells, as p53 is stabilized in the absence of Mdm2 during embryogenesis and in cells, when 
binding of Mdm2 to p53 is prevented. 
 
1.4.6  Regulation of p53 localization. 
In  addition  to  degradation,  p53  activity  can  be  modulated  by  regulation  of  its 
localization (366). It appears that p53 shuttles during the cell cycle locating to the nucleus 
during  G1  and  G1/S  and  to  the  cytoplasm  in  the  S  phase  (367).  p53  is  known  to  be   48 
regulated by nuclear import and nuclear export mechanisms (368). There are three NLSs in 
the C-terminus of p53, of which the most active one is the bipartite NLS, which consists of 
two basic motifs K305-306 and K316-322 and a spacer between them (369). p53 contains  
two  CRM-1  dependent  nuclear  export  signals  (NES)  in  the  N-terminus  and  in  the  C-
terminus (11-27aa, 340-351aa respectively) (157, 370). Several studies suggest that nuclear 
export of p53 is mediated mainly via c-NES (157, 224, 371). c-NES resides within the OD 
of p53  and is masked when p53 is a tetramer. Ubiquitination of C-terminus of p53 results 
in exposure of c-NES of p53, leading to its relocation to the cytoplasm (157, 224, 371). 
When Mdm2 levels are low, Mdm2 monoubiquitinates p53 and leads to its nuclear export 
(251, 372-374). The current model suggests that ubiquitination of p53 by Mdm2 promotes 
further modifications of p53 by other E3, such as PIASγ, which leads to release of Mdm2 
and nuclear export of p53 (224). In addition, p53 can be exported in Mdm2-independent 
manner as demonstrated by a p53 mutant, which cannot interact with Mdm2 but undergoes 
nucleocytoplasmic shuttling (157).  
p53 has been also reported to be sequestered in the cytoplasm by interaction with 
other proteins. Parc – Parkin-like ubiquitin ligase – forms a stable 1 MDa complex with 
p53 in the cytoplasm (375). Parc has an intrinsic ubiquitin ligase activity, however it fails 
to  ubiquitinate  p53.  Parc  binds  to  the  C-terminus  of  p53  and  sequesters  p53  in  the 
cytoplasm, by masking p53 NLS and therefore blocking p53 nuclear import (375). Another 
ubiquitin ligase WWP1 has been reported to ubiquitinate p53 and increase its cytoplasmic 
localization,  leading  to  inactivation  of  p53  (358).    Another  report  suggests  that  E2-
conjugating enzyme Ubc13 can promote ubiquitination and cytoplasmic localization of 
p53 (363). Interaction with an Hsp70 family member, Mot2, can also tether p53 in the 
cytoplasm and inhibit its nuclear import (376). Relocation of p53 to the cytoplasm can 
represent the means of inhibiting transcriptional activity of p53 by keeping it away from its 
target  genes  or  by  degrading  in  cytoplasmic  proteasomes.  It  may  also  promote  the 
cytoplasmic function of p53 in inducing apoptosis, which is still a subject of extensive 
investigation (377-379). 
Many neoplasms display cytoplasmic wild type p53 suggesting it is the way of 
inactivation of p53 function (380-384). In neuroblastomas p53 is virtually exclusively wild 
type and is sequestered in the cytoplasm (382). It has been found that p53 translocates to 
the  cytoplasm  due  to  enhanced  nuclear  export  and  is  sequestered  in  the  cytoplasm  by 
binding to Parc in cell lines derived from neuroblastomas. Inactivation of Parc can restore 
nuclear localization of p53 and cause p53-dependent apoptosis in neuroblastoma cell lines 
(375).  
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1.5  p53‐like proteins. 
 
1.5.1  p53 isoforms. 
The  human  p53  gene  is  composed  of  19,  200  bp,  spanning  over  11  exons  on 
chromosome 17p13.1 (NC_000017). Until recently only 3 mRNA splice variants of p53 
have  been  known,  which  encode  full-length  p53,  p53i9  (385)  and  p53Δ40  (386,  387). 
p53i9 results from alternative splicing at exon 9 and encodes a protein truncated of the last 
60 amino acids, which is defective in transcriptional activity. p53Δ40 (other names p47 
and ΔNp53) protein is truncated of the first 40 amino acids and can be generated by two 
mechanisms:  either  by  an  alternative  splicing  of  the  intron  2  (387)  or  by  alternative 
initiation of translation (386). p53Δ40 contains the second transactivation domain and is 
capable  of  activating    some  of  the  p53  target  genes.  Interestingly,  it  can  also  inhibit 
transcriptional activity of the full-length p53 in a dominant-negative way (387). A recent 
study reports that the structure of the p53 gene is much more complex than previously 
thought  and  many  more  p53  isoforms  exist  (388).  The  structure  of  p53  gene  and  the 
currently known p53 isoforms are summarized on Figure 1.9. The p53 gene is transcribed 
from two distinct sites upstream of exon 1 and from an internal promoter located in intron 
4.  The  alternative  promoter  leads  to  the  expression  of  an  N-terminally  truncated  p53 
(Δ133p53), which lacks the entire TA domain and part of the DNA binding domain. Usage 
of alternative promoter in intron 4 gives rise to Δ40p53 with truncation of N-terminal 
FIGURE 1.9. Human p53 gene.  
The structure of p53 gene and the alternatively spliced p53 isoforms are depicted. 
(Adopted from Murray-Zmijewski, F., D. P. Lane, et al. (2006). Cell Death Differ 
13(6): 962-72).  
   50 
transactivation domain. In addition alternative splicing at intron 9 gives rise to α, β and γ 
isoforms.  Therefore  at  least  9  different  isoforms  of  p53  can  be  generated.  These  p53 
isoforms have been shown to be expressed at both mRNA and protein levels. It was found 
that  p53  isoforms  have  different  subcellular  localisations,  suggesting  the  possibility  of 
differential regulation of their activities. p53 isoforms, like p63 or p73 isoforms, have 
distinct  transactivation  functions.  p53β  binds  preferentially  to  the  p53-responsive 
promoters p21 and Bax, rather than Mdm2, and can specifically enhance the transcriptional 
activity of full-length p53 at Bax promoter in response to cellular stress. This leads to an 
interesting interplay between p53 isoforms where p53-mediated apoptosis is increased by 
p53β, which can be inhibited by the action of Δ133p53 (388). Many of the p53 isoforms 
are differentially expressed in normal human tissues, which explain the mechanism of the 
tissue-specific regulation of p53 transcriptional activity. This suggests that deregulation of 
p53 isoforms could be another way to down-regulate p53 function in cancers. Indeed, head  
and  neck  and  some  breast  tumours  show  abnormal  expression  of  p53  isoforms  (389). 
Transactivation-capable  isoform  p53β  is  lost,  whereas  dominant-negative  Δ133p53 
isoform  is  overexpressed  frequently  in  breast  tumours,  consistent  with  their  tumour-
suppressive  and  oncogenic  functions  respectively.  The  differential  expression  of  p53 
isoforms can also alter drug sensitivity of some human cancers which retain wild type p53 
(141, 389). 
 
1.5.2  p53 family members.  
p53  family  members  p63  (390)  and  p73  (391)  show  significant  structural  and 
sequential  homology  to  p53,  and  are  even  more  similar  to  each  other.  Sequence 
comparison  suggests  that  p63  and  p73  are  evolutionary  more  ancient,  as  the  p53-like 
protein in lower species is more similar to p63 and p73. Both proteins retain some of the 
p53 functions, but also play distinct roles during development. p63 and p73 contain three 
functional domains with significant amino acid sequence homology to those of p53: DNA 
binding  domain  (65%  homology)  with  most  of  the  structural  and  contact  residues 
conserved, N-terminal domain (25%), and oligomerization domain (35%). p63 and p73 
also have a unique sterile alpha motif (SAM) domain within their C-termini, which is 
involved in protein-protein interactions (392-394). Similarly to p53, p63 and p73 can be 
upregulated by oncogenes and DNA damage and both function as transcription factors and 
can upregulate many of the p53 target genes and induce growth arrest and apoptosis (102, 
395-399). There are some target genes, which are differentially regulated by p53 family 
members (400, 401).    51 
However, unlike p53, both p63 and p73 are necessary for normal development. 
Original  studies  have  shown  that  p53-null  mice  are  viable  and  do  not  have  any  gross 
developmental abnormalities (45, 46), although small developmental defects have been 
noticed. A fraction of female p53-null embryos show exencephaly due to the failure of the 
closure of the neural tube (402) and some p53-null animals have a reduced fertility (403). 
p73-null mice suffer from different neurological abnormalities, such as hydrocephalus and 
hippocampus dysgenesis, and inflammatory defects and die within the first two months 
(404). p63 knock-out mice have the most severe phenotype: they are born alive but do not 
survive beyond a few days postnatally due to severe abnormalities in development (390). 
Their limbs are truncated or absent and they also display craniofacial malformations. The 
skin  of  p63-null  mice  does  not  progress  past  an  early  developmental  stage  and  lacks 
stratification. This severe phenotype suggests p63 plays an essential role in ectodermal 
differentiation during early embryogenesis (390).  
In all studied adult tissues p73 is expressed at very low levels with differential 
expression of some isoforms. The expression of p63 is restricted to the nuclei of basal cells 
of normal epithelia (skin, prostate, esophagus) and also to some populations of basal cells 
of glandular structure (prostate, breast, bronchi) (394). 
Both p63 and p73 are expressed as multiple isoforms due to usage of different 
promoters and alternative splicing (391, 405). The two promoters give rise to full-length 
transcriptionally active TA isoforms and N-terminally truncated ΔN isoforms, which act as 
dominant  negative  inhibitors  of  all  full-length  members.  Both  p63  and  p73  undergo 
additional splicing at the C-terminus, which generates at least 9 forms of p73 (α, β, γ, δ, ε, 
ζ, η, η1, φ) and 3 for p63 (α, β, γ).  Structurally, γ isoforms are the most similar to p53, 
harbouring a small C-terminal extension beyond the last 30 amino acids stretch of p53. 
ΔNp73 seems to be the most highly expressed isoform in the brain, suggesting differential 
expression of isoforms in tissues (394, 406).  
N-terminally truncated (ΔN) isoforms of p63 and p73, which are also present in all 
possible C-terminal variations, lack the TA domain and are incapable of inducing gene 
expression (406, 407). However, ΔN isoforms oligomerize with TA isoforms of p63 and 
p73, and inhibit their transactivation ability in a dominant-negative effect, promoting cell 
survival. In addition, ΔNp73 inhibits p53 transactivation ability. This seems to occur via 
competition  for  the  same  DNA  binding  sites  (408).  Interestingly,  p53  and  TAp73  can 
induce  the  expression  of  ΔNp73  through  p53-responsive  element  in  its  promoter,  in  a 
negative feedback loop (409, 410).    52 
Despite having functional similarities to p53, p63 and p73 are rarely mutated in 
cancers (<1%) (392, 393). Their role in cancers appears to be more complicated due to 
existence of TA and ΔN isoforms which can have opposing effects on tumour progression. 
The current knowledge suggests that TA isoforms can play a tumour-suppressive role, 
whereas ΔN isoforms can be oncogenic by inhibiting TA isoforms (411, 412). p63 gene 
maps  to  chromosome  3q27-28  region,  which  is  frequently  amplified  in  squamous  cell 
carcinomas  (413),  though  it  is  not  clear  whether  it  is  the  targeted  gene  driving  the 
amplification in this locus. Numerous studies have shown that p63 is overexpressed in 
nearly 80% of primary head and neck squamous carcinomas and in some other types of 
epithelial  cancers  due  to  genomic  amplification  or  other  mechanisms  (392).  The  early 
studies  of  p63  expression  did  not  discriminate  between  the  different  isoforms.  Recent 
approach  using  the  isoform-specific  RT-PCR  has  shown  that  TAp63  mRNA 
overexpression  is  a  rare  event  and  ΔNp63  is  the  predominant  form  in  squamous  cell 
carcinomas. However, at later stages of tumour development the p63 expression seems to 
be  unfavourable  and  is  often  lost  with  progression  to  invasion  and  metastasis,  which 
correlates with poor prognosis (414).  
Like p63, p73 has been supposed to play a tumour suppressor role, based on its 
relation to p53 and the fact that its cytogenetic locus 1p36.33 is commonly deleted in a 
variety of cancers (391). Overexpression of p73 mRNA and/or protein has been shown in a 
large variety of tumour types, suggesting oncogenic role for p73. The only exception is 
lymphoid malignancies, where p73 is often silenced due to hypermethylation (392). Recent 
studies, which analyzed isoform-specific expression of p73, have found that both ΔN and 
TA-isoforms are upregulated in tumours compared to normal tissues (412, 415). However, 
the exact functions of overexpressed p63 and p73 isoforms in cancers and the extent of 
their contribution to tumour development are still unclear. 
In addition to their regulation at transcriptional level, p63 and p73 are subjected to 
regulation at the level of protein stability. Like p53, p73 protein turnover is mediated by 
proteasomal degradation, as shown by stabilization of p73 isoforms by the proteasome 
inhibitors (416). All three p53 residues essential for binding to Mdm2 (F19, W23 and L26) 
are conserved on both TAp63 and TAp73. Mdm2 binds to N-terminus of TAp73, however 
it fails to ubiquitinate or degrade it (416-418). This may be due to the absence of C-
terminal  lysines  on  p73,  which  are  preferentially  targeted  by  Mdm2  on  p53.  Motif-
swapping  experiments  have  also  shown  that  region  of  93-112aa  of  p53  which  is  not 
conserved  in  p73  could  be  the  reason  for  resistance  to  degradation  by  Mdm2  (419). 
However, the interaction with Mdm2 inhibits the transcriptional activity of p73 (416-418).    53 
Other  ubiquitin  ligases  have  been  found  to  interact  with  p63  and  p73.  NEDL2 
(NEDD4-related protein), a HECT-domain ubiquitin ligase, has been identified as a protein 
interacting with the C-terminal proline-rich region of p73. NEDL2 efficiently ubiquitinates 
p73, although this leads to stabilization of p73, rather than proteolysis, and enhances the 
p73-dependent  transcriptional  activation  (420).  Another  NEDD4-related  HECT-domain 
ubiquitin ligase Itch has been shown to regulate the protein degradation of both p63 and 
p73 (421, 422). Itch interacts with the proline-rich domains of TA and ΔN isoforms of p63 
and p73, ubiquitinates and targets them for degradation, however does not degrade p53. 
Itch regulates p63 and p73 protein levels both in normal and in stress conditions. p73α but 
not  p73β  can  be  sumoylated  on  lysine  627  and  this  has  been  shown  to  potentiate  its 
proteasomal degradation (423). This modification seems to be specific for p73α and not 
other splice variants, suggesting possible differential regulation of the isoforms.  
It is emerging that p63 and p73 have an important role in cancer development, 
however  their  contribution  is  complex  due  to  existence  of  TA  and  ΔN  isoforms  with 
opposing  functions.  Generation  of  isoforms-specific  knock-out  mice  would  help  to 
understand the functions of p63 and p73 in cancer. Recently the mice knock-out for TA 
isoforms of p73 have been generated (424). The mice have an intermediate phenotype 
between the p73-/- and p53-/- mice. Similarly to p73-/- mice TAp73-/- mice are infertile. 
In addition, TAp73-/- mice have mild defects in brain morphology. Interestingly, 30% of 
TAp73+/-  and  70%  of  TAp73-/-  mice  spontaneously  develop  tumors,  suggesting  that 
TAp73  isoforms  play  tumor-suppressive  role.  Interestingly,  TAp73-/-  mice  develop 
different spectra of tumors compared to p53-/-mice, suggesting differences in the roles of 
p73 and p53 in tumor suppression (424). 
 
1.6  Mutant p53. 
1.6.1  Mutations of p53 in cancer. 
 
1.6.1.1 Li-Fraumeni syndrome. 
Li-Fraumeni syndrome (LFS) is a rare inherited cancer predisposition syndrome, 
affecting individuals before the age of 45 years. Unlike other inherited cancer syndromes, 
LFS is characterized by a variety of different cancers, predominantly sarcomas, breast 
cancers, brain tumours and adrenocortical carcinomas, though other cancers have also been 
reported. LFS is dominantly-inherited and is associated with high mortality. Analysis of 
the LFS families has shown that around 70% of these families have a germline mutation in   54 
the p53 gene. Li-Fraumeni-like syndrome (LFL) describes a similar syndrome, which does 
not have all features of the classical LFS and similarly has been found to have germ-line 
mutations in p53 gene (44, 425, 426). In a few cases where no germline mutation in p53 
has been described, the mutation in Chk2 has been reported (427, 428). From the database 
information it is revealed that most of the p53 mutations are missense mutations (72%) and 
some are deletions (10%). About 46% of the mutations were located at the codons 175, 
213, 245, 248, 273 and 282 in the DBD of p53, which correspond to hotspot mutations in 
sporadic cancers (26). It should be noted however that most studies analyzed the mutations 
in  exons  5-8  and  therefore  were  biased  to  identify  the  mutations  in  the  DNA  binding 
domain.  There  is  some  correlation  between  the  type  of  the  mutation  and  the  type  of 
tumour. Moreover, the mutations within the DNA binding domain of p53 have generally 
more  cancers  and  at  younger  ages  than  families  with  null  mutations,  suggesting  a 
functional importance of type of the mutation in tumour progression in humans (27). 
 
1.6.1.2 p53 in sporadic cancers. 
As  already  mentioned,  p53  gene  is  found  mutated  in  nearly  half  of  all  human 
cancers analyzed. In many other types of cancers p53 pathway is inactivated by other 
ways, such as inactivation of ARF or overexpression of Mdm2. Unlike most of the tumour-
suppressor genes, more than 80% of the p53 alterations are missense mutations which lead 
to generation of full-length p53 with single amino acid substitution (26, 429, 430). The 
initial observations, which showed that p53 mutations are a frequent event in many tumour 
types, were made some twenty years ago (431-433). Those studies demonstrated that most 
of  the  mutations  are  localized  in  the  exons  5-8,  which  lead  to  a  single  amino  acid 
substitution of the DNA binding domain. Therefore most of the later studies (40% of all) 
have focused on the characterization of these mutations, which mostly affect the DNA 
binding domain. The database of p53 mutations has been updated and includes the analysis 
of some of the recent studies have found that mutations also occur outside exons 5-8 (about 
10%) (Fig.1.10) (26, 434).  The biochemical and functional consequences of the mutations 
can be described as heterogeneous, but most of the frequently found mutations inactivate 
the tumour-suppressive p53 function and confer novel oncogenic properties upon mutant 
p53.  
 
1.6.1.3 Structure of p53 mutations. 
The current version of the TP53 mutation database reports about 24000 different 
mutations most of which occur as single amino acid substitutions in the DNA binding 
domain of p53 (http://www-p53.iarc.fr). Most of the mutations locate within the highly   55 
evolutionary conserved regions of the DBD of p53 (boxes II-V). The hotspots of mutations 
are  codons  175,  245,  248,  249,  273  and  282  and  account  for  about  30%  of  all  p53 
mutations (Fig.1.10) (26, 429). The core domain of p53 is highly flexible and rapidly 
 
 
changes between folded and unfolded states, which can explain such high concentration of 
the mutations found in this domain (152, 435). Each residue in the DBD has been found 
mutated,  with  frequency  ranging  from  two  to  one  thousand  times.  There  are  several 
structural changes conferred by mutations on the DBD of p53. Many mutations alter the 
conformation of the DBD to a various degree and can lead to its unfolding (147, 435, 436). 
The change was originally described based on the reactivity with the wild type and mutant 
conformation-specific  antibodies,  pAb1620  and  pAb240  respectively.  The  pAb1620 
antibody is specific for wild type conformation and does not bind to mutant p53 with 
altered structure of the DBD (437). This antibody recognizes a specific structural motif on 
the surface of the core domain, which involves residues R156, Leu206, R209 and Asn210 
(438). The pAb240 antibody is directed against the cryptic epitope on the β-strand S7 
(213-217aa) which becomes accessible only upon unfolding of the region and recognizes 
many of p53 mutants, which originally suggested the change in the conformation (439). 
However, some of the commonly found p53 mutants retain wild type conformation and are 
not recognized by the unfolded-conformation specific antibody. Structural studies have 
characterized most of the hot spot p53 mutants (154, 440-443). These structural studies 
have shown that mutations can either affect the residue which directly contacts the DNA 
without the effect on the conformation of DBD or can alter the overall structure of the 
FIGURE 1.10. Mutational frequency of p53.  
The frequency of the point mutations of each codon of p53 found in tumors 
(IARC database, R12 release, 2006, www-p53.iarc.fr). 
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DBD (441, 442). Based on the reactivity with the conformation-specific antibodies and 
structural data, p53 mutants have been classified as either contact or structural mutants. 
Contact mutants usually have substitutions at residues R248 (to W or Q) and R273 (to C or 
H). These changes result in the loss of contact with the DNA and have only a minor effect 
on the thermodynamic stability of the protein. The structural changes are very localized 
and do not perturb the overall structure of the DNA binding domain (441). However, in 
some cases contact mutants can undergo some structural alterations and can exhibit the 
mutant-conformation specific epitope, and therefore are described as flexible (436). The 
structural mutations reduce thermodynamic stability of p53, causing it to unfold at body 
temperature both in vitro and in vivo. The L3 loop in the minor-groove-binding region is 
the site of the hotspot mutations G245S and R249S. G245S induces small conformational 
changes that weaken DNA binding. The R249S has more severe effect on conformation 
and results in substantial impairment of DNA binding and loss of stability (441). R175, 
located in the L2 loop is involved in the coordination of the zinc binding and is one of the 
most  frequent  sites  of  mutation,  R175H.  Although  there  is  no  structural  data  for  this 
mutant yet, it has been proposed that mutation R175H directly affects the zinc binding and 
is highly destabilizing, based on data for other mutants (147, 444). Mutation R282W has a 
destabilizing  effect,  though  causing  only  local  changes  in  conformation,  which  allows 
R282W  to  bind  some  promoters  at  a  subphysiological  temperature  (441).  All  these 
mutations of p53 result in significant loss of binding to its consensus site on DNA, which 
leads to an impaired transactivation ability.  
The discovery of temperature-sensitive p53 mutants has suggested that p53 cancer 
mutants can be pharmacologically rescued by conformational alterations. For example, 
V143A mutant is in mutant conformation and therefore inactive at 37°C, however is in 
wild type conformation and exhibits transactivation ability at 32°C (445, 446). Many other 
temperature-sensitive p53 mutants with similar properties have been isolated (447), that 
show transactivation activity at 30°C. The majority of these mutations cluster in the β-
sandwich region of DBD. This suggests that the conformation of the DBD of p53 mutants 
retains flexibility and can be folded as wild type. 
 
1.6.1.4 p53 polymorphism.  
In  addition  to  mutations,  a  common  polymorphism  is  found  in  the  proline-rich 
domain  of  p53  (R72  or  P72).  The  frequency  of  the  p53P72  allele  varies  between 
populations and is higher in populations living near the equator, which suggests that P72 is 
beneficial  in  the  environment  with  higher  UV  exposure  (448).  The  study  in  cells   57 
demonstrate that in fact R72 is more active in p53 tumour suppressor functions as assessed 
by the ability to induce apoptosis (449). In addition to DBD, the proline-rich region of p53 
contributes to binding to the ASPP family members. Recent study, showing that the anti-
apoptotic iASPP preferentially binds to and inhibits activity of p53P72 more efficiently 
than that of p53R72, which provides the mechanism for more potent induction of apoptosis 
by p53R72 (450).  
 
1.6.2  Properties of mutant p53. 
 
1.6.2.1 Interaction partners of p53 mutants.  
Mutations in the DNA binding domain can affect the interactions with proteins 
binding to p53. It has been long noted that many conformational p53 mutants can associate 
with the molecular chaperones Hsc70, Hsp70 and Hsp90 (41, 439, 451-454). The binding 
sites to the Hsp70 have been mapped and involve the β-sheets of the hydrophobic core of 
the central DNA binding domain, where the majority of the mutations are found (452). 
Mutant p53 bound to heat shock proteins Hsp70 and Hsp90 can be recognized by the 
ubiquitin ligase CHIP, which leads to its degradation (355, 455). Wild type p53 has also 
been reported to interact with the molecular chaperones though only transiently, and can 
also be degraded by CHIP, suggesting that wild type p53 can be unfolded in cells (355).  
ASPP family members bind to the core domain of p53 (103, 456). The crystal 
structure of the DNA binding domain of p53 and C-terminus of ASPP2 (53BP2) has been 
reported (104) and has shown that the binding site for ASPP2 overlaps the DNA-binding 
site. All six p53 hot spot mutants (175H, 245S, 248W, 248S, 273H, 282W) fail to bind to 
ASPP2 (104). The residues on p53 involved in direct contact with ASPP2 are R178, R181, 
M243 and N247 and are found mutated in cancer. Interestingly, p53 with mutation of the 
R181 (to L or K), found in cervical and breast tumours, retains the ability to induce cell-
cycle arrest, but fails to promote apoptosis (457). These mutations also impair the binding 
of p53 to ASPP1 and ASPP2 (105). 
Interestingly, p53 family members p63 and p73 can associate with hot spot p53 
mutants both in vitro and in vivo, but not with wild type p53 (458-464). This interaction is 
direct and involves the corresponding core domains of each protein (460, 461, 464). There 
is a correlation between the unfolded conformation of the DBD of p53 mutant, and the 
ability  to  interact  with  p63/p73,  based  on  the  reactivity  of  p53  with  the  “mutant” 
conformation  specific  antibody  (461).  However,  both  conformational  (R175H  and 
G245W) and contact (R248H) p53 mutants have been shown to interact with p63/p73. The   58 
ability  of  contact  p53  mutants  to  interact  with  p63/p73  might  reflect  some  structural 
distortions of DBD by contact mutations (436). Apart from the unfolded conformation of 
DBD,  there  are  other  structural  requirements  on  mutant  p53  for  interaction.  The 
polymorphism of mutant p53 at residue 72 P/R can affect the affinity of binding to p73 
(459,  463).  Mutant  p53  with  72R  associates  with  p73  more  efficiently,  than  p53  72P 
variant. Though there is not much known yet, several studies suggest the importance of the 
interaction  of  mutant  p53  with  p63  and  p73  in  malignancy.  Mutant  p53  inhibits  the 
transcriptional activity of p63/p73 and their ability to induce growth arrest and apoptosis, 
which has been proposed to contribute to its gain-of-function properties (458-464). This 
could be related to the direct binding of mutant p53 to the core domain of p63/p73, which 
might prevent their binding to DNA. Inhibition of p63/p73 by exogenous or endogenous 
mutant  p53  has  been  suggested  to  confer  chemoresistance  in  tumour  cell  lines,  which 
correlates with the ability of mutant p53 to bind p63/p73 (462). In further support of the 
biological  significance  of  the  interaction,  there  is  a  correlation  between  the  codon  72 
polymorphism in p53 mutants and the response of tumours to the chemotherapy, as shown 
by study of the head and neck cancers (463). The polymorphism 72R in mutant p53, which 
is  associated  with  better  binding  to  p63/p73,  in  many  cases  correlates  with  the  worse 
response to chemoradiotherapy.  
 
1.6.2.2 Loss-of-function. 
Biochemical studies have shown that p53 mutants exhibit certain heterogeneity in 
terms of structural alterations and loss of DNA-binding activity. The DNA-binding site 
recognized by p53 is highly degenerated and the affinity of p53 for target sites varies 
(465). Though many p53 mutants exhibit total loss-of-function, some p53 mutants retain 
partial transactivation ability. Tumour-derived point mutants p53175P and p53181L retain 
the ability to activate p21 and induce cell cycle arrest, however fail to induce other target 
genes, which impairs their ability to induce apoptosis (457). Mice homozygous for R172P 
mutation (equivalent to R175P in humans) are defective in p53-dependent apoptosis, but 
retain a partial cell cycle checkpoint function. Importantly, these mice have a delayed 
tumour onset compared to p53-/- mice indicating that cell cycle arrest partially contributes 
to tumour suppression, however the ability to induce apoptosis is needed to prevent tumour 
development  (466).  A  large-scale  study  of  over  2000  p53  mutants  with  an  attempt  to 
correlate  structure  and  transcriptional  activity  of  p53  was  conducted  in  a  yeast-based 
functional  assay  (467).  This  study  has  analyzed  all  possible  amino  acid  substitutions 
caused by a point mutation throughout the protein and indicates a strong correlation of p53 
structure and transactivation function and with frequency of the tumour-derived mutations.   59 
Most of the DNA binding mutations impair the ability of p53 to transactivate to a various 
extent. All p53 mutants most frequently found in cancers (such as R175H, R273H, R248H) 
exhibit a complete loss of the transactivation ability.  
In addition to loss-of-function, p53 mutants acquire cancer promoting properties 
(38, 39, 41, 468), which have been attributed to the ability of mutant p53 to inhibit wild 
type p53 in a dominant-negative  manner and by  gain-of-function effect. 
 
1.6.2.3 Dominant-negative effect.  
Overexpression studies in cells have shown that mutant p53 inhibits the function of 
wild type p53 acting in a dominant-negative manner (469-473). This results in interference 
with several p53-mediated biological processes, such as: apoptosis (474), growth arrest 
(475), differentiation (476), genetic stability (477) and transformation suppression (478, 
479). One of the explanations was that mutant p53 can induce a conformational change in 
wild type p53 (480). However, structural studies suggest that contact mutants do not have a 
gross  change  to  their  structure,  though  are  capable  of  inhibiting  wild  type  p53  when 
overexpressed (470, 472). The current mechanism of the dominant-negative effect suggests 
the formation of mixed tetramers of mutant and wild type p53 proteins, which reduces the 
level of fully active homotetramers of wild type p53 (469, 470, 472, 473, 481, 482). One 
report suggests that at least three mutant molecules are required per tetramer to inactivate 
the transactivation ability of p53 (483). This suggests that dominant-negative effects of 
mutant p53 can be biologically relevant only when the levels of mutant p53 are high.  
Indeed, recent studies of mutant p53 knock-in mice allele suggest that in normal cells 
expressing one wild type and one mutant allele derived from these animals, wild type p53 
retains its transactivation ability, suggesting that mutant p53 does not inhibit wild type p53 
at low levels (484, 485). It is possible that in tumour cells, where mutant p53 accumulates 
to high levels, it might lead to inhibition of the wild type p53. In the course of tumour 
progression the wild type allele is often lost (431, 484-488). This might imply that wild 
type p53 retains its function to some extent in the presence of mutant p53, as there is a 
selective pressure to lose it.  
 
1.6.2.4 Gain of function. 
Experimental systems on a p53-null background have demonstrated novel tumour-
promoting properties of mutant p53, which is known as “gain-of-function” effect. One of 
the early studies showed that mutant p53 expression in cells lacking p53 enhanced their 
tumourigenic potential (39). Mutant p53 can enhance the transformation potential of p53-
null cells as assessed by colony formation assay and leads to enhanced growth of the cells.   60 
Several studies have shown that exogenously expressed mutant p53 confers tumourigenic 
potential in several p53-null cell types : murine fibroblasts, murine L-12 pre-B cells and 
human osteosarcoma cell line (39, 489, 490). The increase in tumourigenic potential could 
be mediated via the increase in genomic instability. Several reports indicate that mutant 
p53  increases  genomic  instability,  which  could  underlie  the  ability  to  increase 
tumourigenic potential. This is reflected by impaired mitotic spindle checkpoint in Li-
fraumeni-derived fibroblasts expressing mutant p53 (491). Expression of mutant p53 in 
mouse fibroblasts following DNA damage leads to aberrant centrosome number (492) and 
in  Saos-2  cells  results  in  gene  amplification  (493).  Mutant  p53  also  enhances  colony 
formation upon overexpression in p53-null cells (492, 494-496) and increases proliferation 
of  these  cells  (496).  Another  gain-of-function  property  of  mutant  p53  is  the  ability  to 
interfere with the induction of apoptosis in response to various stress signals, such as DNA 
damage and growth factor deprivation when overexpressed in cells (497-502). However, 
most of these studies describe the role of the exogenous mutant p53. Studies showing that 
LFS-fibroblasts  exhibit  increased  resistance  to  apoptosis  in  response  to  UV  and  IR, 
compared to p53-/- cells, indicate that endogenous mutant p53 behaves similarly (491). 
Mutant  p53  actively  contributes  to  cancer  cells  proliferation,  chemoresistance  and  the 
ability to form tumours in mice, as evidenced by down-regulation of the expression of the 
endogenous  mutant  p53  in  various  cancer  cell  lines  (503-505).  However,  the  most 
convincing evidence for the gain-of-function effect is provided by the study of knock-in 
mice with “hot-spot” mutations in p53. p53 mutant mice with mutation at either R172H 
(equivalent to 175 in humans) or R270H (equivalent to 273 in humans), belonging to 
structural and contact class of hot-spot mutants respectively, have been generated (484, 
485). Both mutant p53 knock-in and p53-null mice develop tumours, however mutant p53 
knock-in  mice  exhibit  different  spectra  of  tumour  spectrum,  with  predisposition  to 
carcinomas and endothelial tumours. Tumours in mutant p53 knock-in mice display more 
aggressive phenotypes and metastasize with higher frequency. Further analysis of MEFs 
derived  from  mice  expressing  mutant  p53  has  shown  that  mutant  p53  confers  higher 
growth rate and increases transformation potential by Ras in MEFs derived from these 
mice  compared  to  p53-null  counterparts  (484).  Interestingly,  there  are  some  clear 
differences  in  tumour  spectra  between  172/+  and  270/+  mice.  172/+  mice  also  have 
increased  frequency  of  metastatic  osteosarcomas  compared  to  270/+  mice  (485).  This 
provides  evidence  for  functional  difference  between  contact  and  structural  classes  of 
mutants in tumour progression. These findings provide the most physiologically relevant 
evidence for the gain-of-function effect of certain p53 mutants (484, 485). The mechanism 
of the gain-of-function effect of p53 mutants has been proposed to be mediated via their   61 
interaction with p63/p73. In support of this, mutant p53 interacts with both p63 and p73 in 
the metastatic tumour cell line established from p53172/+ mice. Mutant p53 inactivates 
transcriptional activity of p63 and p73 in MEFs derived from these mice (484). Some of 
the phenotypes of the mutant p53 mice, such as increased metastasis, can be recapitulated 
in mice with only one copy of p53 and one copy of p63 and p73 (506), suggesting that the 
gain-of-function is mediated via inactivation of p63/p73. However, the exact mechanism of 
gain-of-function of mutant p53 is still unknown.  
Although mouse p53 gene is similar to human p53 gene, with 91% homology in the 
DNA  binding  domain,  the  existing  differences  prompted  the  researchers  to  develop  a 
humanized p53 knock-in (HUPKI) mouse model (507). HUPKI is composed mostly of the 
human sequence of p53 (amino acids 33-332) and has the murine p53 N- and C-termini. It 
is  considered  to  be  functionally  similar  to  mouse  p53  (507,  508).  Recent  study  has 
addressed the gain-of-function effects of p53 hot spot mutations (R248W and R273H) by 
introducing them into the HUPKI allele (509). In agreement with the studies described 
above, mice with R248W develop different tumour spectra compared to tumours in p53-/- 
mice,  providing  further  support  for  the  gain-of-function  effect.  Mutant  p53-expressing 
cells  also  exhibit  impaired  G2-M  checkpoint  after  DNA  damage.  The  gain-of-function 
effect of mutant p53 in this system has been attributed to the active disruption of the DNA 
damage-response pathway. This seems to occur via physical interaction of p53 mutants 
with the nuclease Mre11 in p53 mutant knock-in mouse cells and human cancer cells 
(509). The interaction inhibits the binding of the MRN (Mre11-Rad50-NBS1) complex to 
DNA double-stranded breaks, leading to the impaired activation of the ATM.  
Another mechanism of the gain-of-function of mutant p53 involves regulation of 
the expression of a specific set of genes. One of the first genes shown to be upregulated by 
mutant  p53  was  MDR-1,  which  was  suggested  as  a  mechanism  underlying 
chemoresistance promoted by mutant p53 (510). Mutation of L22 and W23, required for 
transcriptional activity of p53, abrogated the ability of mutant p53 to transactivate MDR-1 
and enhancement of tumourigenic potential of the cells by mutant p53 (511). This study 
has provided the evidence for transcriptional regulation mechanism of the gain-of-function 
of  mutant  p53.  Several  other  studies  have  show  that  p53  mutants  can  upregulate  the 
expression of genes involved in growth regulation, such as EGFR (512), PCNA (490) and 
c-Myc (501). Microarray analyses have shown that several p53 mutants can regulate the 
expression of genes involved in various processes, such as growth regulation, angiogenesis 
and  genomic  stability,  which  can  promote  tumour  development  (494,  497,  513-515). 
Another study suggests that CD95/Fas/Apo1 gene, encoding a death receptor is negatively 
regulated by mutant p53, which can contribute to its antiapoptotic activity (498). These   62 
studies  have  also  compared  different  p53  mutants  and  show  that  they  can  share  some 
transcriptional  targets,  however  they  may  possess  distinct  gain-of-function  phenotypes. 
Interestingly, mutant p53 can also increase NF-kB activity, which can play an important 
antiapoptotic  role  in  many  human  cancers  (514).  The  mechanism  of  how  mutant  p53 
regulates gene expression is not known. Mutant p53 is found at the promoters of its target 
genes (494, 497, 498), however, it is not known whether it can directly bind DNA. The 
mutant p53 consensus site has not been found so far. It is likely that mutant p53 is engaged 
in  protein  complexes,  which  target  it  to  specific  promoters.  A  recent  report  has 
demonstrated that mutant p53 associates with the transcription factor NF-Y and is recruited 
to the NF-Y target genes involved in regulation of cell cycle, such as cyclin A, cyclin B1 
and cdk1. Upon DNA damage, mutant p53 recruits p300 and upregulates the expression of 
these genes, leading to cell cycle progression  (503). Though it is possible, that mutant p53 
inhibits transcriptional function of p63 and p73, most of the target genes of mutant p53 do 
not  have  the  p53  consensus  sequence.  The  contribution  of  these  gain-of-function 
mechanisms to the tumour promotion by mutant p53 remains to be elucidated.  
 
1.6.3  Accumulation of mutant p53 protein. 
In the first studies describing p53 it was noted that p53 protein is highly expressed 
in many transformed cell lines, whereas in normal cells its expression is low (29-31, 516). 
Though wild type p53 is a short-lived protein in  normal cells, mutant p53 protein has 
increased half-life in transformed cells (41, 517, 518). High levels of mutant p53 protein in 
cancer cells has become a characteristic feature of cancers with mutant p53 (430, 432, 
488). This suggests the selection for overexpression of mutant p53 in the process of tumour 
development. Though many potential explanations have been suggested, it is still not clear 
why mutant p53 is stable in tumours. First, it was thought that mutant p53 is not degraded 
via normal mechanisms. However after Mdm2 was shown to bind and degrade mutant p53 
when overexpressed in cells (246, 519), the inability to transactivate Mdm2 was proposed 
to underlie the stability of mutant p53 proteins. Though this mechanism can account for 
stability of mutant p53 in some cases, the situation seems to be more complex. Recent 
studies  of  mouse  models  expressing  only  mutant  p53  show  that  while  mutant  p53 
accumulates in most tumours, it remains unstable in normal cells. In agreement with other 
reports, accumulation of mutant p53 does not correlate with the loss of heterozygocity 
(484, 485, 488). This suggests that mutant p53 protein is normally degraded in normal cells 
and therefore the failure to transactivate Mdm2 is not the underlying cause of mutant p53 
stability  in  tumours.  Further  supporting  this,  it  has  been  reported  that  mutant  p53   63 
accumulates to high levels in normal cells when Mdm2 is simultaneously inactivated in 
mice expressing mutant p53 (520). This suggests that Mdm2 can degrade mutant p53 in 
normal cells, but not in tumour cells.  Indeed, high levels of Mdm2 are found in many 
tumour cell lines that express high levels of mutant p53 (518). Another study shows that 
though Mdm2 interacts with mutant p53, it still fails to degrade the protein in some tumour 
cell  lines  (518).  It  is  possible  that  secondary  events  might  occur  during  tumour 
development, which contribute to stabilization of mutant p53. Given the gain-of-function 
effect, mutant p53 can be favorable for tumours, however particularly adverse for cancer 
patients. High levels of mutant p53 protein are often correlated with the worse clinical 
prognosis (521-529). Therefore studying how the stability of mutant p53 is regulated can 
help  to  understand  why  it  is  stable  in  tumours,  which  can  have  important  therapeutic 
implications.  
 
1.7  p53 and cancer therapy.  
Recent  studies  have  shown  that  similarly  to  “oncogenes  addiction”,  tumours 
depend on having p53 inactivated for their continued growth. Three recent mouse tumour 
models studies have shown that restoration of p53 function in established tumours causes 
regression of tumour growth and can be a potent way to treat cancers (530-532). One study 
has generated mice with switchable p53 in all tissues (531). In this system when p53 is 
inactivated  mice  develop  lymphomas  and  sarcomas.  Restoration  of  p53  leads  to  a 
pronounced  regression  of  both  types  of  tumours,  though  by  different  mechanisms  – 
apoptosis in lymphomas and cellular senescence in sarcomas. Interestingly, re-expression 
of p53 does not induce toxicity in normal tissues, suggesting that oncogenic environment 
of  the  tumour  is  needed  for  full  activation  of  p53  function  (531).  Another  group  has 
developed a mouse model of hepatocellular carcinoma with activated Hras, in which p53 
expression can be downregulated by switchable short hairpin RNA against p53 (530). The 
injection of Hras-expressing p53-inactivated cells into immunodeficient mice results in 
formation  of  invasive  hepatocarcinomas.  When  p53  function  is  restored,  even  if 
transiently,  tumours  completely  regress.  Similarly  to  sarcomas,  activation  of  p53  in 
hepatocellular  carcinomas  leads  to  induction  of  growth  arrest  with  signs  of  cellular 
senescence (530). Another study used the p53 knock-in mouse model where one gene is 
replaced by a switchable p53 gene on the background of Eµ-myc lymphoma mouse model 
(532).  In this system E-myc mice with one wild type p53 allele and one inducible p53 
allele develop B-cell lymphomas as they lose the wild type p53 allele. Switching on the 
remaining p53 allele causes tumour cell death and prolongs survival of the mice. However,   64 
the mice eventually succumb to tumours, which evade p53 action by loss of p19ARF or by 
deletion of the remaining p53 allele (532). Similarly to two other models this study shows 
that  though  p53  activation  in  tumours  can  have  an  important  therapeutic  benefit  in 
lymphomas, it can be quite short term, suggesting that efficiency of p53 activation might 
vary between tumour types. All in all these three studies strongly suggest the potential 
therapeutic benefit for p53 activation in tumours with inactivated p53. These studies have 
modelled  the  tumours  with  loss  of  p53,  however  the  interesting  question  of  whether 
tumours are arising with mutant p53 can regress upon inactivation of mutant p53, has yet 
to be investigated.  
One of the promising approaches for cancer therapy using p53 pathway has been 
gene  therapy.  The  delivery  of  p53  gene  in  an  adenovirus  vector  has  been  already 
implemented into clinical trials (533). However, specific targeting of the tumours might be 
quite challenging using this approach.  
Several other approaches have been used to activate wild type p53 in tumours (534, 
535).  The  most  successful  strategy  that  has  been  implemented  is  by  blocking  the 
interaction with Mdm2 (536). In about half of all cancers p53 remains wild type and many 
of these tumours overexpress Mdm2, which inactivates p53. Using synthetic peptides and 
protein aptamers it has been shown that inhibition of the interaction between p53 and 
Mdm2 can be used to activate p53 in cells which results in cell cycle arrest and apoptosis 
(276, 277, 344). This suggests that blocking the interaction between p53 and Mdm2 could 
be  implemented  for  cancer  therapy.  Targeting  protein-protein  interactions  by  small 
molecules has been considered difficult, however in the case of p53/Mdm2 only three 
amino  acids  of  p53  F19,  W23  and  L26  are  directly  involved  in  interaction  with  deep 
hydrophobic cleft on Mdm2, which allowed design of inhibitors mimicking the interaction 
(148). Recently highly specific small-molecule inhibitors of the interaction – nutlins - have 
been described which lead to efficient stabilization and activation of p53 in cells, resulting 
in  cell  cycle  arrest  and  apoptosis  (282).  Nutlins  were  identified  from  a  class  of  cis-
imidazoline compounds and can potently inhibit interaction of p53 and Mdm2 in vitro and 
in cells (282, 537). Structural studies have demonstrated that nutlins bind to the p53 pocket 
of Mdm2 and mimic the molecular interaction with p53. Interestingly, though binding 
region  of  Mdm2  is  well  conserved  in  Mdmx,  nutlin  does  not  potently  inhibit  the 
p53/Mdmx interaction (538).  
Nutlins activate p53 pathway with high specificity and only cells with wild type 
p53 are sensitive to these compounds (282). Importantly, treatment of normal fibroblasts 
with  nutlin-3  induces  cell  cycle  arrest,  whereas  cancer  cells  undergo  apoptosis  when 
treated at similar doses with nutlin-3a, suggesting nutlins can be promising candidates for   65 
cancer  therapy  (539).  Treatment  of  human  xenografts  with  nutlins  at  non-toxic  doses 
results in tumour shrinkage, suggesting promising cancer therapy (537).  
Several other inhibitors have been discovered. A class of benzodiazepine Mdm2 
antagonists have been reported to prevent the interaction of Mdm2 with p53 and have been 
shown to be able to suppress growth of cells with wild type p53, however they are much 
less  potent  than  nutlins  (540).  A  structure-based  design  study  has  identified  several 
compounds  with  a  spiro-oxinadole  core  structure,  which  can  potently  inhibit  the  p53-
Mdm2  interaction  in  vitro  (541).  These  compounds  have  been  shown  to  have  anti-
proliferative activity in cells with wild type p53, however their biological activity is not 
well characterized yet.  
Another compound that inhibits p53/Mdm2 interaction - RITA (reactivation of p53 
and  induction  of  tumour  cell  apoptosis)  -  has  been  discovered  based  on  cell-based 
screening with chemical library (542). RITA activates p53 and induces p53-dependent cell 
cycle arrest and apoptosis. In SCID mice RITA inhibits the growth of HCT116 human 
tumour  xenografts.  It  has  been  proposed  that  unlike  nutlins,  RITA  inhibits  p53/Mdm2 
interaction  by  binding  to  p53.  However,  the  mechanism  of  action  of  RITA  remains 
controversial,  as  NMR  structural  studies  reported  that  RITA  does  not  inhibit  the 
p53/Mdm2 interaction (543).  
Other routes to stabilize p53 exploit the ways to inactivate Mdm2. Several studies 
have  inhibited  Mdm2  expression  by  antisense  oligonucleotides  and  have  shown  p53 
stabilization and p53 activation in cancer cells and in tumour xenografts in nude mice 
(544-546).  However,  this  approach  has  not  been  well  characterized  yet.  Inhibiting 
ubiquitin  ligase  activity  of  Mdm2  is  another  important  strategy  to  activate  p53.  This 
approach  emerges  as  particularly  important  since  ubiquitin  ligase  activity  is  a  crucial 
determinant  for  inactivation  of  p53  by  Mdm2.  Recently  small-molecule  inhibitors  that 
specifically  target  the  E3  ligase  activity  of  Mdm2  have  been  identified  in  a  high-
throughput  screen.  Some  of  these  compounds,  named  HLI98,  potently  inhibit  p53 
ubiquitination in vitro and activate p53 in cells, resulting in p53-dependent apoptosis (547, 
548).  However,  some  p53-independent  toxicity  of  these  compounds  in  cells  has  been 
observed. Further steps of optimization of these compounds might be required for this 
approach to be implemented into cancer therapy. 
The success of the therapeutic approach of reactivating wild type p53 in tumours 
will depend on the functionality of the p53 pathway. For example, melanomas have low 
frequency of p53 mutation, however are resistant to chemotherapy. The deregulation of 
downstream  of  p53  signalling  pro-apoptotic  APAF-1  and  BAX  can  account  for  the   66 
chemoresistance  (549).  Overexpression  of  Mdmx,  an  inhibitor  of  p53  transcriptional 
activity can attenuate the p53 response to nutlin treatment (538).  
In many tumours where p53 is inactivated by mutation, stabilization of mutant p53 
would be undesirable approach as it can have adverse effects due to gain-of-function of 
mutant p53. The restoration of the activity of mutant p53 has been suggested as a strategy 
for development of therapy for such tumours. Though many p53 mutants are unable to 
bind DNA in p53 target promoters due to conformational changes in the DBD, several 
evidence  have  suggested  that  DBD  of  p53  mutants  is  flexible,  as  exemplified  by  the 
finding of the temperature-sensitive p53 mutations (550-552). In further support, second 
site mutations in DBD of p53 can restore the structure and activity of some of the p53 
mutants,  suggesting  the  possibility  to  reactivate  mutant  p53  (553-555).  Several 
compounds,  which  activate  mutant  p53  in  cell-based  assays,  have  been  described, 
including  CP-31398  (556),  PRIMA-1  (p53  reactivation  and  induction  of  massive 
apoptosis) (557) and MIRA-1 (558). CP-31398 acts by modifying the mutant conformation 
of p53 and can rescue p53 function in some tumour-derived cell lines and xenografts. It 
has been suggested that CP-31398 stabilize wild type conformation by binding to newly 
synthesized protein, however there is no evidence of direct interaction and the mechanism 
of action remains unclear. CP-31398 also has some p53-independent effects and needs to 
be further characterized and optimized (556). PRIMA and MIRA represent another class of 
compounds,  which  have  been  suggested  to  restore  tumour-suppressive  p53  activity  of 
mutant p53 (557-559). These compounds have been identified in a cell-based screen for 
ability to induce apoptosis in a cell line expressing inducible mutant p53 273H. PRIMA 
can induce apoptosis in cells expressing wild type p53, however seems to be more specific 
for  cells  with  mutant  p53.  PRIMA  also  has  some  p53-independent  effects  and  the 
mechanism of its action is largely unknown (557). MIRA is able to suppress growth of 
mutant-p53  expressing  cells  but  not  p53-null  cells.  MIRA  has  been  shown  to  inhibit 
tumour growth of xenografts in SCID mice (558). Both PRIMA and MIRA have been 
suggested to promote wild type conformation of mutant p53 in vitro, however there is no 
data for direct binding of these compounds to p53. These compounds have not been fully 
characterized and optimized yet. The discovery of such compounds suggests potentially 
promising approach for refolding conformation of mutant p53 by small molecules. This 
approach is particularly attractive as it will target specifically tumour cells which bear 
mutant p53 and not cells with wild type p53. 
Clearly the strategy of the therapies should be completely different dependent on 
whether tumours have wild type or mutant p53. In the first case the approach would be to   67 
activate  p53,  whereas  cancer  therapy  of  tumour  cells  with  mutant  p53  should  aim  at 
downregulating mutant p53 expression.  
 
1.8  Aims.  
The aim of this study has been to analyze the contribution of the DNA binding 
domain (DBD) of p53 to regulation of its stability. Specifically, the contribution of the 
conserved boxes of DBD of p53 and of point mutations of p53 found in tumours has been 
addressed.  Chapter  3  describes  the  contribution  of  DBD  of  p53  to  regulation  of  p53 
stability  by  Mdm2.  In  chapter  4  the  contribution  of  Mdm2-independent  pathway  to 
ubiquitination  of  p53  has  been  investigated.  In  chapter  5,  the  role  of  DBD  of  p53  in 
regulation of subcellular localization has been analyzed. Involvement of DBD of p53 to 
interaction with its family members has been studied in Chapter 6.    68 
 
 
 
 
 
 
 
 
 
Chapter 2. Materials and methods. 
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2  Materials and Methods. 
 
2.1  Materials. 
All general laboratory reagents used in this study are listed in table 2.1. 
Table 2.1. General chemicals and reagents. 
Reagent  Source 
Agarose  Sigma 
Acrylamide 29:1  National diagnostics 
SDS (sodium dodecyl sulphate)  Fisher 
APS  Sigma 
TritonX-100  Sigma 
BSA (bovine serum albumin)  Sigma 
DTT (dithiothreitol)  Sigma 
Na2HPO4   Fisher 
KH2PO4   Fisher 
NaCl  Fisher 
KCl  Fisher 
PFA (paraformaldehyde)  TAAB labs 
Tris-HCl  Sigma 
MgCl2  Sigma 
Methanol  Fisher 
Ethanol  Fisher 
ATP (Adenosine-5'-triphosphate)  Roche 
Agar  Fluka 
β-Mercaptoethanol  Sigma 
NP-40  Roche 
DMSO (dimethyl sulfoxide)  Sigma 
TEMED (Tetramethylethylenediamine)  Sigma 
Tween-20  Sigma 
Protease inhibitors cocktail  Roche 
Nutlin-3A  Cayman chemicals 
Cycloheximide  Sigma 
DAPI (4',6-diamidino-2-phenylindole)  Sigma 
ECL (enhanced chemiluminescence) reagent  Perbio 
Nitrocellulose membranes  VWR 
Leptomycin B  Sigma 
Kanamycin  Sigma 
Ampicillin  Sigma   70 
All general buffers and solutions used in this study are listed in Table 2.2. 
Table 2.2. Solutions and buffers. 
Solution  Composition 
Phosphate Buffered  
Saline (PBS) 
170 mM NaCl  
3.3 mM KCl  
1.8 mM Na2HPO4  
10.6 mM KH2PO4  
pH 7.4 
Tris-buffered saline (TBS)  25 mM Tris-HCl pH 7.4 
137 mM NaCl  
5 mM KCl 
TBS-T (TBS-Tween)  TBS+0.1%Tween-20 
Lysogeny broth (LB)  1% Bacto-tryptone  
86 mM NaCl  
0.5% yeast extract 
LB Agar  1% Bacto-tryptone 
86 mM NaCl 
0.5% yeast extract  
1.5% agar 
Tris-EDTA (TE)  10 mM Tris-HCl pH 8.0 
 1 mM EDTA 
2x SDS-PAGE sample buffer  125 mM Tris pH 6.8 
 4% SDS  
10% ß- mercaptoethanol 
15% glycerol 
0.01% bromophenol blue 
SDS-PAGE running buffer  0.1% SDS 
192 mM glycine 
 25 mM TrisH-Cl pH8.3 
Electroblotting buffer  192 mM glycine 
 25 mM Tris 
 20% methanol 
NP-40 buffer  20 mM Tris-HCl pH 8 
120 mM NaCl 
1mM EDTA 
0.5% NP-40 
Lysis buffer (in vitro ubiquitination) 
 
50mM Tris-HCl pH7.5 
100mM NaCl  
1% Triton  
0.8 mg/ml DTT 
supplemented with PMSF 
Reaction buffer (in vitro ubiquitination) 
 
50mM Tris-HCl pH8 
 2mM DTT  
5mM MgCl2  
2mM ATP 
Blocking solution (western blotting)  5% milk powder in TBS-T 
Blocking solution (immunostaining)  1% BSA  in PBS 
Permeabilizing solution (immunostaining)  0.2% TritonX-100 in PBS 
Fixing solution  4% PFA in PBS 
Resolving gel  8-10% acrylamide 
375mM Tris pH8.8 
0.1% SDS 
0.1% APS  
50mM TEMED  
Stripping buffer  0.2M Glycine 
1% SDS 
pH 2.5 
   71 
2.2  Methods. 
 
2.2.1  DNA preparation. 
DNA preparations were carried out as described previously (560). E. Coli (strains 
DH5α  or  TOP-10)  competent  cells  (Molecular  Biology  services,  Beatson  Institute, 
Glasgow, UK) were thawn on ice. The DNA plasmid was added to 30-100 µl of competent 
cells, mixed and incubated on ice for 20 min. After a heat shock of 45 seconds at 42 °C the 
cells were grown in 0.5 ml LB for 30 min at 37°C with shaking at 450rpm. Cells were 
seeded  on  agar  plates  with  ampicillin  or  kanamycin  and  grown  upside  down  at  37°C 
overnight. The next day the colonies were inoculated in LB with ampicillin or kanamycin 
and grown overnight at 37°C whilst shaking. Small scale or large scale plasmid DNA 
preparations  were  performed  using  Qiagen  kits  following  manufacturer’s  instructions 
(Qiagen, UK).  
 
2.2.2  Site‐directed mutagenesis. 
Point mutations were introduced by site-directed mutagenesis Quick Change kit 
(Stratagene) following manufacturer’s instructions. Briefly, oligonucleotide primers were 
designed  by  web-based  design  program  (Stratagene)  containing  the  desired  mutations 
(Table 2.3). Primers were synthesized and purified (MWG).  
The reaction was set up in 50 µl containing 30ng plasmid DNA, 1µM primer, 1 µl 
of  0.2mM  dNTP  mix,  5µl  of  10xreaction  buffer  (Stratagene)  and  1µl  PfuTurbo  DNA 
polymerase  (Stratagene)  (2.5U/µl).  The  reaction  was  cycled  using  the  following 
parameters.  
Cycles  Temperature  Time 
1  95°C  30’’ 
17  95°C 
55°C 
68°C 
30’’ 
1’ 
8’ 
After  brief  incubation  on  ice  1  µl  of  DpnI  restriction  enzyme  (10U/µl)  (New 
England biolabs) was added and reaction was incubated for 3h at 37°C. Then 10µl of the 
reaction was transformed into E.Coli Top10 competent cells. All constructs were verified 
by sequencing (Research services, Beatson Institute). 
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2.2.3  RNA extraction and RT‐PCR. 
Cells  were  washed  twice  in  PBS  and  total  RNA  was  isolated  with  RNeasy 
extraction  kit  following  manufacturer’s  instructions  (Qiagen).    To  synthesize  cDNA 
reverse  transcription  reactions  were  set  up.  First  RNA  (1.4µg)  and  200ng  random 
hexamers and 1mM dNTP were mixed in 10µl and denatured at 65°C for 5 min. Next the 
10xreaction buffer, 10mM MgCl2 and 20mM DTT and 1µl RNASe OUT recombinant 
ribonuclease inhibitor (40u/µl) were added and primers were annealed at 25°C for 2 min 
without reverse transcriptase (RT) and for 10 min with 1µl SuperScript II RT (GIBCO). 
The cDNA synthesis was carried out at 42°C for 50 min. Then reaction was stopped by 
heat  inactivation  at  70°C  for  15  minutes.  To  remove  RNA  the  reaction  mixes  were 
incubated with 1 µl RNase H (2u/µl) for 37°C for 20 min and cDNAs were stored at -
20°C. 
For polymerase chain reactions 2µl cDNA was mixed with 0.2µM corresponding 
forward and reverse primers, 1U AmpliTaq DNA polymerase, 10x PCR buffer, 1.5 mM 
MgCl2 and 0.2mM NTP in 50 µl volume. For analysis of CHIP and GAPDH expression 
the following primers were used (Table 2.3).  
Table 2.3  RT-PCR primers. 
GAPDH-fw  
GAPDH-rv 
GCAGAGATGATGACCCTTTTGGCT 
TGAAGGTCGGATCAACGGATTTGGT 
CHIP-fw 
CHIP-rv  
TCATTTTGACCCCGTGACC  
ACCTCAGTAGTCCTCCACC 
 
Reactions were cycled for 25 cycles in a Peltier Thermal Cycler (MJ research, 
Helena Bioscience), using the following parameters and transferred to 4°C.  
Cycles  Temperature  Time 
1  95°C  30’’ 
25  95°C 
60°C 
72°C 
30’’ 
40’’ 
1’ 
Reaction products were resolved by agarose gel electrophoresis. 
 
2.2.4  Agarose gel electrophoresis. 
1%  Agarose  (Sigma)  in  TAE  buffer  was  boiled,  mixed  with  0.5µg  Ethidium 
bromide and allowed to solidified in gel chamber. DNA samples diluted in 5x loading 
buffer (30$glycerol, bromphenol blue) were electrophoresed at 120V in 1xTAE running 
buffer and visualized by UV transilluminator.   73 
2.2.5  Plasmids. 
All p53, Mdm2 and other expression plasmids with deletions and mutations of the 
indicated amino acids used in this study are shown on table 2.4.  
Table 2.4. Plasmids. 
A. p53 constructs. 
name  mutation  vector  source 
wt  Wild type p53  Pcb6+; 
pGEM 
(561) 
ΔI  Δ13-19aa  Pcb6+; 
pGEM 
(561) 
ΔII  Δ117-142aa  Pcb6+; 
pGEM 
(561) 
ΔIII  Δ171-181aa  Pcb6+; 
pGEM 
(561) 
ΔIV  Δ234-258aa  Pcb6+; 
pGEM 
(561) 
ΔV  Δ270-286aa  Pcb6+; 
pGEM 
(561) 
ΔNES  L348A,L350A  Pcb6+ 
 
(224) 
ΔNLS  K305A, R306A, K319A, K320A, K321A  Pcb6+  (224) 
175H  R175H  Pcb6+  Site directed 
mutagenesis 
273H  R273H  Pcb6+  Site directed 
mutagenesis 
175/ΔI  R175H; Δ13-19aa  Pcb6+  Site directed 
mutagenesis 
ΔV/ΔI  Δ270-286aa; Δ13-19aa  Pcb6+  (561) 
ΔII/ΔI  Δ117-142aa; Δ13-19aa  Pcb6+  (561) 
175/ΔNLS  R175H;  
K305A, R306A, K319A, K320A, K321A 
Pcb6+  Site directed 
mutagenesis 
175/ΔNES  R175H; L348A,L350A  Pcb6+  Site directed 
mutagenesis 
 
B. Mdm2 constructs. 
wt  Wild type Mdm2  pCHDM1A  (562) 
ΔR  Δ440-497aa  pCHDM1A  (562) 
464  C464A  pCHDM1A  (563) 
ΔN  Δ58-89aa  pCHDM1A  (256) 
ΔA  Δ212-296aa  pCHDM1A  Provided by Dr. 
Uldrijan 
ΔC  Δ483-497aa  pCHDM1A  Provided by Dr. 
Uldrijan 
ZF  C305A, C308A  pCHDM1A  Provided by Dr. 
Uldrijan 
GFP-RING  GFP-384-491aa  pEGFP-C1  (270) 
GST-Mdm2  GST-tagged wild type Mdm2  pGEX  (564) 
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C. Other constructs. 
V5-S4 
V5-S5α 
V5-S6α 
V5-S6β 
pcDNA3  Provided by prof. Blattner 
HA-p73α  pcDNA3  Provided by prof. G Melino 
FLAG-p73α  pcDNA3  Provided by prof. G Melino 
HA-Ub  pMT123  Provided by prof. R.Hay 
FLAG-Parc  pcDNA3  Provided by prof. W.Gu 
pEGFP-N1  pEFGP  Clontech 
 
Constructs encoding human wild type p53 and p53 deletion mutants (ΔI, ΔII, ΔIII, 
ΔIV,  ΔV,  ΔV/ΔI,  ΔII/ΔI)  in  mammalian  expression  vector  pcb6+  were  made  in  the 
laboratory by Dr. N Marston and were characterized previously. p53 ΔNLS, p53-C6 and 
p53  ΔNES  in  vector  pcb6+  were  kindly  provided  by  Dr.  Stephanie  Carter  and  are 
described  previously  (224).  p53175H,  p53273H,  p53175H/ΔI,  p53273H/ΔI, 
p53175H/ΔNLS,  p53175H/ΔNES  and  p53175H-C6  in  pcb6+  vector  were  made  by 
introducing point mutations R175H and R273H by site-directed mutagenesis (QuikChange 
site-directed mutagenesis kit; Stratagene, La Jolla,
 CA) with the corresponding p53 primers 
(Table 2.4). The polymorphic codon 72 in all p53 constructs was mutated from P to R if 
needed, using corresponding primers (Table 2.5). For in vitro translation p53ΔV, ΔIV, 
ΔIII, ΔII in pGEM vector, previously described, (561) and p53175H in pSp65 vector, made 
by site-directed mutagenesis, were used. All p53 contsructs were verified by sequencing 
(Research services, The Beatson Institute) with p53-specific primers (Table 2.6).  
 
 
Table 2.5. Primers used for site-directed mutagenesis of p53. 
p53R175Hfw 
p53R175Hrv 
ACGGAGGTTGTGAGGCACTGCCCCCACCATGAGCGCTGCT 
TGCCTCCAACACTCCGTGACGGGGGTGGTACTCGCGACGA 
p53R273Hfw 
p53R273Hrv 
ACTGGGACGGAACAGCTTTGAGGTGCATGTTTGTGCCTGTCCTGGG 
TGACCCTGCCTTGTCGAAACTCCACGTACAAACACGGACAGGACCC 
p53P72Rfw 
p53P72Rrv 
CCAGAGGCTGCTCCCCGCGTGGCCCCTGCACC 
GGTCTCCGACGAGGGGCGCACCGGGGACGTGG 
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Table 2.6. Primers used for sequencing of p53. 
146-fw  ATATTGAACAATGGTTC 
189-rv  TGCTTCATCTGGACCTGG 
282-fw  ATCTTCTGTCCCTTC 
361-fw  TCTGTGACTTGCACGTAC 
661-fw  GAGCCGCCTGAGGTTGGC 
887-rv  ACTCCGAGGGGAAAGAACGCCTC 
971-fw  ATGGAGAATATTTCACCCTT 
 
Plasmids  expressing  wild  type  Mdm2  (562),  C464A  Mdm2  (563),  GST-Mdm2 
(564),    Mdm2Δ58-89  (256),  Mdm2  ΔR  (562)  were  described  previously  (Table  2.3). 
Plasmids encoding Mdm2ΔA and Mdm2ZF were kindly provided by Dr. Stjepan Uldrijan 
(Table 2.3).  
Plasmid  encoding  HA-tagged  ubiquitin  was  kindly  provided  by  Prof.  R.  Hay. 
pEGFP-N1 encoding
 GFP was obtained from Clontech (Palo Alto, CA).  FLAG-Parc was 
kindly provided by Prof. W. Gu. Constructs encoding HA-p73α and FLAG-p73α were 
generously provided by Prof. G. Melino.   
 
2.2.6  Cells. 
H1299  is  a  human  non-small  cell  lung  adenocarcinoma  with  a  homozygous 
deletion of p53 (565). 
U2OS is a human osteosarcoma expressing wild type p53 (566) (ATCC). 
MCF7-p53ΔII  human  breast  cancer  cells  expressing  wild  type  p53  and  stably 
transfected with p53ΔII mutant were previously made in the laboratory (567).  
MCF7-p53ΔII/ΔI human breast cancer cells expressing wild type p53 and stably 
transfected with p53ΔII mutant were previously made in the laboratory (567). 
p53-/-mdm2-/-  mouse  embryonic  fibroblasts  (DKO)  cells  were  described 
previously (249).  
 
2.2.7  Growth conditions. 
Cell  lines  were  maintained  in  Dulbecco’s  modified  Eagle’s  medium  (DMEM) 
(Invitrogen)  medium  supplemented  with  10%  fetal  bovine  serum  (FBS)  (Autogen 
bioclear), 2mM glutamine and 60 µg/ml penicillin, 200µg/ml streptomycin (Invitrogen) at 
subconfluent conditions. Cells were maintained in a humidified incubator at 37°C in 5% 
CO2 and split every 3-4 days at a 1/5-1/10 ratios. Medium was aspirated and cells were   76 
washed once with TE+0.25% trypsin, followed by incubation with trypsin for 2-3  minutes. 
Cells were collected into fresh media and seeded for maintenance or transfections.  
For transfections cells were seeded at 30-50% confluency and allowed to adhere 
overnight unless otherwise stated.  
For  long-term  storage  cell  lines  were  cryo-frozen.  Cells  were  trypsinized  and 
pelleted.  After  one  wash  with  fresh  medium,  cells  were  resuspended  in  90%FBS  and 
10%DMSO, frozen in cryotubes at -70°C overnight and stored in liquid nitrogen.  
 
2.2.8  Transfections. 
Transfections of cells with plasmids were performed with Effectene transfection 
reagent  (Qiagen)  or  lipofectamine  2000  (Invitrogen)  following  the  manufacturer’s 
instructions.  DKO  were  transfected  with  Effectene  reagent.  For  immunoprecipitation 
experiments U2OS and H1299 were transfected with lipofectamine reagent. Transfection 
of  U2OS  cells  for  in  vivo  ubiquitination  was  carried  out  with  effectene,  for 
immunofluorescence  and  subcellular  fractionation  experiments  U2OS  cells  were 
transfected by calcium phosphate precipitation similarly to as described previously. For 6-
well plate 2-4 µg total amount of appropriate DNA plasmids were diluted in 110 µl of 
sterile water and 15 µl of 2M CaCl2 was added and mixed. The mix was added dropwise to 
125 µl of 2xHBS (pH 7) and vortexed. The precipitates were allowed to form for 30 
minutes at room temperature and added to the cells dropwise. Approximately 5-6 hours 
later the medium was changed and the cells were harvested 36-48 hours after transfection. 
For transfections of larger plates the amounts were scaled according to the surface area.  
Short interfering RNA (siRNA) oligonucleotides were transfected into cells with 
lipofectamine  2000  (Invitrogen)  or  Hiperfect  (Qiagen).  For  down-regulation  of  Cop1, 
ARF-BP1 and Mdm2 expression, cells were transfected twice with siRNA with 24 hours 
between  transfections  and  analyzed  48  hours  later.  For  down-regulation  of  CHIP 
expression cells were transfected twice with siRNA with 72 hours between transfections 
and  analyzed  72  hours  later.  For  down-regulation  of  Cop1,  ARF-BP1  and  CHIP 
expression, predesigned pools of four siRNA oligonucleotides were used (SMARTpool, 
Dharmacon).  In  the  control  experiments  non-targetting  siRNA  was  used  (Dharmacon). 
Mdm2-specific siRNA  oligonucleotides were described previously (568). The following 
siRNA oligonucleotides were used (Table 2.7).   77 
Table 2.7 siRNA oligonucleotides. 
Itch1  AAGUGCUUCUCAGAAUGAUGA  (422) 
Itch2  AACCACAACACACGAAUUACA  (422) 
Stub1  CGCUGGUGGCCGUGUAUUAUU  On-target Smartpool (Dharmacon) 
Mdm2  AAGGAAUAAGCCCUGCCCA  (568) 
ARF-BP1  Sequence not provided  On-target Smartpool (Dharmacon) 
Hsp70  GAAGGACGAGUUUGAGCACAA  Designed with Invitrogen RNAi 
designer software 
CHIP3  CAGCUGGAGAUGGAGAGCUAU  Designed with Invitrogen RNAi 
designer software 
CHIP4  CCAACUUGGCUAUGAAGGAGG  Designed with Invitrogen RNAi 
designer software 
GFP  GGCUACGUCCAGGAGCGCACC  (569) 
Cop1  Sequence not provided  On-target Smartpool (Dharmacon) 
 
Cells were treated for indicated time periods with 10-20 µM proteasome inhibitor 
MG132 (Sigma), Nutlin-3a (Cayman chemical), cycloheximide (Sigma) and leptomycin B 
(Sigma) at indicated concentrations. 
 
2.2.9  SDS‐Polyacrylamide gel electrophoresis (SDS‐PAGE). 
Protein  samples  were  subject  to  SDS-PAGE  electrophoresis  as  described 
previously (570). Protein samples were boiled in 2x sample buffer for 10 min at 95°C and 
loaded into SDS-polyacrylamide gels consisting of 5% stacking gel and 8-10% resolving 
gel. Prestained protein markers were used (Benchmark, Invitrogen). Small and large gels 
were  electrophoresed  at  40-50mA  in  1x  SDS-PAGE  running  buffer  on  vertical  tanks 
(Amersham Biosciences, SE400).  
Gels  with  [
35S]-labelled  proteins  were  fixed  in  isopropanol:water:acetic  acid 
(25:65:10) for 30 min, soaked in Amplify reagent (Amersham, UK) for 15 min, dried and 
exposed to X-ray film.  
 
2.2.10 Western blotting. 
Western  blot  analysis  was  carried  out  similarly  to  described  previously  (563). 
Proteins  were  transferred  from  the  gel  to  the  nitrocellulose  membrane  as  described 
previously (571) in 1xtrasfer buffer in Hoefer TE42 Protein Transfer tanks. Small gels 
were transferred in at 200mA for 2h or 10V overnight. Large gels were transferred at 
500mA for 3 h or 30V overnight. The membranes were blocked in 5% milk/TBS-T for 
30min-60min and incubated with the primary antibodies usually at a dilution of 1:1000-
1:2000 in blocking solution for 2-3h at room temperature or overnight at 4°C. Following 3   78 
washes in TBS-T the blots were incubated with the horseradish peroxidase conjugated 
anti-rabbit, anti-mouse or anti-goat HRP-conjugated secondary antibodies (GE Healthcare) 
and visualized with Enchanced Chemiluminescence (ECL, Amersham) detection kit.  
The primary antibodies used in this study are detailed in table 2.8.  
Table 2.8. Primary antibodies 
A. Human p53-specific antibodies.  
  antibody  epitope  Source 
DO1  20-25aa (572)  Beatson Institute 
1801  46-55aa (573)  Calbiochem 
421  371-380aa (574)  Calbiochem 
1620  106 to 114aa 
146 to 156aa (575) (detects for 
wild type conformation) 
Calbiochem 
240  213-217aa (576) 
detects mutant conformation  
Calbiochem 
 
 
 
 
 
p53 
 
CM1  recombinant human p53 (577)  Novocastra 
B. Other antibodies. 
protein  name  Source 
Actin    Chemicon 
ARF-BP1    Provided by Prof. M. Eilers 
Cdk4    Santa Cruz 
CHIP    Abcam 
Cop1    Provided by Prof. V. Dixit 
FLAG (M2)  M2  Sigma 
GFP    Roche 
HA   F7 or Y11  Santa Cruz 
Hsp70    Calbiochem 
LaminA/C    Calbiochem 
Mdm2   Ab-1 
Ab-2 
SMP-14 
Calbiochem 
Calbiochem 
Santa cruz 
p73  sc-20  Santa Cruz 
V5    Calbiochem 
 
2.2.11 Immunoprecipitation under native conditions. 
Immunoprecipitation was carried out similarly to described previously (563). 24h 
before transfection cells were seeded in 6-cm plates. Cells were transfected with 0.6mg 
p53 and 1.2mg Mdm2 using Lipofectamine 2000 reagent (Invitrogen). After 20-24h cells 
were treated with 10µM MG132 for 4h. Cells were washed in cold PBS and lysed in cold 
NP-40 buffer containing proteinase inhibitors (Complete, Roche). Immunoprecipitations 
were performed with Mdm2 or p53-specific antibodies bound to 30ml protein G-Sepharose 
for  1  or  2h  at  4°C.  Mdm2  was  immunoprecipitated  with  0.3-0.6  µg  of  anti-Mdm2 
antibodies Ab-2 (Calbiochem) and SMP-14 (Santa Cruz), p53 was immunoprecipitated   79 
with 0.3-0.6 µg of 1801 and 421 antibodies (Calbiochem). Immunoprecipitated proteins 
were washed with NP-40 buffer and resuspended in 2xSDS sample buffer. Proteins from 
whole-cell extracts and immunoprecipitations were resolved by SDS–PAGE and analyzed 
by Western blotting with anti-p53 polyclonal antibody CM1 (Novocastra) and anti-Mdm2 
Ab-1 and Ab-2 antibodies (Calbiochem). 
 
2.2.12 In vivo ubiquitination of p53. 
Cells  were  seeded  at  60%-80%  confluency  in  6-cm  plates  the  day  before 
transfection. Cells were transfected with 0.3mg p53, 0.6mg hemagglutinin (HA)-ubiquitin 
and with 0.15mg Mdm2 or pcDNA3 where indicated, using Effectene transfection reagent 
(Qiagen). After 20-30h cells were treated with 10-20 mM MG132 for 4-5h. Cells were 
washed  twice  in  cold  PBS  and  lysed  in  350ml  0.5%  SDS  in  TBS.  After  boiling  and 
vigorous  vortexing,  extracts  were  supplemented  with  1ml  1.5%  Triton  X-100  in  TBS. 
Protein G sepharose beads were washed in Np-40 buffer and incubated with DO1 antidoby 
for  1h  at  4°C  rotating.  Lysates  were  added  to  30ml  protein  G  sepharose  beads 
preconjugated to p53-specific DO1 antibody and rotated for 2h at 4°C. The beads were 
washed 3 times in NP-40 buffer and the proteins were extracted by adding 40µl 2x SB and 
boiling for 5 min. Proteins were resolved by SDS-PAGE and analyzed by analyzed by 
Western  blotting  with  monoclonal  anti-HA  antibody  followed  by  anti-light  chain 
secondary antibody. The blot was then reprobed with polyclonal CM1 antibody followed 
by anti-rabbit secondary antibody. 
 
2.2.13 In vitro ubiquitination of p53. 
In vitro ubiquitination of p53 was carried out similarly to described previously 
(270). DHL5a E. coli cells were transformed with pGEX-Mdm2 and grown at 37°C to 
approximately log phase. Protein expression was induced by addition of IPTG (300 mM) 
for 3h. Cells from 10 ml of night culture were lysed in 5 ml of lysis buffer and sonicated. 
GST-Mdm2 was purified on 100 µl glutathione-Sepharose beads (Amersham), mixed with 
20  µl  in  vitro-translated  p53  (TNT  Quick  Coupled  Transcription/Translation  System, 
Promega) and incubated at 4°C for 1 h. The beads were washed three times with 50mM 
Tris pH7.5 and incubated with 50ng mammalian E1 (Affiniti), 200ng human recombinant 
UbcH5B  E2  (Affiniti)  and  5µg  ubiquitin  or  methylated  ubiquitin  (Sigma)  in  reaction 
buffer. The reaction was incubated at 37°C for 2h and then stopped by the addition of 2x   80 
SDS  sample  buffer.  Reaction  products  were  resolved  by  SDS-PAGE  and  analyzed  by 
Western blotting with anti-p53 DO-1 antibody.  
 
2.2.14 Analysis of half‐life of p53 by cycloheximide treatment.  
The day before transfection 10
5 p53-/-mdm2-/- (DKO cells) were seeded in 6-well 
plates.  Cells  were  transfected  with  150ng  of  p53  with  Effectene  transfection  reagent 
(Qiagen). After 24h cells were treated with 50mg/ml cycloheximide (Sigma) and collected 
at indicated time points. Cell lysates were subjected to Western blot analysis with p53-
specific DO1 antibody. 
 
2.2.15 Analysis of half‐life of p53 by pulse‐chase. 
The day before transfection, 10
5 p53
−/− mdm2
−/− (DKO) cells were seeded into six-
well plates. Cells were transfected with 400 ng of p53 with Effectene transfection reagent 
(QIAGEN). The pulse-chase experiment was performed 24 h later. Cells were incubated in 
methionine/cysteine-free  DMEM  with  5%  dialyzed  serum  (GIBCO)  for  30  min.  The 
medium was then removed and replaced with DMEM with [
35S]methionine-cysteine (50 
µCi/ml; Promix [Amersham]) for 2 h. Cells were washed twice with phosphate-buffered 
saline (PBS) and chased with DMEM supplemented with 15 mg of methionine/liter and 24 
mg of cysteine/liter (both from GIBCO) for the times indicated below. Cells were washed 
in PBS and lysed in NP-40 buffer. Cell lysates were immunoprecipitated with p53-specific 
DO1 antibody and analyzed by SDS-PAGE electrophoresis. 
 
2.2.16 Subcellular fractionation. 
The day before transfection U2OS cells were seeded at 30-50% confluency. Cells 
were transfected with 7 µg of p53 plasmids by calcium phosphate precipitation method. 
After 48h fractions of cells were extracted using Subcellular fractionation kit () following 
manufacturer’s instructions. The cell lysates were mixed with 2x Laemmli sample buffer 
and resolved by SDS-PAGE, followed by Western blot analysis.  
 
2.2.17 Immunofluorescence labeling. 
DKO  or  U2OS  cells  were  seeded  onto  coverslips  and  transfected  as  described 
above  for  in  vivo  ubiquitination  of  p53.  After  20-30h,  cells  were  treated  with  20  µM   81 
MG132 for 5 h. Cells on coverslips were washed three times with PBS and then fixed in 
4%  paraformaldehyde/PBS  for  10  min  at  room  temperature.  After  fixation,  cells  were 
washed three times in PBS and permeabilized in PBS containing 0.2% Triton X-100 for 5 
min.  Cells  were  blocked  in  PBS  containing  0.5%  bovine  serum  albumin  at  room 
temperature for 30 min and then incubated for 2 h at room temperature with mouse anti-
p53  DO1  or  goat  anti-p73  antibody  at  1:150  dilution  in  blocking  solution.  Cells  were 
washed three times with PBS and incubated for 2 h at room temperature with fluorescein 
isothiocyanate-conjugated  anti-mouse  or  Alexa  494-conjugated  anti-goat  secondary 
antibodies at 1:150 dilution and in blocking solution containing DAPI (4′,6′-diamidino-2-
phenylindole 1 µg/ml; Sigma). Cells were washed three times with PBS, and slides were 
mounted with Vectashield hard set (Vector Laboratories, Peterborough, United Kingdom). 
Cells were visualized with Fluoview 1000 Olympus confocal microscope by acquiring 
fluorescence for DAPI, FITC and Alexa 494 at the corresponding emission wavelength. To 
detect co-localization, the channes of red and green were merged and appearance of yellow 
color was analyzed. The cells with cytolasmic p53 were counted and the average from 
several experiments and standard deviation for at least three experiments was calculated 
and presented as a graph. Images representative of the majority of the cells were acquired. 
 
2.2.18 Mdm2‐mediated p53 degradation. 
The day before transfection 10
5 DKO or H1299 cells were seeded in 6-well plates. 
Cells  were  transfected  with  150ng  plasmid  encoding  wild  type  p53  or  indicated  p53 
mutants and 450ng (DKO cells) or 600ng (H1299 cells) plasmid encoding wild type Mdm2 
or indicated Mdm2 mutants or same amount of pcDNA3.1 (Invitrogen). Each transfection 
mixture also contained 50ng pEGFP-N1 to control for transfection efficiency. Cells were 
collected 30-40h after transfection, washed with PBS and lysed with 200-250ml 2x SDS 
sample  buffer.  Proteins  were  resolved  by  SDS-polyacrylamide  gel  electrophoresis  and 
analyzed by Western blotting with anti-p53 1801 antibody (Calbiochem), anti-Mdm2 Ab-1 
and Ab-2 antibodies (Calbiochem) and anti-GFP antibody (Roche).   82 
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3  Contribution of the DNA binding domain of p53 to regulation 
of its degradation by Mdm2.  
Although previous studies have shown that tumour-derived p53 mutants can be 
targeted for degradation by Mdm2 when overexpressed in cells (246, 519), the recently 
identified contribution of the DNA binding domain of p53 to Mdm2 binding (265, 578) 
has suggested that mutant p53s may show some alterations in their sensitivity to Mdm2. 
Together, these observations suggest a more complex relationship between Mdm2 and p53, 
and that the degradation of mutant p53 might be selectively compromised in tumour cells.  
Most p53 mutations found in tumours occur as point mutations in the DBD of p53 
and localize to highly conserved regions of the DBD - boxes II, III, IV, V (143). Based on 
structural studies and reactivity with the antibodies, p53 mutants can be largely divided 
into  structural  and  contact  mutants,  affecting  the  conformation  of  DBD  or  residues 
contacting DNA, respectively (147, 441). Structural p53 mutations alter the conformation 
of the DBD of p53 (436, 579), resulting in the exposure of an epitope recognized by the 
mutant p53-specific antibody (pAb240), which does not efficiently recognize native wild 
type p53 (576). This has been described as unfolded or “mutant” conformation and has 
been  associated  with  many  hot  spot  p53  mutants.  Wild  type  p53  is  preferentially 
recognized  by  wild  type  conformation  antibody  (pAb1620),  which  fails  to  recognize 
unfolded p53 mutants (437, 580).  In our study we have utilized previously characterized 
p53 mutants with deletions of the conserved boxes of DBD - p53 ΔII, ΔIII, ΔIV and ΔV 
(561) (Fig. 3.1), as well as two hot spot tumour derived point mutants, structural - 175H, 
and  contact  -  273H.  Similarly  to  tumour  derived  p53  mutants  (581),  each  of  the  p53 
deletion mutants fails to bind DNA and is therefore transcripitionally inactive (561). Each 
of  the  deletion  mutants,  like  175H,  adopt  the  “mutant”  conformation  associated  with 
structural tumour-derived p53 mutants (582). The 273H mutant is recognized by both wild-
type and mutant p53 specific antibodies, and appears to show a flexible conformation (583, 
584).  
In  this  chapter  the  contribution  of  mutations  and  deletions  in  the  DBD  of  p53 
deletions to interaction, ubiquitination and degradation of p53 by Mdm2 was examined. 
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3.1  Analysis of the interaction of p53 DBD mutants with Mdm2.  
 
3.1.1  Mutant conformation of DNA binding domain of p53 promotes binding of 
Mdm2 outside box I.   
To analyze the contribution of the DBD previously characterized p53 constructs 
with deletions of conserved boxes of DBD p53 ΔII, ΔIII, ΔIV and ΔV and tumour-derived 
p53  point  mutants  p53175H  and  p53273H  were  used  (Fig.  3.1).  For  analysis  of  the 
contribution of Mdm2 binding the following p53 mutants lacking N-terminal box I were 
used:  previously  described  p53ΔI,  p53ΔV/ΔI  and  p53ΔII/ΔI,  and  p53175H/ΔI  and 
p53273H/ΔI, made by site-directed mutagenesis (Fig.3.1). All p53 mutants were sequenced 
and  72P/R  polymorphism  was  checked.  To  avoid  potential  differences  due  to 
polymorphism, all mutants were made to have the same 72R polymorphism.  
 
FIGURE. 3.1. Structural organization of wild type p53 and p53 mutants 
used in the study.  
The main domains of p53, nuclear export (NES), nuclear localization (NLS) 
signals and the location of the conserved boxes I, II, II, IV and V and the 
corresponding deletions and point mutations 175H and 273H are shown.  
TA - transactivation domain, DBD - DNA binding domain, PD – proline-rich 
domain, OD - oligomerization domain. 
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Previous studies have shown that the p53 mutants with deletion of each of the 
conserved boxes of DBD retain the ability to interact with Mdm2 in vitro (561). To assess 
their ability to interact in vivo co-immunoprecipitation analysis of each of the p53 DBD 
deletion mutants ΔII, ΔIII, ΔIV and ΔV (Fig.3.1) and wild type Mdm2 was carried out in 
H1299  cells.  H1299  is  a  non-small  cell  lung  carcinoma  cell  line,  which  is  easily 
maintained  and  transfected.  H1299  cells  are  p53-null  and  express  low  amounts  of 
endogenous Mdm2, which makes it a convenient system to use for transient transfection of 
p53  constructs.  As  a  negative  control,  p53  lacking  box  I  –  p53ΔI,  which  has  been 
previously  shown  to  lack  the  ability  to  interact  with  Mdm2,  was  also  used  in  this 
experiment. H1299 cells were transfected with expression vectors encoding wild type p53, 
or p53ΔI or with p53 deletion mutants p53ΔII, ΔIII, ΔIV and ΔV along with wild type 
Mdm2  or  empty  vector  (Fig.3.2).  The  p53  protein  and  its  interacting  partners  were 
immunoprecipitated with p53-specific antibody 1801 and the Mdm2 protein was detected 
by Mdm2-specific antibodies (Ab-1, Ab-2). The 1801 antibody recognizes epitope 46-55 
aa in the N-terminus of p53 and therefore should immunoprecipitate all p53 mutants used 
in this experiment. In this experiment wild type p53 was expressed less well than p53 
mutants, though this was probably due to difference in the transfection efficiency of the 
wild type p53 construct as this was not observed in the subsequent experiments (Fig.3.2).  
p53 deletion mutants migrated slightly faster than wild type p53 on the gel, as expected. 
The levels of Mdm2 in the total cell lysates were not detected, however transfected Mdm2 
protein was detected in the immunoprecipitates (Fig.3.2). Mdm2 protein is detected as a 
doublet, which migrates around 80 kD on the gel and represents full length p90 Mdm2 
protein (337, 585)  (Fig.3.2).  It  is not known  what the  double bands  are and could be a 
modified form of Mdm2. All p53 mutants were efficiently immunoprecipitated with p53-
specific antibody. Consistent with previous reports, wild type Mdm2 associated with wild 
type p53, but not with the p53ΔI lacking box I (Fig.3.2) (561), suggesting that Mdm2 binds 
to the N-terminus of wild type p53 and other regions on p53 do not appear to contribute. 
Though there have been reports of the interaction between the core domain of p53 and 
Mdm2 (264, 265), the interaction was not detected in this experiment. Similar amounts of 
Mdm2  were  immunoprecipitated  with  all  the  p53  DBD  deletion  mutants  (Fig.3.2).  To 
confirm this observation, the immunoprecipitation was also carried out in reciprocal way 
with Mdm2 specific antibodies and p53 bound to Mdm2 was detected by Western blot 
with  p53-specific  antibodies.  Some  amount  of  endogenous  Mdm2  was 
immunoprecipitated,  however  much  more  Mdm2  was  detected  when  overexpressed 
(Fig.3.2). The expression of endogenous Mdm2 increased when p53ΔI was co-expressed,   86 
which may be due to transcriptional activation of Mdm2 by p53ΔI (Fig.3.2). Wild type p53 
was  readily  co-immunoprecipitated  with  overexpressed  Mdm2  (Fig.3.2).  In  agreement 
with  previous  reports,  p53ΔI  did  not  associate  with  transfected  or  endogenous  Mdm2 
(Fig.3.2). Weak p53 signal was detected in the lanes where no Mdm2 was overexpressed, 
which is probably due to interaction with endogenous Mdm2 (Fig.3.2). Each of the p53 
DBD deletion mutants interacted with Mdm2 similarly to wild type p53 (Fig.3.2). The 
results of the reciprocal immunoprecipitation indicates that only part of p53 is engaged in 
complex with Mdm2 and not all Mdm2 is interacting with p53. Consistent with in vitro 
data (561), this experiment shows that the change in conformation of DBD of p53 does not 
affect the ability to interact with Mdm2 in cells. 
Mdm2 is known to interact with both the N-terminus (256, 561) and the central 
DBD of p53 (578). To evaluate the contribution of the N-terminal binding site (box I) to 
the interaction between mutant p53 and Mdm2, the ability of Mdm2 to interact with p53 
DBD  mutants  lacking  conserved  box  I  was  tested  -  (Fig  3.1).    To  this  end  co-
immunoprecipitation analysis of the p53 mutants with wild type Mdm2 was carried out in 
H1299 cells (Fig.3.3). This and all the following experiments were done in the presence of 
proteasome inhibitors to avoid effects of different degradation rates of transfected proteins, 
as shown in Figure 3.2. Mdm2 was efficiently immunoprecipitated with wild type p53, but 
not with p53 lacking box I (Fig.3.3). In addition to the p53 band, slower migrating form of 
FIGURE 3.2 p53 mutants with deletions of the conserved boxes of DBD interact with 
Mdm2.  
H1299 cells were transfected with indicated p53 constructs and with empty vector or with 
wild  type  Mdm2.  Cell  lysates  were  immunoprecipitated    with  Mdm2  or  p53  specifc 
antibodies and analyzed by Western blotting. 
IP: immunoprecipitation. IB: immunoblotting. 
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p53  was  detected  with  p53  specific  antibody  (Fig.3.3).  This  modified  form  of  p53 
correlated with binding of Mdm2 to p53, suggesting it could be ubiquitinated form of p53.  
Slightly  more  Mdm2  was  co-immunoprecipitated  with  p53175H  and  p53ΔV  than  with 
wild type p53 and similar amount of Mdm2 was immunoprecipitated with p53273H as 
with wild type p53 (Fig. 3.3). Interestingly, p53 DBD mutants lacking conserved box I - 
ΔV/ΔI,  175H/ΔI  and  273H/ΔI  clearly  retained  the  ability  to  bind  Mdm2,  although  the 
interaction was reduced compared to the DBD mutants retaining box I - 175H, 273H and 
ΔV (Fig. 3.3). These results suggest that mutation in the DBD of p53 promotes alternative 
interaction between Mdm2 and p53, which occurs outside box I of p53. This result was 
confirmed at least four times in independent experiments. 
 
 
 
 
FIGURE 3.3. Mdm2 interacts with p53 DBD mutants lacking the N-terminal 
Mdm2 binding site.  
H1299 cells were co-transfected with indicated p53 mutants and with empty vector or 
with indicated Mdm2 constructs. Cells were treated with MG132. Cell lysates were 
immunoprecipitated  with  p53-specific  antibodies  and  immunoblotted  with  p53-  and 
Mdm2-specific antibodies. 
IP: immunoprecipitation. IB: immunoblotting. 
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3.1.2  The RING domain of Mdm2 contributes to the interaction with p53 DBD 
mutant lacking box I. 
Next, the analysis of the functional domains on Mdm2 involved in the interaction 
with mutant p53 was carried out. To this end Mdm2 mutants with deletions or mutations of 
functional domains, shown in Figure 3.4, were used. 
The N-terminal domain on Mdm2 is involved in interaction with p53 and Mdm2 
mutant lacking the region 58-89aa - Mdm2ΔN - fails to bind p53 and inactivate p53 (256) 
(Fig.3.4). Mdm2ΔA, has a deletion of a large part of the central acidic domain (212-296aa) 
which covers the region previously shown to bind ARF and involved in interaction with 
DBD  of  p53.  Mdm2ZF  mutant  has  two  point  mutations  in  the  zinc  finger  domain 
substituting structurally important cysteins C305 and C308 with alanines (Fig.3.4). The 
previously characterized mutant Mdm2ΔR is truncated from the amino acid 440 in the C-
terminus, which deletes the RING finger domain and the extreme C-terminus of Mdm2, 
and is deficient in the ubiquitin ligase activity, however Mdm2ΔR retains the ability to 
interact  with  p53  (256).  Mdm2  C464A,  previously  characterized,  has  a  substitution  of 
cysteine  464  with  alanine  in  the  RING  domain  of  Mdm2,  which  is  involved  in  the 
 
FIGURE 3.4.  Structural organization of the wild type Mdm2 and Mdm2 
mutants. 
The main domains of Mdm2 - p53-binding domain, acidic domain, RING domain 
and zinc finger domain - and the corresponding Mdm2 deletion and point mutants 
are shown.  
N – N-terminal p53 binding site, R – RING domain, A – acidic domain,  
ZF – zinc finger, C – C-terminus. 
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coordination of zinc atom and abolishes ubiquitin ligase activity of Mdm2 (175). This 
mutation abrogates the structure of the RING domain of Mdm2 and this mutant also fails 
to oligomerize with wild type Mdm2. The Mdm2ΔC has a truncation of the 14 last C-
terminal  amino  acids  just  after  the  RING  domain (Fig.3.4)  and  has  been  made  in  our 
laboratory by Dr. Uldrijan. The C-terminus of Mdm2 has been shown to contribute to the 
ubiquitin  ligase  activity  of  Mdm2.  GFP-tagged  RING  domain  expresses  the  region  of 
Mdm2 384–491aa, which encompasses the RING domain and a few adjacent residues and 
was described recently (270)  (Fig.3.4).  
 
The contribution of the domains of Mdm2 to interaction with p53 mutant outside 
the N-terminus was analyzed. To this end a co-immunoprecipitation analysis of Mdm2 
mutants was carried out with the p53 DBD mutants lacking box I. Recent studies have 
shown that Mdm2 can interact with the DBD of p53 via its acidic domain (265, 266). To 
test whether the binding to p53 mutants outside box I involves the acidic domain of Mdm2, 
co-immunoprecipitation analysis of Mdm2 mutant ΔA lacking acidic domain (Δ212-296aa) 
with p53 DBD mutants lacking box I - ΔV/ΔI, ΔII/ΔI and 175/ΔI was carried out (Fig.3.5). 
Mdm2ΔA migrates lower than wild type Mdm2 around 65 kD and is detected as a single 
band (Fig.3.5). Similarly to the results shown in Fig.3.3, wild type Mdm2 did not interact 
with p53ΔI, however Mdm2 readily associated with all of the p53 DBD mutants lacking 
box I (Fig.3.5). However, deletion of the acidic domain of Mdm2 did not prevent the 
FIGURE  3.5.  The  acidic  domain  of  Mdm2  is  not  required  for  the  interaction  of 
Mdm2 with p53 DBD mutants lacking box I.  
H1299 cells were co-transfected with indicated p53 and Mdm2 constructs. Cells were 
treated with MG132. Cell lysates were immunoprecipitated with p53-specific antibodies 
and immunoblotted with p53- and Mdm2-specific antibodies. 
IP: immunoprecipitation. IB: immunoblotting.  
   90 
interaction with wild type p53 or the DBD mutants lacking box I (Fig.3.5). The modified 
form of p53 was slightly reduced upon expression of Mdm2ΔA (Fig.3.5), suggesting that 
the acidic domain of Mdm2 is important for modifying p53, which could be ubiquitinated 
p53.  This  is  consistent  with  previous  results  showing  that  acidic  domain  of  Mdm2  is 
critical for ubiquitin ligase activity (261, 262). The modified form can also be neddylated 
p53, which is known to be mediated by Mdm2 (223). 
Though previous reports have shown that acidic domain contributes to interaction 
with  wild  type  p53  (264-266),  it  was  not  detected  in  this  experiment.  The  reason  for 
discrepancy is not clear, and is possibly due to difference in the cell types used.  
 
To  determine  which  region  on  Mdm2  interacts  with  mutant  p53  outside  box  I 
several additional Mdm2 mutants targeting functionally important regions were examined: 
N-terminus - ΔN, zinc finger domain - ZF and RING finger domain - ΔR (Fig.3.4) (484). 
FIGURE 3.6. Analysis of functional domains of Mdm2 involved in the interaction of 
Mdm2 with p53175/ΔI. 
H1299 cells were co-transfected with indicated p53 and Mdm2 constructs. Cells were 
treated with MG132. Cell lysates were immunoprecipitated with p53-specific antibodies 
and immunoblotted with p53- and Mdm2-specific antibodies. After Western blotting with 
p53 the membrane was reblotted for Mdm2 to detect Mdm2ΔA in the immunoprecipitated 
samples. 
IP: immunoprecipitation. IB: immunoblotting.  
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The Mdm2 ΔA mutant was also included again. Mdm2 ZF migrates slightly higher than 
the full-length Mdm2, probably due to change of the charge of the protein, and is detected 
as a single band, suggesting mutation of the cysteins prevents the modification of Mdm2 
(Fig.3.6). As expected, Mdm2ΔN and Mdm2ΔR migrate on the gel slightly faster than wild 
type Mdm2 and appear as a doublet (Fig.3.6). Consistent with previous data, p53 lacking 
box I – p53ΔI - was deficient in the ability to bind wild type Mdm2 or Mdm2ΔRING 
(Fig.3.6). However weak interaction of p53ΔI with Mdm2ZF and Mdm2ΔN was detected 
(Fig.3.6),  suggesting  that  other  regions  on  p53  can  contribute  to  the  interaction  with 
Mdm2. Confirming the results described above, wild type Mdm2 co-immunoprecipiated 
with p53175H/ΔI, and interaction was not affected by deletion of the acidic domain ΔA. 
Deletion of N-terminal p53 binding site on Mdm2 did not prevent the interaction (Fig.3.6), 
consistent with the structural studies suggesting that N-terminus of Mdm2 interacts onlwith 
N-terminus on p53, and not elsewhere on p53 (266). Mdm2ZF mutant also was able to 
interact with p53 175/ΔI with a similar affinity to wild type Mdm2 (Fig.3.6). However, 
deletion  of  RING  almost  completely  abolished  the  ability  of  Mdm2  to  interact  with 
p53175/ΔI (Fig.3.6). This observation was made in three independent experiments. Next, 
to confirm this result and to test the contribution of the RING domain to interaction with 
full-length  p53  proteins  co-immunoprecipitation  anaysis  of  wild  type  or  p53175H,  full 
length or lacking box I, with wild type Mdm2 or Mdm2ΔR, was carried out. Interestingly, 
deletion of the RING domain also decreased the interaction of wild type p53 with Mdm2 
(Fig.3.7), suggesting that this region contributes to the interaction with wild type p53. 
Consistent with previously shown results, Mdm2 interacted with p53175H slightly better 
than with wild type p53, and retained the ability to interact with p53 175/ΔI though the 
interaction was reduced. Deletion of the C-terminus of Mdm2 significantly reduced the 
interaction with p53175H and with p53175/ΔI, suggesting that much of the interaction 
between  Mdm2  and  mutant  p53  occurs  via  RING  finger  domain  (Fig.3.7).  RING  is 
involved in binding to E2 and is required for ubiquitin ligase activity by Mdm2. A point 
mutation replacing cysteine residue 464 with alanine (C464A) abrogates zinc coordination 
and  disrupts  the  structure  of  RING  domain,  inhibiting  the  ubiquitin  ligase  activity  of 
Mdm2 (175). To examine whether the E3 activity of Mdm2 is required for the interaction 
with  p53,  Mdm2  mutant  C464A  was  included  in  the  co-immunoprecipitation  analysis. 
Mdm2 C464A protein interacted with p53175/ΔI similarly to wild type Mdm2 (Fig.3.7), 
indicating that the ubiquitin ligase activity of Mdm2 is not important, but that the entire 
RING  finger  domain  is  required  for  the  interaction  of  Mdm2  with  mutant  p53.  These 
results also suggest that binding of p53 to Mdm2 is distinct from E2-binding, which is   92 
abrogated by C464A mutation. Mdm2ΔR mutant lacks the RING domain and the extreme 
C-terminus, which also contributes to ubiquitin ligase activity of Mdm2 (270).  
 
To test which part of the C-terminus of Mdm2 contributes to the interaction with 
mutant p53 Mdm2 ΔC lacking the last 14 amino acids, but retaining the RING domain and 
construct  expressing  GFP  tagged  RING  domain  was  used  (Fig.3.8).  Co-
immunoprecipitation assay of p53 175/ΔI with GFP-RING or Mdm2 mutant lacking the 
extreme C-terminus from 483aa - Mdm2ΔC - was carried out (Fig.3.8). RING has been 
also  reported  to  interact  with  the  acidic  domain  of  Mdm2  (586),  therefore  in  this 
experiment GFP-RING was also co-expressed with Mdm2ΔR to test if RING can rescue 
the ability of Mdm2ΔR to interact with mutant p53. GFP-RING is expressed in cells and is 
readily  detected  with  the  GFP-specific  antibody  as  a  single  band  (Fig.3.8).  RING  co-
immunoprecipitated with p53175/ΔI, suggesting that RING binds to mutant p53, however 
it remains to be confirmed in vitro. 
FIGURE 3.7. Deletion of the RING domain on Mdm2 abrogates its ability to 
interact with p53175/ΔI. 
H1299 cells were co-transfected with indicated p53 and Mdm2 constructs. Cells were 
treated with MG132. Cell lysates were immunoprecipitated with p53-specific antibodies 
and immunoblotted with p53- and Mdm2-specific antibodies.  
IP: immunoprecipitation. IB: immunoblotting.  
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 whether the interaction is direct. Mdm2ΔC, retaining RING, associated with mutant p53 
(Fig.3.8), implying that extreme C-terminus is not required for the interaction. Expression 
of RING did not rescue the ability of Mdm2ΔR to interact with p53 mutant. Taken together 
these results show that while both mutant and wild type p53 bind Mdm2, the mechanisms 
of  binding  are  quite  distinct.  Whereas  wild  type  p53  and  Mdm2  associate  via  the 
corresponding N-termini of each protein, interaction of mutant p53 and Mdm2 can occur 
outside  N-terminus  on  mutant  p53.  These  results  suggest,  that  in  addition  to  the  N-
terminus, RING domain of Mdm2 is involved in the interaction with both wild type and 
mutant p53.  
 
3.2  Analysis of the ubiquitination of p53 DBD mutants by Mdm2. 
 
3.2.1  p53 mutants are less efficiently ubiquitinated by Mdm2 in vitro.  
To test whether the difference in the interaction between Mdm2 and mutant p53 
affects the ability of Mdm2 to ubiquitinate mutant p53, the efficiency of Mdm2-mediated 
ubiquitination of wild type p53 and p53 mutants in vitro was examined. In vitro translated 
wild type p53 or p53 DBD mutants were prebound to GST-purified Mdm2 and in vitro 
ubiquitination reactions were set up with E1 enzyme, ubiquitin and ATP in the presence or 
FIGURE 3.8. RING domain of Mdm2 is involved in interaction with p53175/ΔI. 
H1299 cells were co-transfected with indicated p53 and Mdm2 constructs. Cells were 
treated with MG132. Cell lysates were immunoprecipitated with p53-specific antibodies 
and immunoblotted with p53- and Mdm2-specific antibodies.  
IP: immunoprecipitation. IB: immunoblotting.  
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absence  of  E2  enzyme  as  a  negative  control.  Wild  type  p53  was  extensively 
polyubiquitinated by Mdm2 when all components of ubiquitination reaction were present 
(Fig.3.9). It should be noted that in the negative control reactions, where E2 was omitted, 
some modified forms of p53 were present (Fig.3.9), suggesting that some of the E2 activity 
came from the reticulocyte lysate. Interestingly, each of the p53 deletion mutants was 
substantially less well ubiquitinated than wild type p53 (Fig. 3.9A). A similar reduction in 
the ability to be ubiquitinated by Mdm2 was also seen using the p53175H point mutant 
(Fig. 3.9B). This suggests that the wild type conformation of the DBD is required for the 
efficient ubiquitination of p53 by Mdm2. The difference in the interactions of wild type 
and mutant p53 with Mdm2 could be the reason. Binding of p53 to the N-terminus of 
Mdm2 is required for activation of the ubiquitin ligase activity of Mdm2. Interaction of 
mutant p53 with Mdm2 does not require the N-terminus, suggesting that the ubiquitin 
ligase activity might not be activated properly.    95 
 
FIGURE 3.9. Analysis of ubiquitination of p53 DBD mutants in vitro.   
A,  B.  Wild  type  p53  and  p53  mutants  with  deletions  of  the  indicated  conserved  and 
p53175H (B) were in vitro translated and bound to GST-Mdm2. In vitro ubiquitination 
reactions were carried out and analyzed by Western blot with a p53 specific antibody 
(DO1). B (right panel). In vitro translated reactions prior to in vitro ubiquitination reaction 
were subject to Western blot analysis 
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3.2.2  p53 mutants are more highly ubiquitinated in vivo independently of 
Mdm2.  
The results presented so far showed that Mdm2 less efficiently ubiquitinates mutant 
p53 in in vitro reactions than wild type p53. To detect ubiquitinated p53 in cells, the in vivo 
ubiquitination  assay  was  carried  out  in  p53-/-mdm2-/-  mouse  embryonic  fibroblasts 
(DKO), which provide a clean system to analyze the activity of transfected Mdm2. Wild 
type p53 was expressed with wild type Mdm2 or Mdm2C464A, a mutant that is inactive 
for E3 activity along with HA-tagged ubiquitin. Use of HA-tagged ubiquitin allows to 
specifically  detect  ubiquitinated  p53,  and  not  other  ubiquitin-like  modifications.    To 
prevent  degradation  of  ubiquitinated  p53,  cells  were  treated  with  proteasome  inhibitor 
MG132.  Cells  were  lysed  under  strong  denaturing  conditions  in  order  to  disrupt  the 
interaction of p53 with its binding partners, so that only p53 would be immunoprecipitated 
with p53-specific antibodies. Following the lysis, p53 was immunoprecipitated with p53-
specific antibody (DO1) and ubiquitinated p53 was detected with anti-HA antibody. Some 
weak residual ubiquitination was detected when p53 was expressed on its own in DKO 
cells (Fig. 3.10), possibly due to some contribution of other endogenous ubiquitin ligases.  
 
 
Consistent with previous reports, when wild type Mdm2, but not E3-inactive Mdm-464, 
was co-expressed, heavily polyubiquitinated p53 was detected (Fig.3.10). Some modified 
FIGURE 3.10. In vivo 
ubiquitination assay. 
p53-/-mdm2-/-  cells  were 
transfected with wild type p53 
and  HA-tagged  ubiquitin 
(HA-Ub)  and  with  empty 
vector, wild type (wt) Mdm2 
or  Mdm2  C464A  mutant 
(464). Cells were treated with 
MG132  and  lysed  under 
denaturing  conditions.  Cell 
lysates  were 
immunoprecipitated with p53-
specific  antibody  (DO1)  and 
Western blotted with either an 
anti-HA antibody or the p53-
specific CM1 antibody. 
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forms of p53 were detectable in the total cell lysate by direct Western blotting with the 
p53-specific antibodies, which may be monoubiquitinated p53. Polyubiquitinated p53 was 
not visible with p53-specific antibodies, possibly due to masking of p53 by ubiquitination.  
This assay was repeated in other cell types with similar results and was routinely used to 
analyze ubiquitination of p53.  
 
Next, ubiquitination of p53 DBD mutants by Mdm2 in vivo was tested in DKO 
cells (3.11). While little ubiquitination of wild type p53 was detected in the absence of co-
expressed Mdm2 (Fig.3.11), all of the p53 mutants that adopt an altered conformation 
(DBD deletions and p53175H) were already heavily ubiquitinated in the absence of Mdm2 
(Fig.3.11). This may be due to the activity of the endogenous ubiquitin ligases, which 
selectively ubiquitinate mutant, but not wild type p53. This suggests that mutation in the 
DBD promotes Mdm2-independent ubiquitination of p53. To test if “mutant” conformation 
of DBD is required for Mdm2-independent ubiquitination, the contact p53 mutant 273H 
was included. The p53273H mutant behaved much more like wild type p53 in the in vivo 
ubiquitination assay. The p53273H was not ubiquitinated in the absence of Mdm2, and 
only  when  Mdm2  was  co-expressed  polyubiquitination  was  detected  (Fig.3.11). 
FIGURE 3.11. Analysis of ubiquitination of p53 DBD mutants in p53-/-mdm2-/- 
cells. 
p53-/-mdm2-/-  cells  were  transfected  with  wild  type  p53  or  the  indicated  p53 
mutants  and  HA-tagged  ubiquitin  (HA-Ub)  and  with  empty  vector  or  wild  type 
Mdm2. Cells were treated with MG132 and lysed under denaturing conditions. Cell 
lysates  were  immunoprecipitated  with  p53-specific  antibody  (DO1)  and  Western 
blotted with either an anti-HA antibody or the p53-specific CM1 antibody. 
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Expression of Mdm2 substantially increased the levels of ubiqutination of the wild type 
p53 protein, but had a less pronounced effect on enhancing the ubiquitination of the p53 
mutants (Fig.3.11). This is consistent with the less efficient ubiquitination of p53 mutants 
by Mdm2 seen in vitro (Fig.3.9). In other words, though wild type p53 and p53 mutants are 
ubiquitinated to similar levels when Mdm2 is overexpressed, ubiquitination of wild type 
p53 is almost entirely mediated by Mdm2, whereas ubiquitination of p53 mutants results 
from  Mdm2-independent  and  Mdm2-mediated  ubiquitination.  Given  that  Mdm2  is 
overexpressed,  it  seems  that  the  contribution  of  endogenous  ubiquitin  ligase  to 
ubiquitination of mutant p53 is quite pronounced. These results were reproduced several 
times. To confirm the results in other cell types, the ubiquitination assay was repeated in 
H1299 cells (Fig.3.12).  
 
 
To test if the endogenous Mdm2 can contribute to ubiquitination of mutant p53 in 
H1299 cells, the assay was carried out with wild type p53, p53ΔI, p53ΔV and p53ΔV/ΔI, a 
DBD  mutant,  deficient  in  N-terminal  interaction  with  Mdm2  (Fig.3.13).  The  weak 
FIGURE 3.12. Analysis of ubiquitination of p53 DBD mutants in H1299 cells.  
H1299 cells were transfected with wild type p53 or the indicated p53 mutants and HA-
tagged ubiquitin (HA-Ub) and with empty vector or wild type Mdm2. Cells were treated 
with  MG132  and  lysed  under  denaturing  conditions.  Cell  lysates  were 
immunoprecipitated with p53-specific antibody (DO1) and Western blotted with either an 
anti-HA antibody or the p53-specific CM1 antibody. 
   99 
polyubiquitination signal on wild type p53 was observed in this experiment (Fig.3.13), and 
p53 lacking box I, incapable of interacting with Mdm2, was ubiquitinated similarly to wild 
type p53, suggesting that residual ubiquitination of wild type p53 observed in these cells 
was  not  mediated  by  Mdm2  (Fig.3.13).  Consistent  with  previous  data,  p53ΔV  was 
hyperubiquitinated, and deletion of box I did not reduce ubiquitination (Fig.3.13). These 
data confirm the result in DKO and were reproduced in 3 independent experiments. The 
observation that box I is not required for this alternative ubiquitination also suggests there 
is no competition between Mdm2 and this other E3.  
 
In summary, Mdm2 contributes to ubiquitination of mutant p53, though to a lesser 
extent  than  to  that  of  wild  type  p53.  The  conformational  change  in  the  DNA  binding 
domain  promotes  the  Mdm2-independent  ubiquitination  of  p53  mutants.  The  Mdm2-
independent ubiquitination is discussed in more details in chapter 4.  
 
3.3  Analysis of degradation of p53 DBD mutants by Mdm2. 
Despite the weak effect of Mdm2 on ubiquitination of the mutant p53s, previous 
reports have shown clearly that Mdm2 can contribute to the degradation of the p53 DBD 
mutants in cells (246, 519). The data of previous subchapter suggest that Mdm2 may play a 
role in the degradation of mutant p53s that is distinct from ubiquitination. Indeed, two 
FIGURE 3.13. Deletion of Mdm2-
binding site on p53 mutant does 
not reduce ubiquitination in 
H1299 cells. 
H1299  cells  were  transfected  with 
wt  p53  or  indicated  p53  mutants 
with  empty  vector  or  wild  type 
Mdm2  and  with  HA-ubiquitin  and 
treated  with  MG132.  Cell  lysates 
were immunoprecipitated with p53-
specific  antibody  (DO1)  and 
Western blotted with either an anti-
HA  antibody  or  the  p53-specific 
CM1 antibody. 
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roles for Mdm2 in the degradation of wild type p53 have been suggested recently – one to 
ubiquitinate p53 and one to deliver it to the proteasomes (328-330). The ability of Mdm2  
to degrade p53 DBD mutants and the contribution of its ubiquitin ligase activity were 
investigated in this subchapter. 
First, the degradation ability of Mdm2 towards wild type p53 was verified in the 
DKO cells. In this experiment DKO cells were transfected with wild type p53 along with 
empty vector or wild type Mdm2. In order to analyze the degradation of p53 protein more 
accurately, GFP was co-transfected to control for the transfection efficiency. Cells were 
untreated or treated with proteasome inhibitor MG132 and protein levels of p53 and GFP 
were assessed with the p53- and GFP-specific antibodies by Western blotting (Fig.3.14). 
p53 protein levels were significantly decreased upon the co-expression of Mdm2.  
 
  
(Fig.3.14).  This  was  inhibited  when  cells  were  treated  with  proteasome  inhibitors, 
confirming that Mdm2 degrades p53 by targeting it to the proteasomes. Appearance of 
higher  modified  forms  of  p53  was  seen,  when  cells  were  treated  with  proteasome 
inhibitors,  which  may  be  ubiquitinated  p53.  It  should  be  noted,  that  the  efficiency  of 
Mdm2-mediated degradation varied to a certain extent between the experiments, however 
usually the ratio 3:1 of Mdm2 to p53 plasmids was used for degradation effect. 
 
FIGURE 3.14. Mdm2-mediated 
proteasomal degradation of p53. 
p53-/-mdm2-/-  MEFs  were 
transfected  with  wild  type  p53  and 
with empty vector or wild type Mdm2 
and  were  untreated  or  treated  with 
proteasome  inhibitor  MG132  where 
indicated. GFP was co-transfected to 
control  for  transfection  efficiency. 
Western blot analysis was done with 
p53 and GFP-specific antibodies. 
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3.3.1  p53 DBD mutants are degraded by Mdm2 in vivo independent of the N‐
terminal interaction. 
After the system was set up, the degradation of p53 DBD mutants - p53175H, 
p53273H,  p53ΔV  and  p53ΔIII  -  was  tested  in  DKO  cells.  All  experiments  in  this 
subchapter were done in the absence of proteasome inhibitors (Fig.3.15). Though mutant 
p53 protein accumulates to high levels in tumours and was shown to have an extended half 
life in some tumour cell lines (41, 517-519), p53 mutant proteins were expressed at levels 
similar to wild type p53 protein when transiently expressed in cells (Fig.3.15). This was 
observed in many experiments, though with some variation of the expression levels. Equal 
levels  of  GFP  were  expressed  in  this  experiment,  suggesting  similar  transfection 
 
efficiency. Similarly to Fig. 3.14, wild type p53 was degraded by Mdm2 in this experiment 
(Fig.3.15), though the degradation appeared to be somewhat less efficient than in the result 
in Fig.3.14. However, there was no apparent difference in the ability of Mdm2 to degrade 
p53  DBD  mutants  (Fig.3.15),  consistent  with  previous  reports  (158).  Mdm2  degraded 
conformational 175H and contact 273H p53 mutants with similar efficiency to wild type 
p53  (Fig.3.15),  suggesting  the  ability  of  Mdm2  to  degrade  p53  does  not  depend  on 
conformation  of  p53  DBD.  The  result  of  this  experiment  was  confirmed  in  several 
independent experiments, some of which are discussed later.  
FIGURE 3.15. p53 DBD mutants are degraded by Mdm2. 
p53-/-mdm2-/- cells were transfected with indicated p53 plasmids and with empty 
vector  or  wild  type  Mdm2.  GFP  was  co-transfected  to  control  for  transfection 
efficiency. Western blot analysis was carried out with p53-specific (DO1), Mdm2-
specific and GFP-specific antibodies. 
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As shown above, Mdm2 can interact with mutant p53 lacking the N-terminal binding site 
(Fig.3.3).  Therefore, the ability of Mdm2 to degrade p53 proteins lacking box I was tested 
in  DKO  cells  (Fig.  3.16).  Consistent  with  published  reports  (246),  wild  type  p53  was 
efficiently  degraded  by  Mdm2,  whereas  deletion  of  box  I  rendered  p53  resistant  to 
degradation (Fig.3.16). This is consistent with the crucial role of the N-terminal interaction 
between p53 and Mdm2 in the ability of Mdm2 to ubiquitinate and degrade wild type p53 
(Fig.3.16).  Interestingly,  Mdm2  was  also  able  to  target  the  degradation  of  p53  DBD 
mutants lacking box I, although clearly to a lesser extent than p53 DBD mutants that retain 
box I (Fig.3.16). This is consistent with the ability of Mdm2 to interact with the p53 DBD 
mutants lacking box I. This result was confirmed in at least four independent experiments. 
In  this  experiment  the  levels  of  Mdm2  were  slightly  higher  when  co-transfected  with 
mutant p53, which can be explained by higher transfection efficiency as evidenced by 
higher GFP levels. This result implies that the mechanism of Mdm2-mediated degradation 
of mutant p53 does not require the N-terminal interaction between p53 mutant and Mdm2, 
suggesting that the E3 activity of Mdm2 does not need to be activated. This suggests that 
Mdm2 can directly target p53 mutants that have been ubiquitinated by other E3 to the 
proteasomes. 
To support these observations, the effect of Mdm2 mutant lacking the N-terminus 
Mdm2ΔN (Δ58-89) was examined. The N-terminus of p53 has been reported to interact 
only with the N-terminal p53 binding site on Mdm2 (266, 587). Therefore, if box I is not 
required  for  degradation  of  p53  mutants  by  Mdm2,  Mdm2ΔN  should  still  be  able  to 
degrade  mutant  p53.  To  test  this,  wild  type  p53,  p53ΔV  or  p53175H  mutants  were 
expressed along with wild type Mdm2 or with Mdm2 ΔN (Fig.3.17). In agreement with the 
published data (563), Mdm2ΔN only weakly degraded wild type p53, confirming that the 
N-terminal p53 binding site on Mdm2 is required for efficient degradation of wild type 
p53.  (Fig.3.17).  Mdm2  (Δ58-89aa)  retained  some  ability  to  degrade  the  p53  mutants 
(Fig.3.17), consistent with the ability of Mdm2 to degrade p53 mutants in the absence of    103 
FIGURE 3.16. p53 DBD mutants lacking box I are degraded by Mdm2. 
p53-/-mdm2-/- cells (A, B, C) were transfected with wild type p53 and ΔI and 
p53 DBD mutants: ΔV and ΔV/ΔI (A); 175H and 175H/ΔI (B); ΔII and ΔII/ΔI 
(C) along with empty vector or wild type Mdm2. GFP was co-transfected to 
control for transfection efficiency. Western blot analysis was carried out with 
p53-specific (1801), Mdm2-specific and GFP-specific antibodies.  
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the  N-terminal  interaction.  The  result  of  this  experiment  was  reproduced  in  two 
independent experiments.  
These  results  are  consistent  with  a  model,  in  which  mutant  p53  has  been 
ubiquitinated independently of Mdm2 and can be targeted to the proteasome by Mdm2. 
This  activity  of  Mdm2  does  not  appear  to  require  the  interaction  between  N-terminal 
domains of Mdm2 and p53. However, it was consistently noticed that this degradation of 
mutant p53 was less efficient than that seen when the N-terminal interaction site was intact  
(Fig.3.16, 3.17), suggesting that the mechanisms that degrade wild type p53 still contribute 
to the degradation of the mutant p53s.  
 
To test the contribution of the N-terminal interaction to degradation of p53 mutants 
by Mdm2 in another cell type the experiment was repeated in H1299 cells (Fig.3.18). Wild 
type p53 or p53ΔI and p53175H or p53175/ΔI were co-transfected with empty vector or 
wild  type  Mdm2.  In  these  cells  wild  type  p53  was  degraded  by  Mdm2  much  less 
efficiently  than  in  DKO  (Fig.3.18).  Similarly  to  the  result  in  DKO  cells,  p53ΔI  was 
resistant to degradation by Mdm2 (Fig.3.18). In this experiment, the expression levels of 
different  p53  mutants  were  somewhat  variable,  although  this  was  not  seen  in  other 
experiments in H1299 (Fig.3.18). Both p53 DBD mutants lacking box I were resistant to 
degradation by Mdm2 (Fig.3.18), which is inconsistent with the observation seen in DKO 
cells (Fig.3.18). This result was observed in another independent experiment. It is not clear  
FIGURE 3.17. Mdm2 lacking N-terminus retains the ability to degrade p53 
DBD mutants.  
p53-/-mdm2-/- cells were transfected with wild type p53 or indicated p53 DBD 
mutants along with empty vector or wild type Mdm2 or Mdm2 with deletion of 
58-89aa  (ΔN).  GFP  was  co-transfected  to  control  for  transfection  efficiency. 
Western blot analysis was carried out with p53-specific (1801), Mdm2-specific 
and GFP-specific antibodies.  
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why Mdm2 fails to degrade mutant p53 lacking box I in this system and may be due to less 
potent ability of Mdm2 to degrade wild type p53 in this system. It is possible that in the 
process of tumourigenesis H1299 have lost one of the factors necessary for the efficient 
degradation of p53 in the proteasomes. It would therefore seem possible that the efficiency 
with which Mdm2 can target mutant p53 for degradation varies between cell types. 
The binding studies showed that the interaction of mutant p53 that is independent 
of the N-terminal binding region (box I) requires the C-terminal RING domain (Fig.3.7). 
Therefore the ability of Mdm2 lacking this region to target the degradation of the DBD p53 
mutants (ΔV and 175H) lacking box I in DKO cells was tested. Consistent with studies by 
others (270), ubiquitin ligase inactive Mdm2 mutants ΔR and 464 were expressed higher 
than wild type Mdm2 (Fig.3.19). This is probably due to inability of these mutants to 
autoubiquitinate and degrade themselves (175). As expected, deletion of box I in wild type 
p53 prevented degradation by all forms of Mdm2 (Fig.3.19). As shown above (Fig.3.13), 
wild type Mdm2 retained some ability to degrade p53 DBD mutants, lacking the box I 
(Fig.3.16). This activity was lost by deletion of the RING domain of Mdm2 (Mdm2ΔR) 
but was retained by the Mdm2-464 (Fig. 3.19), which has lost E3 activity but still binds to 
the p53 DBD mutant (Fig.3.7). These results therefore support the model in which Mdm2 
can target degradation of the mutant p53s through a mechanism, which does not require the 
E3 activity of Mdm2. 
FIGURE 3.18. p53 DBD mutants lacking box I are resistant to degradation by 
Mdm2 in H1299 cells. 
H1299 cells were transfected with wild type p53 or the indicated p53 mutants with empty 
vector or wild type Mdm2. GFP was co-transfected to control for transfection efficiency. 
Western blot analysis was carried out with p53-specific (1801), Mdm2-specific and GFP-
specific antibodies.  
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FIGURE 3.19. Mdm2C464A is able to degrade p53 DBD mutants lacking box I.  
p53-/-mdm2-/- cells were transfected with indicated p53 mutants with empty vector or 
with wild type Mdm2, Mdm2 truncated from amino acid 440 (ΔR) or the Mdm2C464A 
mutant (464). GFP was co-transfected to control for transfection efficiency. Western 
blot analysis was carried out with p53-specific (1801), Mdm2-specific (Ab-1, Ab-2) and 
GFP-specific antibodies. 
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Most of the studies described so far depend on the transient expression of p53 and 
Mdm2 mutants. Next the contribution of the endogenous Mdm2 to to the degradation of 
the endogenous wild type p53 and stably expressed mutant p53 was analysed. To this end 
MCF7 breast carcinoma cells, which express endogenous wild type p53 and stably express 
exogenous p53 DBD mutant (p53ΔII) were used (567). The p53 ΔII mutant has a deletion 
of the conserved box II in the DBD. These cells express endogenous Mdm2 to a level that 
can drive the degradation of both the wild type and mutant p53 - although somewhat 
higher basal levels of mutant p53 are maintained in these cells – and exposure of these 
cells to stress leads to the coordinate stabilization of both the mutant and wild type p53 
proteins (567).  In this system, p53 mutant lacking the N-terminal Mdm2 binding domain 
(ΔI) – p53ΔII/I is expressed at high levels and not further stabilized in response to stress 
(567). 
The advantage of this system is that p53ΔII mutant migrates slightly slower than 
wild type p53 on the gel, which allows the analysis of both wild type and p53ΔII proteins 
in  the  same  cell,  under  exactly  the  same  experimental  conditions.  To  examine  the 
contribution of Mdm2 to the stability of wild type p53 and the p53ΔII mutant in this 
system, an siRNA-mediated approach to reduce endogenous Mdm2 was used. Cells were 
transfected with control or Mdm2-specific siRNA oligonucleotides and protein levels of 
p53  and  Mdm2  were  analyzed  (Fig.3.20A).  In  this  and  the  subsequent  experiments  to 
control for equal amount of total protein, cdk4 expression was monitored. In agreement 
with previous publications (567), p53ΔII was expressed at higher levels than wild type p53 
(Fig.3.20A). This can be due to higher stability of p53ΔII in these cells or could be due to 
expression from the efficient CMV-driven promoter. Using previously published Mdm2-
specific siRNA oligonucleotides, Mdm2 expression was significantly reduced (Fig.3.20A). 
Consistent with the ability of Mdm2 to degrade both wild type and mutant p53, wild type 
p53 and the p53ΔII mutant were stabilized to a similar extent when Mdm2 expression was 
down-regulated  (Fig.3.20A).  This  result  was  confirmed  with  another  pair  of  Mdm2-
specific  siRNA  oligonucleotides  in  independent  experiments.  As  shown  above, 
degradation of wild type p53 is entirely dependent on the N-terminal interaction between 
p53  and  Mdm2,  whereas  mutant  p53  can  be  degraded  by  Mdm2  independently  of  N-
terminal interaction (Fig.3.15, 3.16). Therefore it can be predicted that blocking N-terminal 
interaction between p53 and Mdm2 would have a stronger effect on stabilization of wild 
type  p53  than  on  mutant  p53.  To  examine  the  effect  of  disrupting  the  N-terminal 
p53/Mdm2 interaction a small-molecule inhibitor nutlin-3 was used. Nutlin-3 specifically 
binds to the p53-binding pocket in the N-terminus of Mdm2, preventing the interaction   108 
through  the  N-terminal  domains  and  stabilizing  wild  type  p53  (282).  The  effect  of 
treatment with nutlin-3 on stabilization of wild type and mutant p53 proteins was tested in 
MCF7 cells expressing p53ΔII (Fig.3.20B). For initial test of the effect of nutlin-3, cells 
were treated with 5µM nutlin-3 for 3h and 6h and with 15µM nutlin for 6h (Fig.3.20B). As 
expected  wild  type  p53  was  substantially  stabilized  upon  treatment  with  nutlin-3, 
consistent  with  a  major  role  of  the  N-terminal  interaction  between  p53  and  Mdm2  in 
regulation of wild type p53 stability (Fig.3.20B). The stabilization of wild type p53 was 
very  pronounced  already  after  3h  of  treatment  with  5µM  of  nutlin-3  and  was  further 
stabilized when cells were treated for 6h with 15µM of nutlin-3 (Fig.3.20B). Interestingly, 
the p53ΔII mutant was stabilised by nutlin-3 to a much lesser extent than wild type p53 
(Fig.3.20B). And on the short exposure it was observed that wild type p53 was stabilized 
to higher levels than mutant p53, even though wild type p53 was expressed at lower levels 
than p53ΔII in untreated cells (Fig.3.20B). This result is consistent with the observation 
that degradation of mutant p53 does not completely depend on the N-terminal interaction 
between p53 and Mdm2. To test if accumulation of p53ΔII upon treatment with nutlin-3 
was due to contribution of the N-terminal interaction to degradation of mutant p53, MCF7 
cells  expressing  p53  mutant  lacking  box  I  -  p53ΔII/ΔI  –  were  treated  with  nutlin-3 
(Fig.3.20C).  In  these  cells  wild  type  p53  was  stabilized  upon  treatment  with  nutlin-3, 
however nutlin-3 did not lead to accumulation of p53ΔII/ΔI (Fig.3.20C). This could be 
explained by inability of p53ΔII/ΔI to interact with Mdm2 via N-termini. This suggests 
that nutlin-3 specifically inhibits the N-terminal binding of Mdm2 to p53, and therefore 
does not stabilize p53ΔII/ΔI. Therefore, weak accumulation of p53ΔII upon treatment with 
nutlin-3 (Fig.3.20B) is dependent on box I. This is consistent with some resistance of 
p53DBD mutants lacking box I to degradation by Mdm2 (Fig.3.16). In this experiment it 
was also noted that wild type p53 in MCF7p53ΔII/ΔI was stabilized less well than in 
MCF7p53ΔII cells, which suggests that p53ΔII/ΔI inhibits accumulation of wild type p53 
(Fig.3.20C). The experiment was repeated in a different clone of the MCF7/p53ΔII cells. 
Since  the  most  efficient  stabilization  of  wild  type  p53  was  observed  at  higher 
concentration, the experiment was repeated with 20µM of nutlin-3 and cells were treated 
for 4h and 7h (Fig.3.20D). Consistent with previous data, upon treatment with nutlin-3 
wild type p53 protein accumulated, whereas the levels of p53ΔII only weakly increased 
(Fig.3.20D).  The  result  discussed  here  was  observed  in  at  least  four  independent 
experiments. When the film was exposed for longer, modified forms of p53 were noted, 
which increase with longer treatment (Fig.3.20D). This could be ubiquitinated p53, which 
is  inefficiently  degraded.  In  this  system  it  was  not  possible  to  distinguish  between   109 
ubiquitinated wild type and mutant p53 proteins. Nutlin-3 also leads to upregulation of 
Mdm2,  which  has  been  noted  previously  (282)  and  has  been  suggested  to  be  due  to 
 
FIGURE 3.20 p53ΔII is stabilized by nutlin-3 treatment less than wild type p53.  
A. MCF7 cells stably transfected with p53ΔII and expressing endogenous wild type p53 
(MCF7-ΔII) were transfected twice with non-targetting (ctrl) or Mdm2-specific siRNA 
oligonucleotides. Cells were lysed 48 hours later and Western blot analysis was carried 
out with p53-specific (1801), Mdm2-specific or cdk4 specific antibodies. B, C. MCF7-ΔII 
(B) or MCF7-ΔII/ΔI (C) cells were treated with indicated concentrations of Nutlin-3 for 
3h and 6 h. D. MCF7-ΔII cells were treated with 20µM nutlin-3 for 4h and 7h hours. 
B,C,D. Cell lysates were analysed by Western blot with p53-specific (1801) and cdk4 
specific antibodies.  
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transactivation  by  p53  (Fig.3.20D).  This  can  suggest  that  p53ΔII  does  not  impair 
transcriptional activity of wild type p53. It would be interesting to check other target genes 
of p53 in this system and to compare MCF7/ΔII to parental MCF7 cells. However in this 
experiment the levels of Mdm2 protein are markedly increased already after four hours of 
nutlin-3 treatment, suggesting that protein stabilization mechanism can be involved.  
These  results  are  consistent  with  the  observation  that  Mdm2  can  degrade  p53 
mutants  through  a  mechanism  that  does  not  depend  on  the  N-terminal  interaction 
(Fig.3.16).  Degradation  of  wild  type  p53  is  entirely  dependent  on  the  N-terminal 
interaction  with  Mdm2,  therefore  nutlin-3  has  a  much  more  pronounced  effect  on 
accumulation of wild type p53 than of p53 mutant. The fact that wild type p53 is stabilised 
more by treatment with nutlin-3 than mutant p53 might have an important implication for 
cancer treatments of tumours expressing mutant and wild type p53. It would be interesting 
to test the effect of nutlin-3 on endogenous mutant p53 in tumour-derived cell lines. 
 
3.3.2  Mdm2 interacts with the proteasomal subunits. 
The observation that Mdm2 can degrade p53 mutants independently of its ubiquitin 
ligase activity (Fig.3.19) suggests that Mdm2 can play a role in delivery of p53 to the 
proteasomes. Some evidence suggest that the acidic domain of Mdm2 can be involved in 
postubiquitination role of Mdm2 (328-330). Others have shown that Mdm2 can interact 
with the C8 subunit of the proteasome, which is necessary for degradation of Rb protein 
(243). The ability of Mdm2 to interact with subunits of the proteasome was therefore tested 
by co-immunoprecipitation analysis in H1299 cells. These cells were used due to the low 
levels of endogenous Mdm2 and their high transfection efficiency. As shown above, RING 
domain of Mdm2 was important for the interaction and the ability to degrade mutant p53. 
Wild type Mdm2 or Mdm2 lacking RING domain (ΔR) were co-expressed with V5-tagged 
proteasome subunits: S4, S5α, S6α and Sβ (Fig.3.21). The V5 tag allows to easily detect 
the transfected proteins in cells and to discriminate between transfected and endogenous 
proteasome  subunits.  S5α  is  the  non-ATPase  subunit,  S4,  S6α a nd  S6β  are  ATPases, 
which are contained within the regulatory 19S part of proteasome. Cells were treated with 
proteasome inhibitors to prevent degradation of Mdm2. Mdm2 was immunoprecipitated 
with Mdm2-specific antibodies and the proteasome subunits in the immunoprecipitates 
were detected with antibody specific for V5. Direct western blotting analysis was carried 
out with Mdm2-specific and V5-specific antibodies to control for the levels of expression. 
Although  cells  were  treated  with  proteasome  inhibitors,  somewhat  higher  levels  of   111 
Mdm2ΔR were observed, which could be due to more efficient transfection or expression 
of  these  constructs  in  this  experiment  (Fig.3.21).  This  resulted  in  larger  ammounts  of 
immunoprecipitated  Mdm2  mutants  compared  to  wild  type  (Fig.3.21).  All  proteasome 
subunits  were  expressed,  as  visualized  by  the  detection  with  V5-specific  antibody 
(Fig.3.21).  Some  background  band  was  detected  with  V5  antibody  in  the 
immunoprecipitates  where  no  Mdm2  was  expressed  (Fig.3.21).  Interaction  between  all 
proteasome subunits with wild type Mdm2 was detected, which was quite strong with V5-
S6β subunit, but interaction with other subunits - S4, S5α, and S6α - was only slightly 
above the background (Fig.3.21). However, all proteasome subunits interacted with the 
Mdm2ΔR (Fig.3.21). ATPase subunits appeared to interact with Mdm2 better than non-
ATPase subunit S5α. The ability of Mdm2 to interact with several proteasomal subunits 
tested here suggests that Mdm2 might be engaged in complex with the entire proteasome. 
This would suggest that the RING domain is not involved in the interaction of Mdm2 with 
the proteasome, probably due to its binding to p53. To confirm the interaction of Mdm2 
with some proteasome subunits and to test the involvement of other functional domains of 
Mdm2, the co-immunoprecipitation analysis was repeated with wild type Mdm2, Mdm2 
lacking part of the acidic domain (245-295aa) - ΔA and Mdm2 lacking N-terminus ΔN 
with S4 and S6β subunits (Fig.3.22). Some studies have shown the involvement of this part 
of the acidic domain in post-ubiquitination function of Mdm2 (328, 329). The levels of 
wild  type  Mdm2  and  Mdm2  mutant  proteins  were  more  similar  in  this  experiment 
(Fig.3.22).  In  this  experiment  both  S4  and  S6β  subunits  interacted  with  Mdm2  more 
efficiently than in the previous experiment (Fig.3.20). Mdm2 lacking acidic domain (ΔA) 
or N-terminus (ΔN) interacted with S4 and S6β subunits similarly to wild type Mdm2 
(Fig.3.22), suggesting that other regions on Mdm2 mediate the interaction. These suggest 
that Mdm2 can form complex with the proteasome, which can contribute to its degradation 
function.  The  region  Mdm2  involved  in  interaction  with  proteasome  remains  to  be 
determined in future experiments.  
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FIGURE 3.21. Interaction of wild type Mdm2 and Mdm2ΔR with the 
proteasomal subunits. 
U2OS cells were tranfected with wild type Mdm2, Mdm2ΔN or Mdm2ΔR along 
with V5-tagged proteasomal subunits S4, S5α, S6α and Sβ. Cells were treated with 
MG132  and  lysed  4h  later.  Cell  lysates  were  immunoprecipitated  with  Mdm2-
specific antibodies and immunoblotted with Mdm2 or V5. 
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FIGURE 3.22. Analysis of the involvement of the N-terminus and the acidic 
domain of Mdm2 to the interaction with the proteasomal subunits. 
U2OS  cells  were  tranfected  with  wild  type  Mdm2,  Mdm2ΔN  (58-89aa)  or 
Mdm2ΔA (245-295aa) along with V5-tagged proteasomal subunits S4 and S6β. 
Cells  were  treated  with  MG132  and  lysed  4h  later.  Cell  lysates  were 
immunoprecipitated  with  Mdm2-specific  antibodies  and  immunoblotted  with 
Mdm2 or V5. 
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3.4  Summary and discussion. 
In this chapter it has been shown that while Mdm2 retains the ability to interact 
with conformationally altered p53 DBD mutants, this interaction appears to be shifted from 
the N-terminal binding site that is predominantly used on wild type p53, to an alternative 
site on mutant p53. Whereas N-terminus of Mdm2 binds to N-terminus of with wild type 
p53, here it has been found that RING domain of Mdm2 is involved in binding to mutant 
p53. Several recent studies have shown that p53 can bind to Mdm2 through the DBD (265, 
266,  578)  and  it  seems  likely  that  the  conformational  shift  in  mutant  p53  reveals  this 
binding site, thereby enhancing the interaction of mutant p53 with Mdm2 in a conserved 
box I-independent manner. The exact binding site on the DBD of p53 has not been mapped 
and one report suggests it can be between the boxes IV and V (578).  
Mdm2 also contains several sites of interaction with p53 (256, 264-266). Recent 
studies  have  suggested  that  N-terminal  interaction  between  Mdm2  and  p53  triggers  a 
conformational  switch  in  Mdm2  that  is  required  to  promote  a  second  interaction  that 
involves the acidic domain of Mdm2 and DBD of p53 (265). Taken together with this 
study, it would appear that a conformational change in both p53 and Mdm2 contributes to 
their interaction through regions distinct from the N-terminus.  
While other studies have shown an importance of the acidic domain of Mdm2 in 
alternative interactions with p53 (264-266), this study shows that the RING finger domain 
of Mdm2 is involved in binding to mutant p53. Although the RING finger domain of 
Mdm2 is required for ubiquitin ligase activity (564), this function is not necessary for the 
binding  to  mutant  p53,  as  demonstrated  by  the  E3  dead  Mdm2  point  mutant  C464A. 
Furthermore,  the  interaction  of  Mdm2  with  mutant  p53  does  not  lead  to  the  strong 
ubiquitination of p53 that is seen following interaction with the wild type p53 protein. This 
may reflect – to some extent – a lack of interaction with the N-terminus of Mdm2 that has 
been  suggested  to  be  required  to  activate  E3  function  (265).  It  is  also  possible  that 
engagement of the RING domain in the interaction with mutant p53 impedes the binding 
of E2. Mdm2 can function with several E2s – UbcH5-A, -B, -C and E2-25K to ubiquitinate 
p53 in vitro. However, only UbcH5B and C appear to contribute to the regulation of p53 
protein levels in cells (177). It is an intriguing possibility that binding of mutant p53 to the 
RING domain Mdm2 promotes pairing with different E2, which may result in less efficient 
ubiquitination  or  promote  other  type  of  linkage  of  ubiquitin  chain,  and  remains  to  be 
elucidated in future.    115 
Binding of mutant p53 to the RING domain of Mdm2 might impair its ubiquitin 
ligase activity towards its other substrates. Mdm2 can autoubiquitinate itself (564) and 
Mdmx (588, 589). Therefore it is possible that mutant p53 may lead to accumulation of 
Mdm2 and Mdmx, which would inactivate wild type p53. In some tumor cell lines high 
levels of mutant p53 and high levels of Mdm2 are detected (518), supporting this idea.  
The  interesting  question  remains  whether  Mdm2  is  able  to  interact  with  mixed 
tetramers of wild type and mutant p53 and which regions on Mdm2 would be involved in 
such interaction.  It would be interesting to determine which protein, wild type or mutant, 
is dominant in determining whether Mdm2 interacts with the N-terminus or RING and 
whether Mdm2 is able to ubiquitinate and degrade the complex of wild type and mutant 
p53. This question can be investigated by using tagged versions of p53 proteins.  
It would be also interesting to test whether the RING domain of Mdmx, which is 
highly similar to RING domain of Mdm2, plays a role in the interaction with mutant p53. 
Though Mdmx fails to ubiquitinate p53 on its own, Mdmx can restore the E3 activity of 
inactive  Mdm2  mutants  with  point  mutations  in  the  extreme  C-terminus  and  promote 
degradation of p53 (270). The interesting question whether Mdmx can ubiquitinate p53 
mutants, which are not efficiently ubiquitinated by Mdm2, remains to be determined in 
future.   
Results of this chapter show that though the ability of Mdm2 to ubiquitinate p53 
mutants is compromised, it can still efficiently degrade p53 mutants, though through a 
different  mechanism.  The  ability  to  degrade  did  not  absolutely  require  N-terminal 
interaction between mutant p53 and Mdm2 and was also independent of the ability of 
Mdm2 to function as an E3. Previous reports have also suggested that the ubiquitination 
function of Mdm2 can be uncoupled from its ability to target to degradation (328-330). 
This study provides further evidence that Mdm2 can play a post-ubiquitination role in 
degrading p53. The details of such a function of Mdm2 are not yet clear, but have been 
suggested  to  involve  cooperation  with  hHR23A  –  a  protein  thought  to  be  an  adaptor 
between ubiquitinated substrates and the proteasome (330, 331). Another study has also 
shown that Mdm2 can play a role in transport to the proteasomes by directly interacting 
with  the  C8  subunit  of  the  20S  proteasomes  (243).  This  mechanism  of  degradation  is 
important for the degradation of another substrate of Mdm2 – Rb. It has been further 
shown here that Mdm2 can also interact with 19S proteasomal subunits. This data suggests 
that Mdm2 can form a complex with the proteasome and may play a role in the entry of the 
ubiquitinated p53 to the proteasome.  
In  summary,  the  data  presented  here  suggest  that  there  are  differences  in  the 
mechanism of degradation of wild type p53 and mutant p53 by Mdm2. Mdm2 interacts   116 
with wild type p53 via the corresponding N-termini, this activates E3 activity of Mdm2 
and leads to efficient ubiquitination of p53. Ubiquitinated p53 is then delivered to the 
proteasomes by Mdm2. This step may require the binding of Mdm2 via the RING. It is 
possible that ubiquitination unfolds p53 to promote the secondary interaction of Mdm2 
with p53. Mutant p53 is already unfolded and is ubiquitinated by another E3. Therefore the 
second interaction involving the RING of Mdm2 is promoted, which results in proteasomal 
degradation  of  mutant  p53.  This  suggests  Mdm2  plays  a  postubiquitination  role  in 
degrading mutant p53 and is able to mediate the delivery of mutant p53 to the proteasome.  
The important observation of this chapter is the distinct the mechanism of Mdm2-
mediated degradation of mutant p53 which can have an important implication for tumour 
therapy. It was found here that inhibition of the N-terminal interaction by treatment with 
nutlin can stabilize wild type p53 much more than mutant p53. It would be interesting to 
test the effect of the inhibitors of E3 activity of Mdm2 on the levels of wild type and utant 
p53  proteins.  The  prediction  would  be  that  wild  type  p53  will  accumulate  more  than 
mutant p53, as its degradation is more dependent on the ubiquitin ligase activity of Mdm2. 
This remains for future investigations.   117 
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4  Analysis of Mdm2‐independent ubiquitination of p53 DBD 
mutants. 
 
The results described in chapter 3 showed that conformational p53 mutants were 
hyperubiquitinated by Mdm2-independent mechanism. It was therefore of interest to try 
and  identify  the  E3  responsible  for  this  ubiquitination.  Wild  type  p53  is  known  to  be 
ubiquitinated by many different E3s (83, 84, 178, 185, 354, 360, 361, 590) (Table 2), some 
of which may also ubiquitinate mutant p53. In this chapter the contribution of Mdm2-
dependent  and  some  Mdm2-independent  mechanisms  to  ubiquitination  of  p53  DBD 
mutants was assessed. 
 
4.1  Contribution of Mdm2‐dependent and Mdm2‐independent 
mechanisms to ubiquitination of mutant p53.  
First, an siRNA-mediated approach to downregulate the expression of the ubiquitin 
ligases was carried out using pools of four siRNA oligonucleotides (Dharmacon). The 
effect  of  reduction  of  endogenous  Mdm2,  Cop1,  ARF-BP1  (Fig.4.1,  4.2)  and  CHIP 
(Fig.4.3, 4.4) on the ubiquitination of wild type p53 and p53175H was examined in U2OS 
cells and H1299 cells. U2OS cells express endogenous wild type p53 and endogenous wild 
type Mdm2 and are efficiently transfected by siRNAs. The expression of the Mdm2, Cop1 
and ARF-BP1 was down-regulated in both cell types by the siRNA oligonucleotides. To 
reduce the expression of Mdm2, previously published siRNA oligonucleotides were used. 
The down-regulation of these E3s was verified by the Western blotting analysis. Equal 
amount of total proteins was verified by actin or Hsp90 proteins levels. The expression of 
endogenous  Cop1  could  not  be  detected  in  H1299  cells.  Wild  type  p53  was  weakly 
ubiquitinated in U2OS cells, and down-regulation of Mdm2 reduced this ubiquitination of 
wild type p53 in U2OS cells, suggesting contribution of the endogenous Mdm2 (Fig.4.1). 
However, down-regulation of Cop1 and ARF-BP1 also reduced ubiquitination of wild type 
p53 in U2OS cells, suggesting that all these E3s target wild type p53 (Fig.4.1). The weak 
signal of ubiquitination of wild type p53 did not allow an assessment of the individual 
contribution of each of them. In H1299 in this experiment ubiquitination of wild type p53 
was  not  detected  (Fig.4.2),  which  is  probably  due  to  lower  levels  of  expression  of 
endogenous Mdm2 than in U2OS cells. Confirming the data shown above, p53175H was   119 
hyperubiquitinated in U2OS (Fig.4.1) and in H1299 cells (Fig.4.2) and the reduction of 
Mdm2 expression did not decrease its ubiquitination. Therefore, similarly to DKO and 
H1299,  mutant  p53  is  ubiquitinated  by  Mdm2-independent  mechanism  in  U2OS  cells. 
Down-regulation of Cop1 weakly reduced ubiquitination of mutant p53 in U2OS cells 
(Fig.4.1),  but  not  in  H1299  cells  (Fig.4.2).  ARF-BP1  did  not  affect  ubiquitination  of 
mutant p53 in U2OS cells (Fig.4.1) and weakly increased the ubiquitination of mutant p53 
in H1299 cells (Fig.4.2). This experiment was repeated two times and no striking effect of 
Cop1 or ARF-BP1 knock-down was detected.  
FIGURE 4.1. Contribution of Mdm2, Cop1 and ARF-BP1 to ubiquitination of wild 
type p53 and p53175H in U2OS cells. 
U2OS cells were transfected twice with non-targetting (ctrl) or Mdm2, Cop1, ARF-BP1 
specific siRNA oligonucleotides with 24 h between transfections. Cells were transfected 
with wild type p53 or p53175H along with HA-ubiquitin. Cells were treated with MG132 
24h later and lysed under denaturing conditions. Cell lysates were immunoprecipitated 
with p53-specific antibody (DO1) and Western blotted with either an anti-HA antibody or 
the p53-specific CM1 antibody. Direct Western blot analysis was carried out with Mdm2 
Hsp90, Cop1, actin and ARF-BP1 specific antibodies. 
IP: immunoprecipitation. IB: immunoblotting. 
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Next, the contribution of ubiquitin ligase CHIP was investigated. Conformational 
p53 mutants are known to interact with chaperones Hsp70 and Hsp90. CHIP ubiquitinates 
the substrates bound by these chaperones (355), and therefore is an attractive candidate for 
mutant-p53 specific ubiquitin ligase. The contribution of chaperone-associated ubiqutin 
ligase CHIP to ubiquitination of mutant p53 was examined (Fig.4.3, 4.4). Down-regulation 
of  CHIP  resulted  in  a  pronounced  reduction  of  ubiquitination  of  mutant  p53  and  also 
reduced the ubiquitination of wild type p53 to a lesser extent  (Fig. 4.3). These results are 
in agreement with a previous report showing that CHIP can target to degradation both wild 
type  and  mutant  p53  (355).  To  confirm  this  result  the  experiment  was  repeated  with 
individual  siRNA  oligonucleotides.  As  alternative  control  GFP-specific  siRNA 
oligonucleotides were used in this experiment. The CHIP protein levels were difficult to 
FIGURE 4.2. Contribution of Mdm2, Cop1 and ARF-BP1 to ubiquitination of wild 
type p53 and p53175H in H1299 cells. 
H1299 cells were transfected twice with non-targetting (ctrl) or Mdm2, Cop1, ARF-BP1 
specific siRNA oligonucleotides with 24 h between transfections. Cells were transfected 
with wild type p53 or p53175H along with HA-ubiquitin. Cells were treated with MG132 
24h later and lysed under denaturing conditions. Cell lysates were immunoprecipitated 
with p53-specific antibody (DO1) and Western blotted with either an anti-HA antibody or 
the p53-specific CM1 antibody. Direct Western blot analysis was carried out with Mdm2 
Hsp90, Cop1, actin and ARF-BP1 specific antibodies. 
IP: immunoprecipitation. IB: immunoblotting. 
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detect (Fig.4.3), therefore in this experiment the expression of CHIP mRNA was analyzed 
by  RT-PCR  (Fig.4.4).  Similarly  to  Fig.4.3  downregulation  of  CHIP  expression 
significantly decreased ubiquitination of both p53 DBD mutants - p53175H and p53ΔV 
mutants  (Fig.  4.4).  This  observation  was  reproduced  in  at  least  three  independent 
experiments. The remaining ubiquitination of mutant p53 leaves the possibility that other 
unidentified ubiquitin ligases may contribute.   
 
 
Conformational p53 mutants are specifically recognized by molecular chaperones 
cells (41, 453), which can present substrates to the ubiquitin ligase CHIP (C-terminal of 
Hsp-70-interacting protein) (591). To test whether interaction with Hsp70 is required for 
the specific ubiquitination of mutant p53, expression of Hsp70 was reduced by siRNA-
mediated  knockdown  (Fig.4.5).  Down-regulation  of  Hsp70  only  partially  inhibited 
ubiquitination of p53 mutants (Fig.4.5), suggesting that other molecular chaperones may 
be involved.  
FIGURE. 4.3. Contribution of 
CHIP to ubiquitination of wild 
type p53 and p53175H. 
U2OS  cells  were  transfected 
twice  with  with  non-targetting 
(ctrl)  or  with  a  a  pool  of  CHIP 
specific  siRNA  oligonucleotides 
(Dharmacon)  with  72  h  between 
transfections.  Cells  were 
transfected with wild type p53 or 
p53175H  along  with  HA-
ubiquitin. Cells were treated with 
MG132  and  lysed  under 
denaturing  conditions.  Cell 
lysates  were  immunoprecipitated 
with p53-specific antibody (DO1) 
and  Western  blotted  with  either 
an anti-HA antibody or the p53-
specific  CM1  antibody.  Direct 
Western blot analysis was carried 
out  CHIP  and  actin  specific 
antibodies. 
IP:  immunoprecipitation.  IB: 
immunoblotting. 
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The contribution of CHIP to ubiquitination of mutant p53 suggests that CHIP may 
play a role in regulation of stability of mutant p53. Tumour cells accumulate high levels of 
mutant p53 protein, suggesting that inactivation of CHIP would be an advantageous event 
in tumourigenesis. Consistent with this prediction, a locus 16p13 where the CHIP gene is 
located  is  frequently  deleted  in  papillary  carcinomas  of  the  breast  (592).  The  data  of 
Oncomine database suggests that the expression of CHIP mRNA is reduced in several 
types of brain cancers (Oncomine www.oncomine.org) (Fig.4.6). Interestingly, data from 
GEO  profiling  database  (NIH  GEO  profiling)  suggest  that  downregulation  of  CHIP 
expression  can  be  associated  with  advanced  stage  of  colorectal  cancer  (Fig.4.6). 
Comparison of polysomal RNA from isogenic cell lines derived from primary colorectal 
cancer  and  its  metastasis  to  the  lymph  node  shows  that  CHIP  is  downregulated  in 
metastasis  (Fig.4.6).  However,  these  studies  have  not  analyzed  status  of  p53  and  this 
remains to be investigated in future.  
FIGURE. 4.4. 
Contribution of CHIP to 
ubiquitination of wild type 
p53 and p53175H. 
U2OS cells were transfected 
twice  with  with  non-
targetting  (ctrl)  or  with  a 
single pair of CHIP specific 
siRNA  oligonucleotides 
with  72  h  between 
transfections.  Cells  were 
transfected  with  wild  type 
p53 or p53175H along with 
HA-ubiquitin.  Cells  were 
treated  with  MG132  and 
lysed  under  denaturing 
conditions. Cell lysates were 
immunoprecipitated  with 
p53-specific  antibody 
(DO1)  and  Western  blotted 
with  either  an  anti-HA 
antibody or the p53-specific 
CM1  antibody.  RT-PCR 
analysis  was  carried  out 
with  CHIP  and  GAPDH 
specific primers.  
IP:  immunoprecipitation. 
IB: immunoblotting. 
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FIGURE. 4.5. Effect of siRNA-mediated reduction of Hsp70 expression on 
ubiquitination of wild type p53 and p53175H. 
U2OS cells were transfected twice with with non-targetting (ctrl) or with Hsp70 specific 
siRNA oligonucleotides with 40 h between transfections. Cells were transfected with wild 
type p53 or p53175H along with HA-ubiquitin. Cells were treated with MG132 and lysed 
under  denaturing  conditions.  Cell  lysates  were  immunoprecipitated  with  p53-specific 
antibody (DO1) and Western blotted with either an anti-HA antibody or the p53-specific 
CM1  antibody.  Direct  western  blotting  was  carried  out  with  actin  or  Hsp70  specific 
antibodies. 
IP: immunoprecipitation. IB: immunoblotting. 
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FIGURE 4.6. Anaysis of CHIP expression in cancers. 
A. CHIP mRNA expression data in normal tissue (blue) and brain cancers (red) has 
been obtained from Oncomine expression profiling database.  
B. CHIP expression is downregulated in metastatic tumor. Graph shows comparison 
of polysomal RNA from cell lines derived from human primary colorectal cancer and 
lymph node metastasis was obtained from NIH GEO profiling database. 
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4.2  Increase in ubiquitination of p53 mutants is not reflected in increased 
degradation. 
To  investigate  the  consequences  of  hyperubiquitination  of  mutant  p53  first  the 
degradation rate of p53 mutants was tested. To this end half-life of wild type p53 and p53 
mutants was measured in DKO cells. DKO cells were used in order to observe the effect of 
Mdm2-independent ubiquitination. Firstly, the half-life of wild type and mutant p53 was 
analyzed  by  blocking  protein  synthesis  with  cycloheximide  treatment  (Fig.  4.7).  As  a 
control, the levels of actin protein, which is known to have a long half-life in normal cells 
(48h) were monitored (593). The intensity of the protein bands was quantitated and the 
values of p53 were normalized to the values of actin. The results are presented on the 
graph. As expected, transfected wild type p53 had a prolonged half-life in Mdm2-null cells 
(Fig.  4.7),  suggesting  that  p53  is  not  efficiently  degraded  by  Mdm2-independent 
mechanisms.  p53  DBD  mutants  with  deletions  of  conserved  boxes  and  point  mutants 
p53175H and p53273H also had a long half-life,  and with minor variation were slightly 
less  stable  than  wild  type  p53  (Fig.4.7).  This  observation  was  reproduced  in  another 
independent  experiment.  To  confirm  this  observation,  the  half-life  of  wild  type  p53, 
p53175H,  p53ΔV  and  p53ΔIV  proteins  was  also  measured  by  pulse-chase  with 
35S-
methionine  in  DKO  cells  (Fig.  4.8).  The  intensity  of  p53  protein  was  quantified  and 
presented as a graph. Similarly, wild type p53 had a prolonged half-life and all the p53 
DBD mutants were stable similarly to wild type p53 in this experiment. The conclusion of 
this  experiment  was  confirmed  in  another  independent  experiment.  To  confirm  these 
observations in another cell type, the half-life of wild type p53 and p53 DBD mutants was 
measured by cycloheximide treatment in H1299 cells (Fig.4.9). Similarly to DKO, wild 
type p53 had a prolonged half-life in these cells, suggesting that endogenous Mdm2 in 
these  cells  does  not  degrade  transfected  wild  type  p53.  Simirlarly  to  DKO,  p53  DBD 
mutants were only slightly less stable than wild type p53 in these cells, but had quite long 
half-life and around 50% of the protein was present after 9 hours (Fig.4.9). In future it 
would be interesting to test the stability of wild type p53 and p53 DBD mutants in cells 
with higher levels of Mdm2 such as U2OS cells.  
This suggests that though p53 mutants are ubiquitinated much more than wild type 
p53, they are not less stable, suggesting that ubiquitination does not target them efficiently 
to the proteasomes. Ubiquitination can promote nuclear export of p53 (371) and therefore 
localization of p53 mutants is analyzed in Chapter 5.   126 
FIGURE 4.7. Analysis of half-life of p53 in p53-/-mdm2-/- cells by 
cycloheximide treatment.  
p53-/-mdm2-/-  cells  were  transfected  with  wild  type  p53  or  indicated  p53  DBD 
mutants. Cells were treated with cycloheximide 24h after transfection and collected 
at the indicated time points. Western blot analysis was carried out with the p53 
specific (DO1) antibody and an anti-actin antibody. The results were quantitated 
using Scion image software (NIH) and the values of p53 were normalized to the 
values of actin.  
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FIGURE 4.8. Analysis of half-life of p53 in DKO cells by pulse chase.  
p53-/-mdm2-/-  (DKO)  cells  were  transfected  with  wild  type  p53  or  indicated  p53 
DBD mutants. 24h after transfection DKO cells were pulsed [
35S] methionine/cysteine 
and chased for the times indicated. Cell lysates were immunoprecipitated with p53 
specific  antibody  DO1  and  analysed  by  SDS-PAGE.  The  results  were  quantitated 
using Scion image software (NIH). 
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FIGURE 4.9. Analysis of half-life of p53 in H1299 cells by cycloheximide 
treatment.  
H1299 cells were transfected with wild type p53 or indicated p53 DBD mutants. Cells 
were treated with cycloheximide 24h after transfection and collected at the indicated 
time  points.  Western  blot  analysis  was  carried  out  with  the  p53  specific  (DO1) 
antibody and an anti-actin antibody. The results were quantitated using Scion image 
software (NIH) and the values of p53 were normalized to the values of actin.  
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4.3  Summary and discussion. 
In this chapter it was found that despite the reduced sensitivity to Mdm2-mediated 
ubiquitination, conformational p53 mutants are recognized and ubiquitinated by another 
E3. The increased ubiquitination of some p53 mutants with altered conformation has been 
noted previously (594, 595) although here it has been shown that this effect is Mdm2-
independent. A number of other E3s that can target wild type p53 have been described 
recently (83, 84, 178, 185, 354, 360, 361, 590) and it is possible that some of them are 
responsible  for  the  ubiquitination  of  mutant  p53.  The  contribution  of  some  E3s  to 
ubiquitination of wild type and mutant p53 has been evaluated here and these data suggest 
that E3 ligases might differ in their sensitivity to the conformation of the DBD. Consistent 
with previous studies, which have shown that both wild type and mutant p53s are targeted 
to the proteasomes by CHIP (355), here it is shown that CHIP ubiquitinates wild type p53 
and mutant p53. These results suggest that CHIP may play a role in the ubiquitination and 
degradation of mutant p53, and reduced expression of CHIP in some cancers (Oncomine 
database) could contribute to the enhanced stability of mutant p53s. CHIP is implicated in 
the endoplasmic reticulum-associated degradation (ERAD), which represents an important 
means of quality control of its target proteins. Therefore ubiquitination of mutant p53 by 
CHIP can be part of the mechanism of p53 folding control. Given that the contribution of 
CHIP to ubiquitination of mutant p53 was only partial and the existence variety of E3s, 
there may be other E3s that target only mutant p53. It would be interesting to investigate if 
Mdmx contributes to ubiquitination of mutant p53. The other possibility is that wild type 
and mutant p53s differ in their sensitivity to deubiquitinases.  
These data imply that Mdm2-independent ubiquitination does not result in efficient 
degradation of mutant p53 proteins, suggesting that it lacks a degradation signal. It is 
thought that polyubiquitination consisting of at least 4 ubiquitins linked via K48 target 
proteins to the proteasomes (202). In addition, there are 6 more lysines in the ubiquitin, 
which can be used in the formation of the ubiquitin chain and have different functional 
consequences  on  the  substrate.  It  is  possible  that  Mdm2-independent  ubiquitination  of 
mutant p53 is linked via alternative lysine and therefore does not target mutant p53 for 
degradation. This possibility remains to be checked in future. Ubiquitinated mutant p53 
can  be  degraded  by  overexpression  of  Mdm2,  suggesting  it  provides  the  necessary 
degradation signal.    130 
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5  Localization of p53 DBD mutants. 
Ubiquitination of the C-terminus of p53 exposes the nuclear export signal (NES) 
and results in translocation of p53 to the cytoplasm (224, 371). Therefore it was of interest 
to check the localization of hyperubiquitinated mutant p53. The conformation of DBD of 
p53 can also be an important determinant of nuclear localization. Several studies have 
shown that temperature sensitive p53 mutant V135 localizes to the nucleus at 32°C when 
in  wild  type  conformation  but  is  in  the  cytoplasm  at  37°C,  when  it  is  in  “mutant” 
conformation,  suggesting  that  conformation  of  p53  can  be  important  determinant  of 
localization of p53 (552, 596-598). Another study has correlated mutant conformation of 
mutant p53 with cytoplasmic localization and transformation potential of 3T3 cells (599).  
In this chapter localization of p53 DBD mutants was analyzed.  
 
5.1  Ubiquitinated p53 mutant proteins localize to the cytoplasm. 
First,  subcellular  localization  of  p53  mutants  was  analyzed  in  DKO  cells.  As 
expected wild type p53 located to the nucleus in the majority of the cells. Though it was 
reproducibly  seen  that  some  small  percentage  of  cells  displayed  wild  type  p53  in  the 
cytoplasm. This could be due to overexpression of p53 in cells, which is not efficiently 
imported into the nucleus. p53273H mutant, which was not ubiquitinated in these cells 
(Figs. 3.11), was also located in the nucleus (Fig.5.1). However, the ubiquitinated p53 
mutants 175H and ΔV were present in the cytoplasm in majority of cells with a variable 
degree of nuclear localization (Fig. 5.1). The results were quantitated by counting the cells 
with cytoplasmic p53 in three independent experiments. This suggests that conformational 
p53 DBD mutants locate to the cytoplasm. This result was reproduced in at least four 
independent experiments. To confirm the results in another cell type the experiments were 
repeated  in  U2OS  cells.  U2OS  cells  express  endogenous  wild  type  p53,  which  could 
complicate the analysis of localization of the transfected p53 with p53-specific antibodies. 
However no signal of endogenous p53 was detected by p53-specific antibodies (Fig.5.2). 
When wild type p53 was transfected, it was detected mostly in the nuclei in U2OS cells, as 
expected (Fig.5.2). Therefore it was possible to use U2OS cells to analyze localization of 
transfected wild type p53 and p53 DBD mutants. Cytoplasmic localization of p53175H and 
p53ΔV was also observed in U2OS cells (Fig. 5.3), though 175H displayed more nuclear 
localization in these cells compared to DKO (Fig. 5.3). As another method of looking at    132   133 
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localization of p53, the subcellular fractionation of U2OS cells transfected with wild type 
p53,  p53175H  or  p53ΔV  was  carried  out  (Fig.  5.4).  The  fractionation  of  nuclear  and 
cytoplasmic compartments was confirmed by the expression of nuclear protein lamin A/C 
and cytoplasmic protein Hsp70 (Fig. 5.4). The conclusion of the localization data was 
reflected by subcellular fractionation in U2OS cells, where most of the wild type p53 was 
in the nucleus, 175H protein was found in both nuclear and cytoplasmic fraction and p53 
ΔV was present more in the cytoplasmic fraction than in the nucleus (Fig.5.4). It was 
consistently noticed that ΔV displayed more cytoplasmic localization than 175H (Fig. 5.1, 
5.3). The U2OS cells appeared to be a better system to analyze the localization of p53 than 
DKO cells, as they were transfected with higher efficiency and cells retained a normal 
morphology after staining. Localization of contact mutant 273H to the nucleus suggests 
that unfolded conformation of mutant p53 is required for localization to the cytoplasm. 
Taken together with the results in previous chapters, it would appear that cytoplasmic 
localization of mutant p53 correlates with their ubiquitination. 
 
 
 
FIGURE 5.4. Mutant p53 is detected in the cytoplasmic fraction of U2OS cells.  
U2OS cells were transfected with wild type p53 or indicated p53 DBD mutants. Cells 
were fractionated and cytoplasmic (C) and nuclear (N) proteins were resolved by SDS-
PAGE and analysed by Western blotting with p53-specific (DO1), Hsp70-specific and 
Lamin A/C specific antibodies.  
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5.2  Cytoplasmic localization is not due to enhanced export. 
Cytoplasmic  localization  of  an  otherwise  nuclear  protein  can  be  a  result  of 
enhanced nuclear export or less efficient nuclear import. To analyze the contribution of the 
nuclear localization (NLS) and nuclear export signals (NES) to localization of wild type 
p53 and p53 175H with mutated c-NES and NLS was analyzed (Fig. 5.5). Mutation of 
NLS, (produced by substituting Lys 305, 319, 320, 321 and Arg 306 to Ala) and has been 
shown  to  prevent  nuclear  import  of  p53  (224,  600).  Mutation  of  c-NES    (L348A  and 
L350A) has been shown to prevent nuclear export of p53 (157). Subcellular localization 
(Fig.5.6) of these p53 mutants was analyzed in U2OS cells. To inhibit nuclear export cells 
were  treated  with  leptomycin  B,  which  blocks  CRM-1-dependent  nuclear  export (601) 
(Fig.5.6). Percentage of cells with cytoplasmic p53 is presented on the graph (Fig.5.7).  
The  average  of  four  independent  experiments  for  wild  type  and  p53175H  and  of  two 
independent experiments for p53 with mutation of NLS and NES is presented (Fig.5.7). 
Wild type p53 located to the nucleus with small percentage of the cells having cytoplasmic 
p53  (Fig.5.6).  The  cytoplasmic  localization  p53  was  not  prevented  by  treatment  with 
leptomycin B or by mutating the c-NES (Fig.5.6, 5.7). This suggests that cytoplasmic 
fraction of wild type p53 is not imported into the nucleus, possibly due to overexpression. 
Leptomycin B treatment or mutation of c-NES did not decrease cytoplasmic localization of 
FIGURE 5.5. Schematic representation of the structure of p53 and p53 mutants. 
The main domains of p53, nuclear export (NES), nuclear localization (NLS) signals and 
the location of the conserved boxes I, II, III, IV and V and the corresponding deletions, 
point mutations R175H and R273H. 
TA - transactivation domain, DBD - DNA binding domain, PD - proline-rich domain, OD 
- oligomerization domain. 
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175H  in  this  experiment  and  175H  with  mutation  of  c-NES  located  to  the  cytoplasm 
similarly to 175H p53 mutant. This suggests that cytoplasmic localization of 175H is not 
due to enhanced nuclear export (Fig.5.6, 5.7). p53ΔNLS and p53175H/ΔNLS were seen 
almost exclusively in the cytoplasm, with no cells displaying distinct nuclear staining of 
p53 (Fig.5.6). This suggests that both wild type and mutant p53 can be recognized by 
nuclear import machinery, which is mediated via c-terminal NLS and other NLSs do not 
appear to contribute. To confirm these results the experiments were repeated in the DKO 
cells (Fig.5.8, 5.9). Similarly to observations made in U2OS cells, blockage of nuclear 
export by leptomycin B treatment did not prevent cytoplasmic localization of p53ΔV or 
p53175H  in  these  cells  (Fig.5.8).  175H  with  mutation  of  NES  displayed  cytoplasmic 
staining similar to 175H, whereas 175HΔNLS located almost exclusively to the cytoplasm 
(Fig.5.9). These results confirm the finding in U2OS cells and suggest that mutant p53 
localization to the cytoplasm is not due to enhanced nuclear export, but could be due to 
cytoplasmic sequestration. 
In addition to C-terminal NES, p53 contains NES in its N-terminus (11-27aa). It is 
possible  that  due  to  binding  of  Mdm2  to  the  N-terminus  of  p53,  n-NES  is  not  easily 
accessible  to  nuclear  export  machinery.  According  to  the  binding  data  presented  here 
Mdm2 can interact outside N-terminus on mutant p53, therefore the contribution of n-NES 
to nuclear export of mutant p53 was tested (Fig.5.10). To this end subcellular localization 
of p53 DBD mutants – 175H, ΔV, and the corresponding p53 mutants lacking box I - 
175H/ΔI and ΔV/ΔI - was analyzed (Fig.5.10). It should be noted, that deletion of box I 
(13-18aa) does not cover the whole region of the described n-NES (11-27aa). The cells 
with cytoplasmic p53 were counted and presented on the graph (Fig.5.10). Deletion of box 
I did not affect localization of wild type p53, which was nuclear in most of the cells 
(Fig.5.10). The cytoplasmic localization of p53 DBD mutants was not decreased when n-
NES was mutated (Fig.5.10).  
These  results  suggest  that  mutant  p53  localizes  to  the  cytoplasm  not  due  to 
enhanced nuclear export, but nuclear import may be less efficient. It should be also noted 
that the percentage of cells with wild type p53 in the cytoplasm did not change when 
nuclear export was inhibited by leptomycin B or N- or C-terminal NES were deleted, 
suggesting that some population of wild type p53 is also sequestered in the cytoplasm. This 
might suggest that a small fraction of wild type p53 adopts a mutant conformation in cells.   137   138   139 
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5.3  Mutant p53 is sequestered in the cytoplasm by interaction with Parc. 
The  results  described  above  suggest  that  mutant  p53  is  sequestered  in  the 
cytoplasm, rather than showing enhanced nuclear export. Parc has been shown to play a 
role as a cytoplasmic anchor protein forming complexes with p53 (375). To test whether 
mutant p53 interacts with Parc, co-immunoprecipitation analysis following co-transfection  
of wild type p53 and p53 DBD mutants along with Parc or empty vector control in U2OS 
cells was carried out. In agreement with previous reports interaction between wild type p53 
and  Parc  was  very  weak,  which  may  be  due  to  mostly  nuclear  localization  of  p53 
(Fig.5.11). Although Parc was also less well expressed in this experiment. Deletion of the 
NLS on p53, which leads to localization of wild type p53 to the cytoplasm, promoted 
interaction with Parc (Fig.5.11). p53 DBD mutants, which locate to the cytoplasm, all 
interacted with Parc (Fig.5.11). Though p53175H/ΔNLS located more to the cytoplasm 
than  p53175H,  there  was  no  increase  in  amount  of  Parc  bound  to  p53175H/ΔNLS, 
probably due to saturation of Parc (Fig.5.11). The experiment was repeated two more times 
and similar observation was made. Consistent with previous reports (375), these data show 
that Parc interacts with cytoplasmic p53, independently of the mutation of DBD of p53. 
This result suggests that p53 mutants can be sequestered in the cytoplasm by interaction 
with Parc. This could be tested by downregulating Parc expression by siRNA-mediated 
approach. Parc is known to interact with the oligomerization domain of p53, and their 
interaction could be inhibited by a p53 C-terminal peptide (602). 
  
 
 
FIGURE 5.11. p53 DBD 
mutants interact with 
Parc. 
U2OS  cells  were 
transfected  with  indicated 
p53  constructs  and  with 
FLAG-tagged  Parc 
construct.  Cell  lysates 
were  analyzed  by 
immunoprecipitation  with 
p53-specific  antibodies 
and  immunoblotting  with 
p53-specific  and  FLAG-
specific antibodies.  
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5.4  Localization of p53 mutants in H1299. 
To extend the study to other cell types, the localization of p53 mutants was tested 
in H1299 cells (Fig.5.12). Intriguingly, in this cell type p53175H located to the nucleus in 
most cells (Fig.5.12). Wild type p53 and p53273H also localized to the nucleus (Fig.5.12). 
p53ΔV located to the cytoplasm in some cells but much less than in U2OS cells (Fig.5.12).  
 
 
Therefore, cytoplasmic localization of p53 mutants seems to be dependent on the cell type. 
p53  DBD  mutants  were  hyperubiquitinated    in  H1299  cells  (Fig.3.12),  implying  that 
ubiquitination  does  not  sequester  p53  mutants  in  the  cytoplasm.  It  is  possible  that 
ubiquitination is required but not sufficient for cytoplasmic localization. There are possibly 
other  changes  in  H1299  cells  which  prevent  cytoplasmic  retention.  It  is  possible  that 
H1299 do not express enough Parc to sequester mutant p53 in the cytoplasm.  
It is of interest to check where endogenous mutant p53 localizes in tumour-derived 
cell  lines.  The  preliminary  analysis  of  tumour  cell  lines  expressing  contact  mutant 
p53273H  mutant  shows  nuclear  localization  of  this  mutant,  consistently  with  the 
experiments when 273H was transiently expressed (Fig.5.1, 5.3). 
 
FIGURE 5.12. 
p53175H displays 
nuclear staining in 
H1299 cells. 
H1299  cells  were 
transfected  with  wild 
type  p53  or  indicated 
p53  DBD  mutants. 
Cells  were  fixed  and 
stained  with  anti-p53 
DO1 and DAPI. 
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5.5  Summary and discussion. 
Whereas  wild  type  p53  localizes  mostly  to  the  nucleus,  here  it  was  found  that 
ubiquitinated p53 DBD mutants display cytoplasmic localization in some cell types. The 
results shown in this chapter indicate that the unfolded conformation of mutant p53 is 
associated with cytoplasmic sequestration, as conformationally unfolded p53 mutants but 
not contact mutant 273H located to the cytoplasm. In agreement with the results presented 
here,  another  report  has  associated  ubiquitination  of  p53  DBD  mutants  and  their 
cytoplasmic  localization  (594).  Interestingly,  sequestration  of  wild  type  p53  in 
neuroblastomas has been recently shown to be due to hyperubiquitination of p53 (603).  
The results in this chapter suggest that mutant p53 is not subject to enhanced nuclear 
export and is sequestered in the cytoplasm. The mechanism for p53 sequestration in the 
cytoplasm  has  been  suggested  to  involve  interaction  with  Parc  (375),  which  inhibits 
nuclear  import.  However,  some  fraction  of  p53  undergoes  normal  nuclear  import, 
suggesting that there are two populations of mutant p53 in the cells, one is sequestered in 
the cytoplasm and the other fraction undergoes normal nucleo-cytoplasmic shuttling. This 
suggests that mutant p53 may exist in mutant conformation sequestered in the cytoplasm 
and  wild  type  conformation,  which  locates  to  the  nucleus.  However,  cytoplasmic 
sequestration of mutant p53 depends on the cell type and in other cells, like H1299, mutant 
p53 is efficiently imported to the nucleus. It is possible that the localization of mutant p53 
to the cytoplasm is representative of protective mechanism against misfolded p53, and 
further in tumourigenesis, cells select for nuclear accumulation of mutant p53. This study 
suggests that ubiquitination of p53 mutants occurs in the cytoplasm. Mutant p53 may be 
ubiquitinated  by  the  activity  of  cytoplasmic  E3s.  Interestingly,  CHIP  localizes  to  the 
cytoplasm and has been shown to cooperate with Parc in ubiquitination of its substrates. It 
would be interesting to determine what is the biological function of localization of mutant 
p53 to the cytoplasm and to extend the study to other tumour-derived cell lines expressing 
mutant p53.     144 
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6  Interaction of p53 DBD mutants with p73.  
Several  p53  DBD  mutants  can  associate  with  p63  and  p73  in  cells,  both 
endogenous and overexpressed, which leads to inactivation of p63/p73 (458-464). The 
interaction is mediated via the DNA binding domains of p53 and p63/p73 (461), though 
the  exact  binding  site  has  not  been  mapped.  In  this  chapter  the  contribution  of  the 
conserved boxes of DBD to the interaction with one of the family members p73 and the 
effect of the interaction on the stability of mutant p53 and p73 proteins were studied.  
 
6.1  p53 with deletions of the conserved boxes of DBD interact with p73. 
p53 with deletions of conserved boxes of DBD ΔV, ΔIV, ΔIII and ΔII adopt a 
“mutant” conformation (582) and therefore predicted to interact with p73. To detect the 
interaction and to test if any of the conserved boxes can be the binding site of p73, co-
immunoprecipitation analysis of p53 DBD mutants with p73 following their co-expression 
in cells was carried out. The polymorphism status of p53 modulates the interaction and 
mutant  p53  with  72R  associates  with  p73  more  efficiently  than  mutants  with  72P 
polymorphism (459, 463). Therefore p53 mutants with 72R polymorphism were used in 
 
FIGURE 6.1. p53 DBD mutants interact with p73. 
U2OS cells were transfected with wild type or indicated p53 DBD mutants and with HA-
p73α.  Cell  lysates  were  immunoprecipitated  with  p53-specific  antibody  (DO1)  and 
analyzed by immunoblotting with CM1 or HA-specific antibodies.  
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this experiment. U2OS cells were co-transfected with p53 ΔV, ΔIV, ΔIII and ΔII as well as 
p53175H and p53273H along with with p73α. Cell lysates were immunoprecipitated with 
p53-specific  antibody  and  p73  was  detected  with  a  p73-specific  antibody.  In  this 
experiment  p73α  was  used,  which  is  the  full-length  TAp73  transcriptionally  active 
isoform. TAp73α has been previously reported to associate with several p53 DBD point 
mutants. Wild type p53 failed to interact with p73 whereas all p53 DBD deletion and point 
mutants  interacted  with  p73α  (Fig.6.1).  This  result  was  observed  in  three  independent 
experiments. Contact mutant 273H interacted with p73 less well than conformational p53 
mutants. In agreement with other reports, these data suggest that unfolded conformation of 
DBD of p53 unveils the cryptic p73 binding site, not accessible in wild type conformation 
of DBD.  
 
6.2  Effect of interaction of p53 mutants with p73 on degradation of p53 
and p73.  
Mdm2 interacts with p73, however Mdm2 fails to degrade p73 or export p73 to the 
cytoplasm (416, 418). The effect of the interaction between mutant p53 and p73 on Mdm2-
mediated degradation was analyzed. Specifically, the following questions were addressed.  
1) Can interaction of p73 with mutant p53 lead to degradation of p73 by Mdm2? 2) Can 
p73 protect mutant p53 from being degraded by Mdm2? To address these questions, p73α 
was expressed along with Mdm2 and with wild type p53 or p53 DBD mutants ΔIII and ΔII  
(Fig.6.2A), which interacted with p73 better than other p53 deletion mutants. GFP was 
used to control for transfection efficiency. The apparent slower migration of GFP in the 
last lane is due to the fracture of the gel (Fig.6.2A). Consistent with the data presented 
above, both wild type and mutant p53 were efficiently degraded by Mdm2, regardless of 
expression  of  p73,  suggesting  that  p73  does  not  protect  mutant  p53  from  degradation 
(Fig.6.2A). Consistent with previous reports, p73 was resistant to degradation by Mdm2, 
whereas  wild  type  p53  and  p53  DBD  mutants  were  efficiently  degraded  by  Mdm2 
(Fig.6.2A). Co-expression of p53 DBD mutants seemed to slightly reduce levels of p73, 
but this was difficult to assess due to strong signal of p73 on this gel. Therefore, the 
western blotting analysis was repeated with the smaller quantity of the cell lysates from 
this experiment using gel with broader lanes (Fig. 6.2B). This result more clearly shows 
that  degradation  of  p53ΔIII  was  not  affected  by  the  presence  of  p73  (Fig.6.2B). 
Interestingly, though p73 was not degraded by Mdm2 when co-expressed with wild type 
p53, p73 protein levels decreased when p53ΔIII was present. This suggests that mutant p53   147 
promotes degradation of p73 by Mdm2. Interestingly, it was noticed that p73 increases the 
expression of Mdm2 – both endogenous and transfected. The mechanism of increasing 
levels of transfected Mdm2 protein may involve protein stability. To analyze if p73 can 
stabilize Mdm2 protein, p73 mutant lacking Mdm2-interaction site or Mdm2 lacking N-
terminus can be tested in future. These observations were reproduced in two independent 
experiments. 
 
FIGURE 6.2. Effect of  p53 and p73α on Mdm2-mediated degradation of p73α and p53. 
U2OS cells were transfected with wild type p53 or indicated p53 DBD mutants along with 
empty vector or wild type Mdm2 and with HA-p73α. GFP was co-transfected to control for 
transfection efficiency. A. Western blot analysis was carried out with p53-specific (DO1), 
HA-specific and GFP-specific antibodies. B. Three times less of the cell lysates of indicated 
samples were subject to repeat SDS-PAGE  and Western blot analysis.  
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The effect of p53 DBD mutant on p73 degradation was quite weak, possibly due to 
rapid degradation of p53 by Mdm2. The aim of the next experiment was to confirm the 
result and to test if p53 175H could also promote degradation of p73 and increase the 
amount of p53 mutant bound to p73, p73 was co-expressed with Mdm2 and p53ΔII and 
p53175H were titrated in (Fig.6.3). Interestingly, when p53175H or p53ΔII mutants were  
expressed at higher levels the p73 protein levels decreased (Fig.6.3). In agreement with 
Figure  6.2B,  this  suggests  that  p53175H  and  p53ΔII  promote  degradation  of  p73  by 
Mdm2, however this needs to be confirmed by treatment with proteasome inhibitors or 
analysing half-life of p73. It will be interesting to test if ubiquitin ligase activity of Mdm2 
is  required  for  the  ability  to  degrade  p73  by  testing  Mdm2-464  mutant.  These  results 
suggest, that p53 mutant can promote degradation of p73 by Mdm2. In future, p53 and p73 
mutants lacking the N-terminal binding to Mdm2 will be tested.  The in vivo ubiquitination 
assay of p73 will also be set up to test if mutant p53 promotes ubiquitination of p73 by 
Mdm2.  
 
 
FIGURE 6.3. Effect of 
p53 DBD mutants on 
degradation of p73α by 
Mdm2.  
U2OS  cells  were 
transfected with HA-p73α 
and empty vector or wild-
type  Mdm2  and  with 
increasing  amounts  of 
p53ΔII  (A)  or  p53175H 
(B) mutants. GFP was co-
transfected  to  control  for 
transfection  efficiency. 
Western blot analysis was 
carried  out  with  p53-
specific  (DO1),  HA-
specific  and  GFP-specific 
antibodies. 
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6.3  p73 inhibits ubiquitination of mutant p53. 
As shown above, conformational p53 mutants are subject to Mdm2-independent 
ubiquitination  and  can  interact  with  p73.  Therefore  it  was  tested  if  p73-specfic  Itch 
ubiquitin ligase can target p53 mutants. To this end Itch expression was down-regulated by 
siRNA-mediated approach with previously published Itch-specific siRNA oligonucleotides 
and the ubiquitination of transfected p53175H was analyzed in U2OS cells. Ubiquitination 
of  mutant  p53  was  only  weakly  reduced  when  Itch-specific  siRNA  was  transfected. 
However, to confirm this the reduction of Itch expression needs to be verified (Fig. 6.4). 
 
Next, the effect of p73 on ubiquitination of mutant p53 was examined. To this end 
wild type p53 or p53175H were expressed in U2OS cells along with the p73 isoforms α or 
β and HA-ubiquitin and in vivo ubiquitination assay was carried out (Fig.6.5). p73β is a 
splice  variant  of  TA  p73  isoform,  which  is  functionally  very  similar  to  p73α.  p73β 
interacts with p53175H similarly to p73α. Interestingly both p73α and p73β decreased the 
ubiquitination of p53 175H, without any effect on the residual ubiquitination of wild type 
p53 (Fig.6.5). This observation was reproduced in two other independent experiments. 
However,  p73  did  not  stabilize  mutant  p53  protein  in  cells  (Fig.6.2).  This  could  be 
explained by the previously described observation that ubiquitination does not efficiently 
degrade mutant p53. It would be interesting to confirm this observation in Mdm2-null cells 
and to test the effects of p73 on the Mdm2-mediated ubiquitination of mutant p53. A 
preliminary experiment suggests that p73α does not inhibit Mdm2-mediated ubiquitination 
of mutant p53.  
FIGURE 6.4. siRNA-mediated 
knockdown of Itch expression does not 
affect the ubiquitination of p53175H.  
U2OS  cells  were  transfected  with  non-
targetting  (NT)  or  Itch-specific  siRNA 
oligonucleotides.  Cells  were  transfected 
with  p53175H  along  with  HA-ubiquitin 
24h later. Cells were treated with MG132 
and lysed under denaturing conditions. Cell 
lysates were immunoprecipitated with p53-
specific  antibody  (DO1)  and  Western 
blotted with either HA-specific or the p53-
specific CM1 antibody. 
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FIGURE 6.5. p73 inhibits ubiquitination of p53175H. 
U2OS cells were transfected with wild type p53 or p53175H along with HA-tagged 
ubiquitin (HA-Ub) and with empty vector or FLAG-p73α or FLAG-p73β. Cells were 
treated  with  MG132  and  lysed  under  denaturing  conditions.  Cell  lysates  were 
immunoprecipitated with p53-specific antibody (DO1) and Western blotted with either 
HA-specific or the p53-specific CM1 antibody. Direct western blotting analysis was 
carried out with p73-specific antibody (sc-20). 
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6.4  Localization of mutant p53 and p73.  
To study if the interaction between mutant p53 and p73 affects the localization of 
each  of  the  proteins,  subcellular  localization  of  wild  type  p53,  p53175H  or  p53ΔV 
expressed along with p73α was analyzed U2OS cells (Fig.6.6). Similarly to results shown 
above,  wild  type  p53  localized  to  the  nucleus  (Fig.6.6A)  and  p53175H  and  p53ΔV 
displayed some cytoplasmic localization (Fig.6.6B, C). Endogenous p73 was not detected 
in these cells with p73-specific antibody, however overexpressed p73 was clearly visible. 
In agreement with previous studies (373, 604, 605) transfected p73 resided in the nucleus 
in most cells with small percentage of cells where p73 was detected in the cytoplasm 
(Fig.6.6A).  The  colocalization  of  p73  with  wild  type  p53  was  visualized  by  confocal 
microscope by merging the channels of green (p53) and red (p73) fluorescence which 
displays colocalization as yellow color. The technical caveat of this experiment is that the 
intensity of the p53 staining was stronger than p73 in this experiment. Wild type p53 and 
p73 only partially colocalized in the nucleus (Fig.6.6A), suggesting that function of p73 
may differ from p53. In addition, p73 was found in distinct structures in the nuclei of some 
cells (Fig.6.6A). The biological significance of these structures is not clear, however they 
seem to localize to heterochromatin regions, as seen by staining with DAPI (Fig6.6A). The 
pattern of localization of p53175H and p53ΔV mutants was similar to described above 
(Fig.5.2). The expression of p53 mutants did not relocalize p73, as it remained in the 
nucleus in most cells when p53175H and p53ΔV were co-expressed (Fig.6.6B,C). The p53 
DBD mutants and p73 also partially colocalized in the nucleus (Fig.6.6B,C). In some cells 
mutant p53 colocalized with p73 in the distinct nuclear aggregates (Fig.6.6B,C). These 
findings are still preliminary. These data suggest that only a fraction of mutant p53 is 
involved  in  interaction  with  p73,  which  takes  place  mostly  in  the  nucleus.  In  future 
experiments it will be important to determine the stoichiometry of the p53/p73 interaction. 
Though p73 inhibits ubiquitination of mutant p53, this might be indirect, as the data of this 
study suggests that ubiquitination of mutant p53 takes place in the cytoplasm.   152   153 
6.5  Summary and discussion.  
In this chapter the interaction of mutant p53 and p73 was analyzed. It was shown 
here that all p53 DBD mutants with deletions of the conserved boxes interacted with p73. 
This together with previous reports (461, 606) suggests that the altered conformation of 
DBD of p53 is the determinant for the interaction. As shown previously, all the p53 DBD 
deletion mutants have “mutant” conformation of DBD and similarly to tumour-derived 
conformational  mutants  display  a  cryptic  epitope  (213-217aa),  recognized  by  the 
conformation-sensitive antibody. The possibility that this region is the binding site for p73 
remains to be checked in future.  
Whereas others have shown that Mdm2 inhibits transcriptional activity of p73, the 
data shown here suggest that mutant p53 can promote degradation of p73 by Mdm2, which 
is not degraded by Mdm2 on its own (416, 418). Studies of p53-p73 chimeras have shown 
that lack of the homology to the region of 92-112aa of p53 can be the reason for resistance 
of p73 to degradation by Mdm2 (419). The data presented here suggest that p73 can be 
degraded when in complex with mutant p53, which may provide such degradation signal. 
This could contribute to the inactivation of p73 by mutant p53. It would be interesting to 
test if mutant p53 can promote ubiquitination of p73 by Mdm2. 
As shown here, p73 can inhibit the ubiquitination if mutant p53. It is not clear 
whether inhibition of ubiquitination by p73 can contribute to accumulation of mutant p53. 
p73 does not seem to protect p53 mutants from degradation by Mdm2, suggesting that p73 
might not inhibit ubiquitination by Mdm2, which has been confirmed in the preliminary 
experiment.  
Since the unfolded conformation of the DBD of p53 is the determinant of both 
binding to p73 and of ubiquitination of mutant p53, it is possible that the ubiquitin ligase 
and p73 compete for binding to the DBD of p53. However, this is unlikely, as localization 
data suggest that mutant p53 and p73 colocalize only partially. It is possible that p73 
inhibits the ubiquitination of mutant p53 indirectly, by sequestering the ubiquitin ligase in 
the nucleus. Another interesting possibility could be that p73 promotes deubiquitination of 
mutant p53 in the nucleus. This also implies that ubiquitination does not sequester mutant 
p53 in the cytoplasm. This is also confirmed by the nuclear localization of p53 mutants in 
H1299 cells, in which ubiqitination of these mutants was clearly detected.  
The  interaction  of  mutant  p53  and  p73  has  been  suggested  to  contribute  to 
oncogenic  properties  of  mutant  p53  and  further  characterization  of  the  molecular 
mechanisms of the interaction and functional consequences can be important for clinical 
implications.    154 
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7  Discussion. 
Mutations in p53 are very frequently found in cancers, suggesting they are selected 
for during malignant progression. Many of the p53 mutations affect the DNA binding 
domain (DBD) of p53, which partially or completely distort its conformation (436, 579). 
Mutations of DBD result in loss of the tumour suppressive function of p53, by inactivating 
its transcriptional activity. Moreover, mutant p53 acquires novel functions and actively 
contributes to cancer progression, known as “gain-of-function” effect. Mutant p53 often 
accumulates to high levels in tumour cells (581), although the reason why mutant p53 is 
not degraded in cancer cells remains unclear. In mice engineered to express only mutant 
p53, stabilization of p53 is seen only in tumours but not in normal cells (484, 485). While 
these mutants do not activate expression of Mdm2, it is apparent that normal cells retain 
sufficient Mdm2 levels to keep the levels of mutant p53 protein low. Secondary events 
may occur which contribute to stabilization of mutant p53 in tumours. It is possible that the 
stabilization  of  mutant  p53  in  tumours  is  related  to  ARF  expression  –  an  inhibitor  of 
Mdm2 – that is specifically activated in tumours (16). This idea is also supported by a 
recent observation that p16 is lost in a proportion of tumours in mice expressing mutant 
p53.  By  inhibiting  E2F  activity,  the  CDK  inhibitor  p16  leads  to  inhibition  of  ARF,  a 
transcriptional  target  of  E2F  (520).  However,  siRNA  mediated  inhibition  of  ARF 
expression in a tumour cell line expressing high levels of mutant p53 did not decrease the 
stability of the p53 (Horn and Vousden, personal communication), suggesting that ARF is 
not the only determinant of mutant p53 stability. The ongoing DNA damage signalling in 
tumour  cells  can  also  contribute  to  accumulation  of  p53.  It  is  therefore  possible  that 
although Mdm2 is able to control the basal levels of mutant p53, it fails to degrade high 
levels of mutant p53 after stress.  However, clearly many tumours express high levels of 
Mdm2  and  high  levels  of  mutant  p53,  suggesting  that  other  mechanisms  account  for 
accumulation of mutant p53. In addition, there are some tissue-specific components of 
regulation of stability of mutant p53, such as Mdm2-independent regulation of mutant p53 
in liver (520). Therefore it appears that a number of different mechanisms can lead to 
accumulation of mutant p53.  
Although p53 mutants are quite heterogeneous, they have common determinants of 
their structure and function, which divide them into conformational and contact mutants. 
The results described in this study suggest a distinct pathway that regulates the degradation 
of conformational p53 mutants. Here it has been demonstrated that mutant and wild type   156 
p53 can be degraded through overlapping, but distinct pathways. Unlike wild type p53, 
mutant  p53  is  specifically  ubiquitinated  in  Mdm2-independent  manner.  It  is  therefore 
possible that the selective stabilization of mutant p53 reflects a tumour-specific defect in 
the  pathways  that  target  mutant  p53  for  degradation.  This  study  suggests  there  are 
differences  in  the  degradation  pathways  that  regulate  the  conformational  and  contact 
mutants. It is clear however that other factors contribute to the stability of contact mutant 
p53 forms in cancers, since p53s mutated at codon 273 – which are ubiquitinated like wild 
type p53 in this study – are frequently found to be stabilized in human cancers.  
Although both wild type p53 and mutant p53 are degraded by Mdm2, there are 
clear differences in the mechanisms of degradation. Whereas wild type p53 degradation is 
entirely dependent on ubiquitination by Mdm2, the ubiquitin ligase activity of Mdm2 is 
less  important  for  degradation  of  mutant  p53.  The  results  of  this  study  propose  the 
following model of degradation of wild type and mutant p53 (Fig.7.1). In the first step, the 
N-terminal  domain  of  Mdm2  interacts  with  N-terminus  of  p53  which  activates  the 
ubiquitin ligase activity of Mdm2 leading to polyubiquitination of p53. In the next step 
polyubiquitination causes unfolding of p53, which promotes interaction of RING domain 
of Mdm2 with p53, possibly in its DBD. This leads to the next step in which Mdm2 
delivers  p53  to  the  proteasomes,  which  involves  the  interaction  of  Mdm2  with  the 
proteasome. In case of mutant p53 the ubiquitination step by Mdm2 is less important. 
Mutant  p53  is  already  unfolded  and  also  highly  ubiquitinated  in  cells  by  another  E3. 
Therefore the second interaction involving RING domain of Mdm2 and mutant p53 is 
promoted.  At  this  step  Mdm2  delivers  mutant  p53  ubiquitinated  by  another  E3  to  the 
proteasomes.  
 
 
FIGURE 7.1. Model of 
degradation pathways of wild 
type and mutant p53.  
This  study  suggests  the 
following model of degradation 
of  wild  type  p53  and  mutant 
p53.  Wild  type  p53  is 
ubiquitinated and targeted to the 
proteasomes  for  degradation 
mainly by Mdm2. Mutant p53 is 
ubiquitinated by other ubiquitin 
ligases,  such  as  CHIP  and 
others unknown  (E3X). Mdm2 
may  play  a  role  in  delivery  of 
the ubiquitinated mutant p53 to 
the  proteasomes  for 
degradation. 
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Hence,  it  is  interesting  to  investigate  whether  this  function  of  Mdm2  is 
compromised in tumours with mutant p53. The other possibility is that mutant p53 is not 
ubiquitinated in tumor cells, which could be due to loss of expression of mutant p53-
specific E3. 
This study shows that degradation of mutant p53 is dependent on Mdm2, however 
it  does  not  require  the  N-terminal  interaction  of  both  proteins.  This  has  an  important 
potential implication for treatment of tumours with the inhibitor of N-terminal interaction  
- nutlin-3. Nutlin-3 may be a promising strategy for the treatment of tumours that retain 
wild type p53. However, given the oncogenic activity, further stabilization of mutant p53 
would be unfavourable for treating cancer. Our study has shown that while nutlin-3 leads  
to  efficient  stabilization  of  wild  type  p53,  it  only  weakly  stabilizes  mutant  p53.  This 
suggests that nutlin-3 can be used to treat tumours, which retain both wild type and mutant 
forms of p53.  
Whereas degradation of wild type p53 is dependent on the E3 activity of Mdm2,  
the data shown in this study suggest that E3 activity is not absolutely required for the 
degradation  of  mutant  p53.  This  suggests  the  possibility  of  using  the  inhibitors  of  E3 
activity of Mdm2 to selectively stabilize wild type p53 but not mutant p53.  
Conformationally altered p53 mutants are selectively ubiquitinated by other E3s, 
independent of Mdm2. Despite being ubiquitinated, mutant p53 is not efficiently degraded, 
which implies the existence of additional signals for proteasomal destruction. Mdm2 may 
provide such a signal, as it readily degrades mutant p53, ubiquitinated by other E3. A 
number of different ubiquitin ligases, which can target wild type p53 have been described 
recently (83, 84, 178, 185, 354, 360, 361, 590). In agreement with other reports (355, 455), 
CHIP contributes to ubiquitination of both wild type and mutant p53. CHIP is involved in 
protein  folding  control  by  ubiquitinating  and  degrading  its  substrates  (607,  608).  This 
suggests that ubiquitination of mutant p53 can be a part of the protective mechanism of the 
cell to eliminate misfolded p53. This also suggests an interesting possibility that mutant 
p53 may induce ER stress, which can be triggered by accumulation of misfolded proteins 
in cells. ER stress has been described to accompany different stages of tumour progression, 
however it has been unclear whether it inhibits or promotes tumour development (609). 
Recent  report  suggests  that  HRas  induced  senescence  is  mediated  by  ER-associated 
unfolded  protein  response,  suggesting  its  anti-oncogenic  role  (610).  It  is  possible  that 
tumours  overcome  this  barrier  by  deregulating  the  components  of  the  ER  associated 
degradation. This role of CHIP in ubiquitination of mutant p53 implies that CHIP can be 
inactivated in cancers, contributing to accumulation of mutant p53. In agreement with this   158 
hypothesis, CHIP expression is reduced in some cancers, however it is not clear whether 
these cancers have mutant p53.  
The contribution of CHIP seems to be partial, leaving the possibility that other E3s 
exist that specifically target mutant p53, or that wild type and mutant p53 differ in their 
sensitivity  to  deubiquitinases.  Discovery  of  other  ubiquitin  ligases  that  specifically 
ubiquitinate  mutant  p53  can  be  addressed  by  analysis  of  specific  binding  partners  of 
mutant  p53  by  proteomics  approach.  Alternatively,  screening  of  all  human  ubiquitin 
ligases can be carried out using the siRNA library that targets all known human E3s for the 
effect of the down-regulation of their expression on mutant p53 ubiquitination.  
Unlike wild type p53, which is mostly nuclear, it has been found here that the 
conformationally altered p53 mutants display enhanced cytoplasmic localization. The data 
presented here suggest that “mutant” conformation of the DBD of p53 is an important 
determinant for localization to the cytoplasm, as contact mutant locates to the nucleus 
similarly to wild type p53. Cytoplasmic localization of wild type p53 has been noted in 
neuroblastomas and has been attributed to enhanced nuclear export. However, according to 
the  results  presented  in  this  study  mutant  p53  is  sequestered  in  the  cytoplasm  and  its 
nuclear import is reduced.   The mechanism of such sequestration is not known, however it 
can involve interaction with Parc. It is likely, that cytoplasmic localization of mutant p53 
requires  the  cryptic  epitope  in  DBD,  which  can  be  involved  in  protein  interactions.  It 
should be noted that some population of mutant p53 undergoes functional nuclear import. 
The reason for heterogeneous behaviour of mutant p53 is not clear, and could be dependent 
on the stage of cell cycle. The findings of this study also suggest that mutant p53 residing 
in the cytoplasm is ubiquitinated. CHIP, which contributes to this ubiquitination of mutant 
p53, has been shown to locate to the cytoplasm. Interestingly CHIP has been shown to 
cooperate with Parc in ubiquitination of the substrates. There are many other cytoplasmic 
ubiquitin  ligases,  which  may  contribute  to  ubiquitination  of  mutant  p53.  Inhibition  of 
ubiquitination  of  mutant  p53  by  p73  does  not  relocate  mutant  p53  to  the  nucleus, 
suggesting that ubiquitination does not sequester mutant p53 in the cytoplasm and is rather 
a consequence of cytoplasmic localization of mutant p53. Interaction of mutant p53 and 
p63/p73 occurs mostly in the nucleus, therefore the nuclear fraction of mutant p53 might 
be contributing to the gain-of-function effect. The function of mutant p53 in the cytoplasm 
is unknown. Although the cytoplasmic function of wild type p53 has been suggested to 
promote apoptosis, mutant p53 does not induce cell death. One speculation can be that 
keeping mutant p53 in the cytoplasm is the means to inactivate it, which could reflect the 
existence of the cellular mechanism to degrade misfolded p53. Inactivation of CHIP or 
Parc at later stages of tumourigenesis can lead to relocation of mutant p53 to the nucleus   159 
where it can exert gain-of-function effect. This may indicate that the nuclear localization of 
mutant p53 would be favoured by tumour. Therefore, it would be interesting to check 
localization of mutant p53 in normal cells and in tumour cells in p53 knock-in mice.  
The data presented here suggest that mutant p53 can target p73 for degradation by 
Mdm2, which can contribute to inactivation of p73 function. By inhibiting ubiquitination 
of mutant p53, p73 can play a role in regulation of stability of mutant p53 and contribute to 
its accumulation in tumours.  
The data of this study suggest that the regulation of stability of mutant p53 differs 
from that of wild type p53. Identifying the E3 responsible for the hyper-ubiquitination of 
mutant  p53  and  investigation  into  the  mechanism  of  Mdm2-mediated  delivery  to 
proteasomes  may  have  important  implication  in  understanding  the  mechanisms  that 
specifically down-regulate mutant, but not wild type p53 in tumours. Further studies of the 
interaction of mutant p53 with its family members and its functional consequences can also 
provide  the  way  of  inactivation  of  the  mutant  p53  oncogenic  function.  This  could 
potentially have therapeutic advantages, since mutant p53s are highly expressed in cancer 
cells and show a clear ability to promote various aspects of tumourigenesis, including 
metastatic spread (484, 485).  
Whereas the strategy to develop cancer treatments for tumors with wild type p53 
would  be  to  stabilize  p53,  in  case  of  tumors  bearing  mutant  p53  the  accumulation  of 
mutant p53 will have adverse effects due to the gain-of-function activites of mutant p53. 
The differences in the mechanisms of degradation of wild type and mutant p53 suggest the 
possibility to develop cancer treatments that specifically stabilize wild type p53 but not 
mutant p53.   
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